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Maternal nutrition is essential to the well being of mother and baby during pregnancy and beyond. 
It is necessary for effective placental accretion, foetal growth and development and optimal 
pregnancy outcomes. Adequate nutrition becomes even more critical when pregnancies are 
complicated with diabetes of any type which includes type 2 diabetes mellitus (T2 DM) and 
gestational diabetes mellitus (GDM). Complementary to other lifestyle factors, nutrition forms the 
cornerstone for achieving euglycemia to reduce potential maternal and foetal risks associated with 
diabetes in pregnancy such as macrosomia, hypertensive disorders and preterm birth.  
T2 DM and GDM are characterised by insulin resistance which affects effective beta cells function 
in the secretion and synthesis of insulin. Additionally, reduced levels of arachidonic acids (AA) 
(omega 6 fatty acids) and docosahexaenoic acids (DHA) (omega 3 fatty acids) have been found in 
maternal red blood cells in pregnancies complicated with diabetes. AA and DHA cannot be 
produced by the body and must be ingested by the mother. Foetal demands for these fatty acids are 
high and these are transferred by placental selection from maternal to placental circulation. It is 
reported that diabetes impairs the activity of delta-6 and delta-5 desaturases which are enzymes 
necessary for the synthesis of AA & DHA. Recent studies have reported significantly lower levels 
of AA & DHA in the red blood cells of pregnant women with GDM and T2 DM, resulting in a 
depletion in placental uptake and transfer of these fatty acids to the foetus and adequate supply for 
the mother, which if remains untreated, may have adverse impact on maternal, foetal and neonatal 
health in the short- and long-term. Therefore, women in these high risk groups need to effectively 
engage with health care professionals (HCPs) involved in their care and the services offered to 
them.  
Insulin therapy and supplementation with these essential fatty acids may correct this depletion. 
However, the impact on pregnancy outcome remains unknown. Newham is one of the most 
deprived boroughs of London and has a high prevalence and incidence of diabetes. Therefore, by 
evaluating the pregnancy outcomes of women with T2 DM and GDM after supplementation with 
essential fatty acids (EFAs), the local service needs would be better understood, and vital answers 
would be provided to optimise the pregnancy outcomes for this client-group which already has 







This study investigated: - 
(1) Socio-cultural and economic factors which influence engagement of pregnant women with 
health care professionals; (2) The impact of early detection of gestational diabetes mellitus (GDM) 
on pregnancy outcome and postnatal maternal health; and (3) The effect of omega-3 fatty acid 
supplementation on the outcome of pregnancy in women with GDM and (4) type 2 diabetes. 
Method 
Pregnant women 17-45 years with diabetes (T2 DM and GDM) and without diabetes and booked at 
Newham University Hospital were recruited during antenatal or home visits.  
In Phase 1 of the study, diabetic (n=594) and non-diabetic (n=243) pregnant women were recruited 
during antenatal or home visits in the first, second and third (up to 32 weeks gestation) trimesters. 
Detailed demographic, socio-cultural and economic data and the interactions of women with HCPs 
and reasons given by women for their engagement or non-engagement with HCPs were collected 
using a questionnaire developed for the study.  
In Phase 2, pregnant women diagnosed with GDM before 24 (n=212) and after 24 (n=226) weeks 
of gestation were recruited after diagnosis on OGTT and up to 32 weeks gestation. Demographic, 
socio-cultural, economic and clinical and obstetric data were collected from hospital records and 
from the participants with the use of a questionnaire.  
One hundred fifty (n=149) women diagnosed with gestational diabetes were recruited up to 32 
weeks gestation and randomised and given DHA (n=75) or high oleic acid sunflower seed oil 
placebo (n=74) supplement until delivery, in Phase 3. Comprehensive data was collected on 
diabetes management regimen, pregnancy complications (preeclampsia, miscarriage, preterm 
labour, etc.), foetal outcome (prematurity, macrosomia, low birth weight, neonatal admission to 
special care baby unit, etc.) and postnatal glycaemic status. Also, detailed demographic, socio-
cultural and economic information was gathered with a questionnaire designed for the study.  
In Phase 4, pregnant women with type 2 diabetes (n=96) were recruited up to 17 weeks gestation 
during their antenatal visits. They were randomised into two groups and given DHA (n=47) or high 
oleic acid sunflower seed oil placebo (n=49) capsules until delivery. Similarly, their matching 
controls (non-diabetics) (n=89) were also recruited in the first trimester on their maternity booking 
appointments or on antenatal clinic visits, and randomised and given DHA (n=40) and placebo 
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(n=49). Demographic, socio-cultural, economic and maternal and foetal outcomes were collected 




Socio-economic, cultural and demographic factors are influential in a pregnant woman’s decision 
on whether or not to engage with HCPs. For Asian Muslims, strong decision-making indicators 
were their ability to speak English (p <0.001), husband and/or family involvement (p <0.000) and 
adequate time to make a decision. Being a singleton (p <0.001), non-Asian (p <0.002) Christian (p 
<0.001) enabled a prompt response to engage. Professional women and those in intermediate jobs 
(p <0.026) and women whose partners were similar jobs (p <0.006) engaged better with HCPs.  
Engagement with HCPs reduced the development of complications in pregnancy (p <0.001) but 
had no positive effect on birth outcome. Stillbirth, neonatal death and miscarriages were more 
common among engaged women. Non-engaged women had more term babies and reduced 
incidence of preterm births and hypertensive disorders (PIH, pre-eclampsia or eclampsia) (p 
<0.006) Engagement made no difference to onset of labour (p < 0.283), mode of delivery (p < 
0.366), and neonates admission to special care baby unit (p < 0.400). Low birth weight infants and 
macrosomia was approximately two-fold higher among non-engaged women (p < 0.037).  
Phase 2 
Family history and BMI ≥30 were strong indicators for screening for gestational diabetes mellitus 
(GDM) (p <0.291). Women diagnosed with GDM <24 weeks gestation had better pregnancy 
outcomes than women diagnosed >24 weeks gestation. Women who were diagnosed <24 weeks 
gestation, premature birth was 13% (26), other groups 3.6% (7) {stillbirth 1% (2), neonatal death 
0.5% (1), miscarriages 2% (4)} and the remaining 83% (163) delivered at full term. For those who 
delivered after 24 weeks, 84% (182) delivered at full term with 17% (36) delivered prematurely (p 
<0.014). Of those diagnosed before and after 24 weeks gestation, 1% / 2% had macrosomia, 12% / 
8% low birth weight and the remainder were normal 88% / 90%, respectively (p <0.380). Post-
delivery, of women with GDM diagnosed <24 weeks, 25% had abnormal OGTT of which 12 % 
were diagnosed with T2 DM. In the ≥24 weeks group, 4% had T2 DM and 9% had either impaired 
glucose tolerance (IGT) (blood glucose between 7.8 & 11.1mmol/l after 2 hours glucose load) or 
impaired fasting glucose (IFG) (fasting glucose >6.1mmol/l). Overall, twenty-five (16 %) were 
diagnosed with T2 DM and 23% had either IGT or IFG on postnatal OGTT (p <0.010). 
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Phase 3  
The demographic and clinical characteristics of the women in the supplemented and non-
supplemented groups were similar. Omega-3 fatty acid supplementation had no effect on maternal 
and foetal health and pregnancy outcomes and postnatal glycaemic control of women with GDM. 
There was no difference in onset of labour (p <0.328), induction of labour (p <0.368), reasons for 
induction (p <0.616), caesarean section rates (p <0.294), prolonged pregnancy (p <0.285), 
reduction in pre-term birth (p <0.096), macrosomia (p <0.124), low birth weight infants (p <0.124), 
hypertensive disorders of pregnancy (p <0.826) and postpartum glycaemic control (p <0.485). The 
incidence of stillbirth (n=1), miscarriage (n=1) and neonatal death (n=1) was found only in women 
without active treatment, but this was not statistically significant (p <0.096).  
Phase 4 
Fish oil supplementation had a positive impact on birth maturity (p <0.005) and reduced pre-term 
births (p <0.011). Less neonates were admitted to SCBU among women with T2 DM (p <0.017), 
and had elective caesarean sections (p<0.007).  The overall caesarean section rate was also reduced 
and this was nearing significant p <0.060. Fish oils supplementation had no impact on reducing the 
rate of induction (p <0.129) and admission to SCBU (p <0.678) and birth weight (p <0.932). 
Glycaemic control was also not impacted by fish oils supplementation (p<0.255).  
Conclusion:  
The findings of this study have demonstrated that NICE current guidelines on screening for the 
early detection of GDM are inappropriate for use in communities like Newham with a high 
disposition of DM. In communities like Newham which are genetically susceptible to T2 DM, risk 
factors for early screening for GDM should be family history of diabetes and BMI ≥30kg/m
2
 , as 
well as previous history of GDM. Early detection of GDM within these groups will facilitate the 
reduction of adverse birth outcomes.  
Results from this study also demonstrated that some benefits can be achieved from taking fish oils 
in pregnancy, particularly among women with T2 diabetes. Although some pregnancy outcome 
measures were not improved, fish oils supplementation as an adjunct management option for 
diabetics should be considered but further evidence is needed to substantiate these findings. 
To optimise maternal and foetal outcomes, women with diabetes in pregnancy need adequate and 
flexible holistic care options, to enable them to make informed choices that would be in the best 
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Abstract A brief description of a completed or proposed study; 
usually located at the beginning of the study/journal article. 
Advocacy Help given to patients by an advocate who can be a family 
member, friend or independent representative, to enable 
them to know the services that are available to them, their 
rights and entitlement and support to enable them to express 
their opinions and make informed decisions. 
Advocate A family member, friend or independent representative who 
has been given the authority to act on behalf of patients. 
Afro-Caribbean Refers to women of African or Caribbean origin.   
Alpha-linoleic acid An omega-3 fatty acid found in plant-based seeds and oils 
from foods like flaxseed, walnut, soy, chia and hemp.  
Amino acids The building blocks of proteins. 
 
Anabolic state A state where the body builds and repairs muscle tissues. 
 
Anaemia Refers to iron deficiency anaemia. Anaemia is the reduced 
level of red blood cells in the blood to carry oxygen to the 
tissues of the body. The deficiency can be treated with iron. 
Analysis A process of organising and synthesizing data in such a way 
that research questions can be answered, and hypotheses 
tested.  
Antenatal Refers to the period of pregnancy form conception and 
throughout to before birth. 
Antepartum Refers to the period of pregnancy form conception and 
throughout to before birth. 
Apgar scores 
 
Scoring system used to assess newborn at interval of 1, 5 & 
10 minutes after they are born.  The maximum score is 10.  
A total of 2 is awarded for each for the following: A- 
appearance, P- pulse, G- grimace, A- activity, R- respiration.  
Low APGAR may indicate that the baby needs special care 
intervention. 
Applications The tasks that computers can be used to perform (e.g. word 
processing, database management, statistical analysis). 
Arachidonic acid A polyunsaturated omega-6 fatty acid found in the 
phospholipids of membranes of the cells of the body. It is 
abundant in the brain, muscles and liver. It can be 
synthesised by linolenic acid.   
Asian Refer to women of Pakistani, Bengali, Indian, Chinese and 
any other Asian background. 
Assisted delivery Any delivery conducted vaginally, aided by the use if 
instruments, such as vacuum extractor or forceps.   
Any delivery conducted vaginally, without the aid was 
considered normal. 
Autoimmune  Relating to disease caused by antibodies or lymphocytes 
produced against substances naturally produced in the body. 
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Bias Any influence that produces a distortion in the results of a 
study. 
Birth maturity   Delivery or birth from 37 to 42 weeks of gestation. 
 
Blinding The concealment of the trial drug the subject of a study is 
taking from one or more individuals eg. research subjects 
and investigators/researchers.  
Booking Also referred to as the booking appointment in which the 
women enters the maternity care pathway. The first antenatal 
appointment a pregnant woman has with her midwife in 
which comprehensive history is taken from the woman to 
plan her pregnancy care.  
Caesarean section A surgical procedure used to deliver a baby through incision 
in the abdomen and uterus. 
Caesarean section -
planned / elective  
Booked dated for delivery by caesarean section, whatever 
the reason/s.  
Caesarean section -
emergency  
Delivery by caesarean section resulting from women status 
requiring immediate intervention. 
Candidiasis A fungal infection caused by a yeast candida 
Cardiotocograph An electronic foetal heart monitor 





Formed in 2010 and consists of several GPs and other health 
professionals who are responsible for the purchasing of 
healthcare.  




Any malformation(s) discovered prior to or immediately 
after birth. 
Constructivist One who believes that people actively construct or make 
their own knowledge and that reality is determined by your 
experiences as a learner. 
Cortisol A steroid hormone often described as the ‘fight and flight 
hormone’ which is designed to sense and alert danger.  
Data collection The gathering of information needed to address a research 
problem. 
Data entry The process of entering data onto an input medium for 
computer analysis.  
Deductive 
Reasoning 
The process of developing specific predictions from general 
principles.  
Delivery The birth of the baby. 
 
Demography The make-up of a population. Often includes one’s age, sex, 
religion, nationality, culture, etc. 
Dependent 
Variable 
The outcome variable of interest; the variable that is 
hypothesized to depend on or be caused by another variable, 
the independent variable. 






Research studies that have as their main objective the 
accurate portrayal of the characteristics of persons, 
situations, or groups and/or the frequency with which certain 
phenomena occur. 
Diabetic fetopathy Features seen in the hyperinsulinemic foetus of a diabetic 
mother which includes macrosomia, postnatal 
hypoglycaemia, polycythemia etc. 
Diabetic status The type of pre-existing diabetes condition (Type 1 or Type 
2) or whether developed during pregnancy. 
Docosachexaeonic 
acid                             
An omega-3 fatty acid that is a primary structural component 
of the human brain, cerebral cortex and retina. It can be 
synthesised by alpha-linolenic acid.   
Double blind A randomised clinical study in which the subjects and the 
researchers are unaware of what group the subjects are 
allocated, that is, the experimental treatment (standard 
treatment) or the placebo group. 
Eligibility criteria The criteria used by a researcher to designate the specific 
attributes of the target population and by which participants 
are selected for participation in a study. 
Embryo  The unborn infant in the process of development in utero. 
 
Empirical evidence Evidence that is rooted in objective reality and that is 
gathered through the collection of data using one’s senses; 
used as the basis for generating knowledge. 
Empiricist One who believes that knowledge is based on experience 
derived from the senses.  
Epigenetics The study of changes in organisms caused by modification 
of gene expression rather than the genetic code itself. 
Epistemological Relates to all aspects of validity, scope and methods of 
acquiring knowledge. 
Essential fatty acids Fatty acids that must be ingested because the body requires 
them for good health but cannot synthesize them. 
Ethics A system of moral values that is concerned with the degree 
to which research procedures adhere to professional, legal 
and social obligations to the study participants. 
Ethnography A branch of human inquiry, associated with the field of 
anthropology that focuses on the culture of a group of 
people, with an effort to understand the world view of those 
under study. 
Euglycemia A normal concentration of glucose in the blood 
Experiment A research study in which the investigator controls 
(manipulates) the independent variable and randomly assigns 
subjects to different conditions. 
Foetal gene 
expression 




Foetal programming is also referred to as prenatal 
programming and occurs during the embryonic and foetal 
developmental stages during pregnancy. It is theorised that 
the environment surrounding the foetus during the 
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developmental phase determines the disease risk during the 
later stages of pregnancy and throughout to adulthood. 
Findings The result of the analyses of the research data; in 





Patients with reading and writing skills that are inadequate to 
manage daily living and employment tasks requiring reading 
skills beyond basic level.  
Further education Refers to education at A levels up to Diploma levels. 
 
Generalizability The degree to which the research procedures justify the 
inference that the findings represent something beyond the 
specific observations on which they are based; in particular, 
the inference that the findings can be generalized from the 
sample to other settings or an entire population. 
Glucose A simple sugar which is an important energy source. It is a 
component of carbohydrates.  
Glycaemia The presence of glucose in the blood 
Glycaemic control Refers to the level of blood glucose control in someone with 
diabetes 
Glycogen Glucose stored as carbohydrates in the tissues of the body.  
 
Gluconeogenesis A pathway used by the body to create glucose from other 
molecules. Through this process, the body stores energy for 
the brain in the form of glucose. 
Haemorrhage Bleeding from a blood vessel 
HBA1c   Refers to glycated haemoglobin which identifies average 
plasma glucose concentrate in one’s blood.   
Health advocate A translator of direct service to non-English speaking 
pregnant women to assist and support them to make health 
care decisions that is appropriate to their individual needs. 
Health care 
professionals 
Refer to the clinicians and allied health professionals 
involved in the care of the women in this study. They 
include obstetricians, diabetologists, midwives, dieticians & 
health advocates. 
Hepatic Relates to the liver 




Commonly referred to as ‘good’ cholesterol.  
Homeostasis Characteristics of a system that regulates its internal 
environment to a level of stability. 
Hormone A chemical substance produced in the body that controls and 
regulates the activity of certain cells or organs.  
Human placental 
lactogen 
A hormone produced by the placenta. It breaks down fat 
from the mother to provide fuel for the growing foetus and 
this can lead to insulin resistance and carbohydrates 






A condition in the newborn in which the lungs are deficient 
in surfactant, which prevents their expansion and causes the 
formation of hyaline material in the lung spaces.  
Hyperglycaemia Blood sugar level much higher than normal range. ≥5.6 
mmol/l on fasting and ≥7.8 mmol/l post meals. 
Hypoglycaemia 
(neonatal) 
Measurement of blood glucose levels lower than 2.5mmols/l 
during the first 48hrs of life. 
Hyperinsulinemia Excessive levels of insulin circulating in the blood relative to 
the blood glucose level. 
Incidence Refers to the number of new cases diagnosed with a disease 
in a given area over a given period of time. 
Induction of labour The use of local prostaglandins with or without the use of 
intravenous infusion of oxcytocin to induce labour. This 
could follow the artificial or spontaneous rupture of 
membranes. 
Interpretivist A tradition from qualitative research. Combines qualitative 
data with propositions that can be tested into systems of 
beliefs whose manifestations are specific to a case.  
Intrapartum The period of pregnancy from onset of labour and 
throughout to the birth of infant/s. 
In utero In the woman’s womb; before birth. 
 
Ketogenesis The biochemical process through which organisms produce 
ketone bodies through the breakdown of fatty acids and 
ketogenic amino acids. 
Level of 
Significance 
Is the probability of rejecting the null hypothesis when it is 
true; for example, a significance level of 0.05 indicates a 5% 
risk of concluding that a difference exists when there is no 
actual difference.   
Linoleic acid An omega-6 fatty acid found mainly in plant-based oils eg 
vegetable oils. It is used in the biosynthesis of prostaglandins 
and cell membranes.  
Lipogenesis The metabolic formation of fat. 
 
Lipolysis The breakdown of fats and other lipids by hydrolysis to 
release fatty acids. Hydrolysis is the chemical breakdown of 
a component due to reaction with water.  
Longitudinal study A study designed to collect data at more than one points over 
short of long periods of time. 
Low density 
lipoprotein 
Commonly referred to as ‘bad’ cholesterol.  




Diseases causing damage to the larger blood vessels. 
Manipulation An intervention or treatment introduced by the researcher in 
an experimental or quasi-experimental study’ the researcher 
manipulates the independent variable to assess its impact on 
the dependent variable. 
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Mean  Often refers to the average of occurrence of a variable. A 
measure of central tendency, computed by adding all scores 
and dividing by the number of subjects. 
Measurement The assignment of numbers to objects according to specified 
rules to characterize quantities of some attribute. 
Median A descriptive statistic that is a measure of central tendency, 
representing the exact middle score or value in a distribution 
of scores; the median is the value above and below which 
50% of the scores lie. 
Metabolite A substance formed in or necessary for metabolism. 
 
Metabolise The process by metabolism 
Metabolism The chemical processes which occur within a living 
organism in order to maintain life. 
Methods (research) The steps, procedures and strategies for gathering and 
analysing the data in a research investigation. 
Micro-vascular 
diseases 
Diseases causing damage to the smaller blood vessels. 
Migration The movement of people in and out of an area. 
 
Miscarriage Defined as any spontaneous onset of delivery before 24 
weeks gestation. 
Mode of delivery Refers to the means by which the baby was born. 
 
Molecule The smallest particle in a chemical element or compound 




Essential fatty acids that help develop and maintain the 
body’s cells. They must be ingested because they cannot be 
synthesized by the body. They are classified as good fats and 
they help to lower bad cholesterol levels.  
Morbidity An alternative way of describing death.  
 
Morphology The study of how things are put together. 
 
Mortality The occurrence of an illness or disease.  
 
Multigravida A woman with one or more children. 
 
Myoinositol A vitamin-like compound structurally similar to glucose 
which is involved in the way the cells of the body 
communicate. 
Naturalistic Imitating real life or nature 
Neonatal A newborn infant under 28 days of age. 
 
Neonatal death Death of babies under four weeks of life. 
 
Neonatal jaundice Yellow discoloration of the baby’s skin up to ten days of 
baby’s life due to high bilirubin levels. 
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Nephropathy Disease of the kidney caused by damage to the small blood 
vessels or the units of the kidneys that clean the blood. 
Neuropathy Disease or dysfunction of one or more peripheral nerves 
typically causing weakness or numbness. 
Nominal Measure The lowest level of measurement that involves the 
assignment of characteristics to categories (e.g., males = 1; 
females = 2). 
Non-alcoholic fatty 
liver 
A build up of fat in the liver which should otherwise have 
very little or no fat. 
Non-esterified fatty 
acids 
Molecules released from triglycerides and are transported to 
the blood bound to albumin. They provide a large part of the 
body’s energy but only form a small part of body fat. 
Normal Delivery Any delivery conducted vaginally, without the use of 
instrumental aid. 
Oestrogen The primary female sex hormone responsible for the 
development and regulation of the female reproductive 
system and secondary sex characteristics. 
Oligouria The production and passing of small amount of urine. It 
measures <1ml/kg/hr. 
Ontological The study of the concept of existence or reality 
Outcome Variable A term sometimes used to refer to the dependent variable in 
experimental research; that is, the measure that captures the 
outcome of the experimental intervention. 
Pancreas A large gland in the stomach which secretes digestive 
enzymes into duodenum. In the pancreas is the islet of 
Langerhams which secretes hormones insulin and glycagon 
in the blood stream. 
Paresthesia An abnormal sensation, typically tingling or pricking, caused 
chiefly by pressure on or damage to peripheral nerves.  
Patient engagement Refers to the process of building the capacity of patients, 
families, carers professionals to facilitate and support the 
active involvement in their care to enhance the delivery of 
safe and quality care services. 








A common circulatory problem in which the arteries become 
narrow reducing blood flow to the extremities of the body, 
usually the limbs but mainly the legs. 
Peptidases An enzyme which breaks down peptides to amino acids. 
 





The failure of the normal circulatory transition that occurs 
after birth. This syndrome is characterised by pulmonary 
hypertension that causes hypoxemia secondary to right to 




Pharmacotherapy Medical treatment by means of drugs. 
Phenomenon The abstract entity or concept under investigation in a study, 
most often used by qualitative researchers in lieu of the term 
variable’. 
Phospholipids A type of lipid molecule that is the main component of the 
cell membrane.  
Placenta Placental development starts during the implantation of the 
blastocyst.  The trophoblast cells form the placenta and the 
inner cell mass forms the foetus and foetal cell membranes. 
Ponderal Index An indicator of relative fatness at birth measured by 
weight/length. Type 1 indicates that baby is proportionate 
while Type 2 is a low PI indicating a disproportionate 
measurement. 
Polyuria Excessive production of urine. 
Polyunsaturated 
fatty acids 
Essential fatty acids that help to develop and maintain cells 
of the body. They must be ingested because they cannot be 
synthesized by the body. These are considered as good fats.  
Polypeptide A linear chain of amino acids linked together. Amino acids 
are the basis building blocks of proteins.  
Population Number of individuals having some common characteristics, 
illness or disease.  
Positivist A tradition from qualitative research. A Positivist seeks to 
identify qualitative data with propositions that can be tested 
or identified in other cases. 
Post maturity Babies born after 42 weeks gestation. 
 
Postnatal Occurring after birth. 
 
Postpartum Refers to the period of pregnancy immediately after delivery 
and up to 6 weeks thereafter. 
Prenatal Occurring before birth. 
 
Preterm delivery Defined as delivery before 37 weeks gestation. 
 
Prevalence The number of people in a given population with a particular 
condition in a given time. The prevalence of a disease is 
calculated based on data collected and held on national 
registers.   
Primagravida A woman pregnant for the first time. 
 
Progesterone A hormone produced by the corpus luteum of the ovary. It 
plays an important part in the menstrual cycle and 
maintaining the early stages of pregnancy.  
Prospective Study A study that begins with an examination of presumed causes 
(e.g., cigarette smoking) and then goes forward in time to 
observe presumed effects (e.g., lung cancer). 
Proteases An enzyme which breaks down proteins to peptides. 
 
Public engagement Involves activities that bring researcher and the public 
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together. It is a process of two-way communication in which 
there is shared learning and both groups benefit from each 
other. 




Research using data obtained by the researcher from direct 
observation, focus groups, interviews, questionnaires and 
recordings made in natural settings. 
Quantitative 
research 
The process of objectively collecting numerical data to 
describe, predict or control variables of interest eg to test 
causal relationships.  
Randomisation The assignment of subjects to treatment conditions in a 
random manner (i.e., in a manner determined by chance 
alone); also known as random assignment. 
Reliability The degree to which a test consistently measured what it sets 
out to measure.  It is to do with whether a test when applied 
repeatedly to the same objects gives the same results every 
time.  Reliability is therefore concerned with consistency, 
stability and dependability.  However, it is not necessarily 
concerned with accuracy. 
Research The attempt to obtain new and transferable knowledge. It 
involves systematic inquiry that uses orderly, disciplined 
methods to answer question or solve problems. 
Research design The plan for addressing a research question, including 
specifications for enhancing the integrity of the study.  
 
Research Question 
A statement of the specific query the researcher wants to 
answer to address the researcher problem. 
Research team Individuals involved in the conduct of the research study. 
 
Results The answers to research questions, obtained through an 
analysis of the collected data; in a quantitative study, the 
information obtained through statistical tests. 
Retinopathy  Damage to the retina caused by abnormal blood flow. Often 
refers to as retinal vascular disease. 
Retrospective 
Study 
A study that begins with the manifestation of the dependent 
variable in the present (e.g., lung cancer) and then links this 
effect to some presumed cause occurring in the past (e.g. 
cigarette smoking). 
Saturated fats These are bad fats. They contain a high proportion of fatty 
acid molecules without double bonds considered to be less 
healthy than unsaturated fatty acids.  
Significant level The probability that an observed relationship could be 
caused by chance (i.e., as a result of sampling error); 
significance at the .05 level indicates the probability that a 
relationship of the observed magnitude would be found by 
chance only 5 times out of 100. 
Socio-economic Relating to or involving social and economic factors. 
 
Sponsor The organisation or partnership which takes overall 
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responsibility for proportionate and effective arrangement 
for the set-up, running and reporting of a research project. 
Spontaneous 
delivery 
Defined as any delivery occurring naturally without any 
external aid. 
Standard deviation Used statistic for measuring the degree of variability in a set 
of scores or dispersion of statistical population. 
Statistic An estimate of a parameter, calculated from sample data. 
 
Statistical analysis The organisation and analysis of quantitative data using 




A term indicating that the results obtained in an analysis of 
sample data are unlikely to have been caused by chance, at 
some specified level of probability. 
Statistical test An analytical procedure that allows a researcher to 
determine the probability that obtained results from a sample 
reflects true population parameters. 
Stillbirth Birth after 24 weeks gestation and no signs of life at birth. 
 
Subject An individual who participates and provides data in a study; 
term used primarily in quantitative research. 
Supplementation The addition of an extra element – omega-3 & -6 and 
placebo. 
Target population The entire population in which the researcher is interested 




Breathing disorder seen shortly after delivery in the newborn 
in early term or late preterm. The condition is characterised 
by rapid abnormal breathing which is short-lived. 
Trans fats A form of unsaturated fat created by hydrogenation where 
liquid oils are converted to semi-solid fats. Trans fats can 
also be found in meat and dairy products. 
Treatment The experimental intervention under study; the condition 
being manipulated – omega 3 & omega 6. 
Triacylglycerols Known as triglycerides which are simple types of lipids 
consisting of 3 long chain fatty acids esterified to glycerol  
Thrombocytopenia A condition characterised by low platelets in the blood. 
Platelets are necessary for clotting of the blood. 
Unblinding The process by which the allocation code of the intervention 
or treatment are broken (revealed) and become known to the 
trial team /subjects etc.  
Unsaturated fats These are good fats. They contain a high proportion of fatty 
acid molecules with one or double bonds in the fatty acid 
chain and are considered to be healthier than saturated fatty 
acids. 
Variable The degree to which values on a set of scores are widely 
different or dispersed. 
White Refers to indigenous British women and Whites from 
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1.1 Introduction and structure of the thesis  
1.1.1 Background 
Diabetes Mellitus (DM) is one of the most common medical disorders in pregnancy 
(Diabetes UK, 2014). Pregnant women can present with either pre-existing DM {Type 1 
diabetes mellitus (T1 DM) or Type 2 diabetes mellitus (T2 DM)} or develop the condition 
during pregnancy {gestational diabetes mellitus (GDM)}. A complex interplay between 
genetic and environmental factors can determine the aetiology of the disease type to be 
discussed in forthcoming chapter 2. T2 DM and GDM form the focus of this study. 
Women who present in pregnancy with T2 DM and GDM pose a huge challenge for 
clinicians who are constantly striving to optimise the care they receive in order to reduce 
potential risks such as miscarriage, pre-eclampsia, macrosomia, pre-term birth, stillbirth 
and birth injury resulting in poorer pregnancy health and outcomes (maternal and foetal) 
compared to non-diabetic women (CEMACH, 2007). Consequently, the cost implications 
of diabetes management to the National Health Service (NHS) and society as a whole are 
vast (Whicher et al, 2020). To narrow this disparity, new and evolving management 
strategies are employed to provide the best possible care by achieving optimal glycaemic 
control. Management includes lifestyle advice on healthy eating and exercise. 
Individualised pharmacological interventions may also be necessary to normalise blood 
glucose control, but achieving this can at times be challenging (Antonio Negrato et al, 
2012).  
Adequate maternal nutrition contributes to effective glycaemic control and is essential for 
foetal growth and development (Ji et al, 2017; Palmer, 2011). Infant growth and 
development, the short- and long-term health of offspring and pregnancy outcomes can be 
affected by dietary fat intake during pregnancy (Koletsko et al, 2007).  Long chain 
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polyunsaturated fatty acids (LCPUFAs) {(arachidonic acid (AA) and docosahexenoic acid 
(DHA)} are structural components of the cell and sub-cellular membranes and are 
necessary for optimal function of the immune, vascular and neuro-visual systems 
(Martinez 1992 & Clandinin et al, 1980). Foetal demand for these fatty acids is high, 
particularly in the third trimester when the brain is growing and rapidly accruing fat (Cetin 
et al, 2009). As the foetus has limited ability of synthesizing AA & DHA, foetal demand 
must be met by the mother through ingestion of foods rich in omega-3 fatty acids or 
supplements (Singh, 2005). LCPUFAs cannot be manufactured by the body and are often 
referred to as essential fatty acids (EFAs) because they must be obtained through oral 
intake (Greenberg et al 2008). Recommended guidelines on oral intake during pregnancy 
vary from 200mg (Koletzko et al, 2007), 250mg (EFSA, 2010) to 300mgs (ISFAAL). In 
the United Kingdom (UK), two to three (2-3) portions of fish with at least 1 portion of oily 
fish (eg. salmon, sardines and mackerel) are recommended weekly (European Food Safety 
Authority Scientific Committee, 2014) as fish consumption in pregnant women and women 
of childbearing ages are consistently low as shown in a European cohort study (1996-2004) 
(Leventakou et al, 2014).   
Previous observational studies have shown possible benefits of fish oils on specific 
maternal and neonatal outcomes. For example, omega-3 fatty acid can prolong pregnancy 
by 4 days (Olsen et al, 1992 & Makarides et al, 2010), which in obstetrics is a huge 
accomplishment which can be the difference between prematurity and maturity of babies 
and their subsequent health and wellbeing. However, most observational studies and 
randomised controlled trials (RCTs) which examined supplementation of pregnant women 
with omega-3 fatty acids, focused only on specific outcomes such as IUGR (Horvath et al, 
2007 & Olsen et al, 2000), preterm birth (Horvath et al, 2007 & Olsen et al, 2000), 
pregnancy induced hypertension (PIH) (Horvath et al, 2007),  pre-eclampsia (Olsen et al, 
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1990 & 2000) and infant and child health in areas such as neurological development 
(Crawford et al, 1976 & Crawford, 1993) and visual acuity (Clandinin et al, 1980). A 
systematic review on pregnancy outcome data (up to March 2006) on high risk women 
after supplementation with omega-3 fatty acid has shown a reduction in pre-term delivery 
but no significant difference in infant birth weight, rate of low birth weight, recurrence of 
IUGR, rate of caesarean section and pre-eclampsia (Horvath et al, 2007). However, those 
studies on pregnancy outcome were done on non-diabetic women.  
Earlier diabetic studies have shown depleted AA & DHA levels in pregnant women with 
T1 DM and their neonates (Ghebremeskel et al, 1998 & 2004), possibly resulting in poorer 
outcomes. The depletion of AA and DHA might be similar for women with T2 DM and 
their neonates as the activity of delta-6 and delta-5 which are necessary for the synthesis of 
AA and DHA were found to be impaired in individuals with T1 and T2 DM (Brenner et al, 
2000 & El Boustani et al, 1989). Reduced plasma fatty acid levels of AA & DHA were 
found in neonates of women with GDM compared to non-diabetics (Thomas et al, 2004; 
Wijendran et al, 2000 & Min et al, 2004), and the depletion of those fatty acids was greater 
in obese and overweight gestational diabetic women (Min et al, 2004).  Regardless, women 
of childbearing age have a great capacity of synthesising DHA (Burdge & Wotten, 2002 & 
Pawlosky et al, 2003) and possibly AA, as these fatty acids share the same synthetic 
pathway (Thomas et al, 2004).  Also, the depletion of AA & DHA can be corrected by 
insulin therapy (Shin et al, 1995). Combined, these factors could have a positive impact on 
the fatty acid status of women with GDM and T2 DM and their subsequent pregnancy 
outcomes. 
Two sub-set studies have been conducted on women with T2 DM and GDM of which I 
was involved. They have since been published (appendix 1.1). These studies have shown 
promising results. Supplementation with 600mgs DHA enhanced both maternal and foetal 
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DHA status in women whose pregnancies were complicated with T2 DM (Min et al, 2014) 
and maternal DHA status in women diagnosed with GDM (Min et al, 2016).  Based on 
these findings, participation in the nutritional study may have benefited women who 
received active supplements and their babies. Although this preliminary data has shown an 
improvement in maternal/foetal DHA status, what remains unknown is the impact that 
improved DHA status had on maternal and foetal wellbeing and pregnancy outcomes. 
More robust research was needed to demonstrate cause and effect. To date, no study has 
examined maternal and foetal outcomes measures (as described in chapter 3 – section 3.4) 
which come in line with other pregnancy outcome studies, following supplementation with 
omega-3 fatty acids. This study was conducted with this aim. The study results will 
contribute to filling that gap. It would be useful to evaluate the pregnancy outcomes of 
supplemented groups with and without diabetes to establish whether supplementation with 
omega-3 fatty acids had any effects on and within the various sub-groups and this was 
explored in chapters 6 & 7. The findings will be invaluable when caring for pregnant 
women with GDM and T2 DM and will act as the ‘pioneer’ of many more research studies 












1.1.2.1 Personal Interest 
For many years, I have worked as part of the multi-disciplinary team in the specialist 
antenatal diabetes clinic (SADC) at Newham University Hospital as an Advanced Clinical 
Practice Midwife in the role of diabetes specialist midwife (DSM). During this time, I have 
worked alongside obstetricians, diabetologists/endocrinologists and dieticians caring for 
women with diabetes in pregnancy and I have witnessed first-hand the adverse impact of 
diabetes on maternal and foetal health and well-being. Those poor outcomes were at times 
cyclical; believed to be associated to the many complex health needs with which some 
women presented. At times, I was consumed by feelings of helplessness. I strongly felt that 
there were several issues that needed to be addressed to optimise the pregnancy outcome of 
the Newham’s pregnant diabetic population which is socio-economically deprived, highly 
diverse and predominantly from South Asia (Pakistan, Bangladesh, India etc).   
Also, I recognised the higher prevalence of diabetes related problems among this high-risk 
group of pregnant women, particularly due to lack of engagement or inadequate levels of 
engagement with health care professionals (HCPs) and the care they provided. From 
observation, it appeared that the more engaged women were with HPs involved in their 
care, the more positive the impact on their and their babies’ health and pregnancy 
outcomes. Evidence from a review has shown a correlation between effective physician-
patient communication and improved health outcomes (Stewart, 1995). Effective 
communication is critical for client engagement. Therefore, one can conclude that client 
engagement is critical for optimising maternal and foetal outcomes; but strong empirical 
data through systematic review and meta-analysis within maternity are lacking. Therefore, 
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this aspect of care needed to be studied to have a better understanding of why these high-
risk women were not fully engaging with HCPs to optimise their and their babies’ health 
and wellbeing. The findings can then be used to better help and support women in this part 
of East London. This hypothesis was explored in the first phase of this study.  
Secondly, I have seen a significant number of women who are diagnosed with GDM on a 
weekly basis. The incidence seemed to be increasing over time and the gestational ages at 
which diagnosis was made appeared to be decreasing. That trend caused me concern. I was 
baffled as to why this was particularly as many of those women had no previous history of 
GDM but had other risk factors like raised body mass index (BMI) ≥30kg/m
2
 and family 
history of diabetes. The National Institute of Health and Care Excellence (NICE) (2015) 
guidance recommends that women with a previous history of GDM should be screened 
early and if the result is normal, repeat testing should be done at 24-28 weeks gestation. 
Women with other risk factors should be screened between 24-28 weeks gestation. From 
observation, it appeared that women with risk factors other than previous history of GDM 
were detected early (within first and second trimester of pregnancy) with GDM. Therefore, 
I wanted to establish the predominant risk factors for early detection of GDM and evaluate 
whether gestational age at diagnosis impacted on pregnancy outcomes. It was also critical 
to examine the appropriateness of NICE’s GDM screening guidance for use within a 
borough like Newham where there is a high multi-ethnic community and a high prevalence 
of diabetes. This area needed to be studied and has led to the second phase of the study 
which has explored the predominant risk factors for the early detection of GDM (<24 
weeks gestation) and the subsequent impact on pregnancy outcomes. The findings of this 
phase could have significant impact on strategic planning with appropriate and adequate 
resource allocation to improve the maternal and foetal health and wellbeing, and pregnant 
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outcomes of local women at risk of GDM, who tend to be obese/ overweight (NICE, 2015 
& Chu et al, 2007) and / or have first degree relatives with diabetes (NICE, 2015).  
As mentioned above, previous evidence has demonstrated that women with diabetes in 
pregnancy have poorer outcomes compared to non-diabetic women. The London borough 
of Newham is ethnically diverse and has a high prevalence of diabetes which resulted in 
women presenting in pregnancy with many co-morbidities which were either diabetes-
related or not. This has led me to believe that the pregnancy health and outcomes of 
diabetic women within my local hospital might be significantly worse compared to other 
boroughs within England where different population profiles exist and where the 
prevalence and incidence of DM vary.  
Also, care of women with GDM upon discharge seemed fragmented. There was no tight 
structure in place to manage women’s postnatal diabetes health following discharge from 
hospital. Prior to discharge, an oral glucose tolerance test (OGTT) appointment for 6-8 
weeks post-delivery was given to women with lifestyle advice. Upon discharge, women 
were re-referred to their general practitioners (GPs) who were responsible for chasing up 
and attending the OGTT results and subsequent annual reviews should T2 DM was not 
detected. Yet, some women with a previous history of GDM were presenting with high 
blood glucose levels in the first trimester in subsequent pregnancies, having not received 
appropriate follow-up care. Follow up care was like a lottery. Some women received 
annual diabetes screening from their GPs while others did not. Post-discharge quality of 
care was GP-dependent and whether women spoke English and were proactive to chase 
their GPs for annual diabetes screening appointments. Previous evidence has shown that up 
to 70 per cent of women with GDM would develop T2 DM within 5-10 years and earlier in 
some cases (Metzger et al, 2002). Therefore, it was critical to establish the postnatal 
prevalence of T2 DM after GDM. With that hard data, adequate resources can hopefully be 
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generated to organise appropriate screening and preventative programmes for the postnatal 
care of women diagnosed with GDM. This can lead to huge cost savings for Women’s 
Health Directorates and the wider National Health Service (NHS) in the immediate and 
long-term. 
As a senior midwife who always strives to provide quality care, I had a keen interest to 
research the areas highlighted above, but I did not have the financial capability and 
research experience to conduct the research. But, when the opportunity presented itself 
when the London Metropolitan University (LMU) collaborated with Newham University 
Hospital (NUH) to conduct a nutritional study among the pregnant diabetic women and 
offered the co-ordinator of that study to register to do a PhD, I positively embraced the 
opportunity. I was then tasked with leading and managing this project from set-up to study 
close-out.  
This nutritional study was conducted because no other well designed study has previously 
been done to evaluate the pregnancy health and outcomes of women with diabetes mellitus 
(DM) after supplementation with fatty acids. This study fills that gap. Also, for factors like 
lack of resources, research into this local client-group has not been conducted. To date, 
assumptions are being made about the pregnancy outcome of clients attending the SADC. 
Care provision is based on observation, intuition, findings from general research evidence 
and directives from bodies like the World Health Organisation (WHO) and NICE. While 
all these directives and measures have their place, true empirical evidence to answers vital 
questions is necessary to optimise the pregnancy outcome for diabetic women within the 





1.1.2.2 Why Newham? 
Newham is one of the most deprived boroughs in London (NCCG, 2017a) and deprivation 
may drive women and their families to engage in cheap and easy food options which can 
be detrimental to their health. Healthy eating forms part of the local Clinical 
Commissioning Group (CCG) agenda. Food vouchers which include fruits and vegetables 
are provided to the less privileged as part of that drive. But, throughout the borough, within 
close proximity to each other, there are many fast-food shops selling mainly ‘chicken and 
chips’ and other foods high in saturated fats and this is likely to inhibit the success of 
promotional work on healthy eating within the borough.  However, engaging with women 
during pregnancy; a time when they are more likely to be motivated to care for their and 
their baby’s well-being, could have been beneficial.     
Local women may simply not have the financial means of having a daily nutritional diet 
and many could be starting pregnant in poor nutritional health. Diets high in saturated fats, 
eaten over a considerable length of time can be detrimental to one’s health, likewise during 
pregnancy. Healthy eating which includes a reduction of saturated fats but an intake of 
polyunsaturated fats from oily fish are encouraged in pregnancy. Adequate nutrition is 
particularly important to promote positive pregnancy health and outcomes and achieve 
optimal glycaemic control in pregnant diabetic women. Saturated fats can impair insulin 
sensitivity which is already a metabolic challenge for diabetics (Riserus et al, 2009). 
Although that impairment may be corrected by insulin therapy (Shin et al 1995), which 
forms part of the management strategy for women with T2 DM and GDM, its effect on 




Therefore, this nutritional study can be justified, particularly as women in the borough do 
not live as long as other women in London and England as a whole (Newham London, 
2017). Women within the borough are predominantly non-Whites and are affected 
disproportionally by local deprivation factors of low income, overcrowding, fuel poverty 
and concern for crime (Newham London, 2017). Consequently, they tended to have poorer 
general health (Newham London, 2017) and presented in pregnancy with much co-
morbidity. Also, the co-morbidities associated with DM in a deprived area like Newham 
would suggest that women could have been starting pregnancy with depleted stores of AA 
& DHA.  
In prospective studies which investigated whether diabetes during pregnancy affected 
maternal and foetal AA and DHA status in women with T1 DM, T2 DM and GDM and 
their babies, it was revealed that the levels of both fatty acids were significantly reduced in 
red cell choline phosphoglycerides of mothers and in red cell and plasma choline 
phosphoglycerides of their neonates (Ghebremeskel et al 2004, Thomas et al 2005). In a 
pilot study of Korean women with GDM and their neonates, compromised red cell AA and 
DHA was found among those mothers, at levels similar to their British counterparts. 
Conversely, among the Korean women, their neonates had normal levels of plasma and red 
cell DHA. Since foetal DHA status is enhanced by increased maternal intake of DHA in 
pregnancy and Korean women had high daily intake of fish (75g/day vs 13-34g/day in 
European) (Ghebremeskel, 2000), it seems intuitive to assume that the normal DHA level 
found in the neonates could be due to the high intake of DHA from fish consumed by 
Korean gestational diabetics women.  Therefore, it seemed reasonable to assume that 
pregnant diabetic women within the borough of Newham could have benefited from the 
effects of fish oils supplementation in pregnancy to rectify their possible depleted stores of 
AA & DHA which in turn could have had a positive impact on their pregnancy health and 
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outcomes. Also, with the high prevalence of pregnant women with T2 DM and GDM 
within the borough and women from the Black and minority ethnic (BAME) groups 
disproportionally having poorer maternal and birth outcomes (Knight et al 2018, Garcia et 
al 2015 & Office of National Statistics 2013), the effects of omega-3 supplementation 
could have been more discernible and impacted on a wider cross-section of women than if 
the study was conducted in a wealthier borough. Ethnically-related differences in maternal 
omega-3 and omega-6 fatty acid intake during pregnancy may exist due to varied levels of 
fish consumption which may lead to disparity in birth outcomes (van Eijsden et al, 2009). 
However, baseline data taken for Min et al (2014 & 2016) studies did not reveal any 
difference in omega-3 fatty acid level between Caucasians & other ethnic groups. An 
overview of each chapter follows. 
 
1.1.3 Overview of each chapter 
Chapter 2 
This chapter has provided a broad overview of the current literature available on T2 DM, 
GDM and the impact of these conditions on pregnancy and pregnancy outcomes. Also, 
current available evidence is provided on essential fatty acids (EFAs) (AA & DHA) 
supplementation during pregnancy and impact on pregnancy outcome. The prevalence 
(global, national and local) of T2 DM (prior to and during pregnancy) and GDM, their 
associated risk factors, aetiology, pathophysiology, diagnosis, complications and 
management with specific focus on supplementation with essential fatty acids (AA & 
DHA) are areas covered within this chapter. This background information sets the scene 




This chapter has outlined the materials and procedures used to conduct the study which 
encompassed the study design including the inclusion/exclusion criteria, recruitment and 
follow up process of participants, intervention and blinding, data collection and analysis. 
These elements provided clarity to the research process and formed the foundation on 
which experimental chapters (4 – 7) were conducted.   
 
Chapter 4 
Chapter 4 explored the socio-cultural, economic and demographic factors that influenced a 
pregnant woman’s decision on whether or not to engage with HCPs on the nutritional study 
and the impact that level of engagement / lack of it had on pregnancy outcomes. Adequate 
nutrition is considered critical to diabetes management and women with T2 DM and GDM 
are considered ‘high risk’ and being offered the opportunity to engage with HPs to improve 
their nutritional status could have been beneficial to maternal and foetal wellbeing. This 
chapter formed the bedrock for this study, has set the scene for the upcoming 3 phases of 
the study in chapters 5 - 7 and has influenced the distribution of subjects in each of those 
phases. 
Particularly, for the RCTs conducted in chapters 6 & 7 to be successful, it was necessary to 
provide women with the information in the language that they understood, preferably face 
to face. Supported by health advocates (HAs) and patient information leaflets (PILs) 
translated into 5 different languages, a better understanding of the factors which fostered 
engagement with HCPs were established. Findings from this chapter were invaluable to 
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HCPs on the approach to take for the recruitment and follow-up processes to be successful. 
For example, offering women the choice of hospital or home visits seemed beneficial.   
 
Chapter 5 
Women with GDM form the largest group of women who attended the specialist 
pregnancy antenatal diabetes clinic (SADC). Therefore, this group would have an 
overwhelming impact on the results of any research conducted on the local SADC. It was 
therefore imperative to assess the local screening programme in meeting the needs of those 
with risk factors of GDM, in order to identify women early and provide optimal care 
management for women at risk and those confirmed with the condition. Predominant risk 
factors for the early detection of GDM were examined and NICE’s recommendation on 
screening for GDM has also been evaluated in the context of its appropriateness for use 
within a highly diverse population like Newham’s. These formed the focus for this chapter. 
This study is the first large scale study to evaluate the pregnancy outcomes of the SADC 




This chapter has utilized data from women who were recruited into the nutritional study to 
evaluate the maternal and foetal health and pregnancy outcomes after supplementation 
with omega-3 fatty acid in women whose pregnancies were complicated with GDM. 
Maternal outcome measures were onset of labour, mode of delivery, pregnancy loss and 
hypertensive disorders in pregnancy while foetal/neonatal outcomes were gestational ages 
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at delivery, low birth weight, prematurity and admissions to special care baby unit 
(SCBU). Pregnancy outcomes were also evaluated in the context of diabetes management. 
Demographic (age, ethnicity, language parity, BMI) and clinical (chronic medical 
problems & pregnancy complications) characteristics were also examined. This chapter 
forms a central part of the thesis and the findings can have huge implications for future 
midwifery practice and research. A comprehensive evaluation of maternal and foetal 
outcomes would therefore be highly beneficial for the nutritional advice provided to 
women at booking and throughout pregnancy.  
 
Chapter 7 
The focus of this chapter was similar to that of chapter 6 except that maternal and foetal 
outcomes were of women with T2 DM and women without any form of diabetes after 
supplementation with omega-3 fatty acid. Demographic and clinical data as outlined in 
chapter 6 were also examined. Women with T2 DM formed the second largest group of 
women who attend the SADC and the results of this chapter coupled with the evidence 
from the two previous chapters on GDM would afford a comprehensive evaluation of the 
SADC and provide invaluable data for future care planning of these high risk groups. This 
chapter also forms a central part of the thesis. 
 
Chapter 8 
Chapter 8 has summarised the main findings of this thesis and the unique contribution this 
thesis has made. Also, I have highlighted the strengths and limitations of each phase of the 




In summary, I have established the factors which have influenced women’s decision on 
whether or not to engage with HCPs on the nutritional study and evaluated the impact of 
engagement /non-engagement on maternal and foetal outcomes. The dominant risk factors 
responsible for early detection of GDM and the impact of those factors and the time of 
diagnosis on maternal and foetal outcomes were examined. Supplementation with fish oils 
in women with GDM and T2 DM on pregnancy outcomes was also explored.  
1.1.4 Structure of the theses 
This thesis is presented over eight chapters and has four phases. This first chapter details 
the purpose of the study and provides an overview which includes my personal and 
professional motivation and how these have influenced the area of study.  The process of 
this study is as demonstrated in (flow chart 1.1).  The structure of this thesis is as described 
hereunder.  
Prior to the exploration of the experimental chapters to address the above issues raised, an 
introduction to the research problem will be made encompassing a brief study overview 
followed by an extensive literature search which draws on previous empirical data to 
outline the research background to this study. This feeds into the chapter on the conduct of 
the study (chapter 3) followed by the experimental chapters (as described in 1.1.3) and 
culminating with the final chapter which revisited the aims to establish whether the data 
presented supported the hypotheses. This was done through a process of reflection on each 
experimental chapter. The strengths and limitations of the study are then described 














Chapter 2:  
 















2.1 Chapter overview 
 
Information pertinent for this thesis is critically examined within this chapter. It sets the 
scene with background information for all preceding chapters of this study. I will also 
attempt to identify gaps in the literature which my study will try to address.  
An overview of the epidemiology, aetiology, complications, management and pregnancy 
outcomes of women with T2 DM and GDM is provided with the latest insight into the 
global and UK epidemic. Information on pregnant women’s (with T2 DM & GDM) 
engagement with HCPs, risk factors associated with early detection of GDM and 
nutritional supplementation with omega-3 and omega-6 fatty acids and their impact on 
maternal and foetal outcomes also form the background of this chapter.   
 
2.2  Search strategy 
2.2.1 Aim and process 
A comprehensive literature review was undertaken for this study. Accuracy and precision 
were aimed for from mainly biomedical published evidence, to achieve a quality search 
from literature written in English but inadequacies in the indexing of research papers, 
human frailty, spelling differences and time constraints were possible limitations to 
capturing all available literature. 
The literature search started from the research idea to put the research problem in context. 
It continued throughout the period of the research study to keep abreast with and facilitate 
the use of newly published relevant data. However, the main bulk of the search was 
conducted in the early stages of the research process.  
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The aim was to obtain evidence which focused on pregnancy outcomes of women with T2 
DM and GDM with reference to client engagement with HPs, risk factors of GDM and 
omega-3 and omega-6 fatty acids supplementation. The postnatal health of women with 
GDM with and without supplementation with fish oils was also included in this aim.  
The objectives while conducting this review were to describe the epidemiology of GDM 
and T2 DM with reference to pregnancy, current screening guidelines and diagnosis of 
GDM, pregnancy complications and management of GDM and T2 DM, factors which 
influence client engagement / lack of engagement with HCPs, the impact of omega-3 and 
omega-6 fatty acids on maternal and foetal wellbeing and the pregnancy outcomes of 
women with GDM and T2 DM with reference to client engagement, early detection of 
GDM and supplementation with omega-3 and omega-6 fatty acids in women with T2 DM 
and GDM; all within the context of the population and health profile of pregnant women 
within the borough of Newham. 
 
2.2.2 Participants  
 
Participants were pregnant women of any gestational age, parity, demographic and socio-
economic background, regardless of their medical and/or obstetric history. All 
observational studies, RCTs, systematic reviews and meta-analysis of RCTs and RCTs of 
pregnant women with or without GDM and T2 DM and supplemented with omega-3 and 
omega-6 fatty acids regardless of time and duration of intervention and dose regimen, were 





2.2.3 Data Sources 
Data sources included Pubmed, Elsevier, Medline, Cinahl, Embase, the Cochrane Library 
databases including the Pregnancy and Childbirth’s Trial Register. Google Scholar 
searches provided most electronic academic journals and hard copies from the local library 
were reviewed as these provided past and recent peer-reviewed articles which denoted 
quality having gone through a rigorous review process. Related articles from references list 
directed searches in a variety of journals and books. The Cochrane database including the 
Pregnancy and Childbirth’s Trial Register provided the best available evidence through the 
reviews of results from RCTs.  
 
2.2.4 Search terms 
Search terms used subjects and text words searches using simple Bolean logic. For 
example, for experimental chapter 1, search terms included client/patient engagement and 
health professional/clinicians, client/patient engagement with NHS / health service, 
client/patient engagement with pregnancy diabetes services / maternity services, barriers / 
influential factors to engagement of women with GDM/T2 DM, deprivation/ethnicity and 
client engagement and client/patient engagement and pregnancy outcomes. Search terms 
used for experimental chapter 2 included gestational diabetes mellitus/ GDM, prevalence 
of gestational diabetes mellitus / GDM, risk factors of gestational diabetes mellitus / GDM, 
ethnicity and risk factors of gestational diabetes mellitus / GDM, screening for gestational 
diabetes mellitus / GDM, screening criteria for gestational diabetes mellitus / GDM, NICE 
guidance on screening and management of gestational diabetes mellitus / GDM, early/late 
detection/diagnosis of gestational diabetes mellitus / GDM, effects  of gestational diabetes 
mellitus / GDM, obstetric / midwifery complications {macrosomia, IUGR, birth weight, 
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hypertensive disorders (high blood pressure, pre-eclampsia, eclampsia), prematurity, 
hypoglycaemia, respiratory distress syndrome, prolonged pregnancy, modes of delivery, 
admission to special care baby unit} and gestational diabetes mellitus / GDM and 
management of gestational diabetes mellitus / GDM. Similarity existed in the search terms 
used for phases 3 and 4 except for the diabetes type (GDM / T2 DM) except where specific 
peculiarities existed with each group eg. postpartum glycaemic status for women with 
GDM and not for women with T2 DM. Search terms included, fish oils, omega-3 fatty 
acids, long chain polyunsaturated fatty acids (LCPUFA) in and outside pregnancy, obesity 
and pregnancy complications / outcomes in GDMs/ T2 diabetics, obesity and fatty acids 
absorption, effects of fish oils on mother / baby (foetus)/neonate.  Pregnancy complications 
/ outcomes were as listed above with focus on maternal (hypertension, pre-eclampsia, 
eclampsia, miscarriages, induction rate, gestational length, reasons for and caesarean 
section rate) and foetal / neonatal (congenital abnormality, stillbirth, neonatal death, 
gestational ages at birth, birth weight, apgar scores, macrosomia, low birth weight, 
admission to special care baby unit and reasons for admission).  
 
2.2.5 Search results  
The literature screening process and results are described in flow chart 2.1. An 
overwhelming number of results were found on T2 DM and GDM (n=17,435). The results 
included literature on prevalence, incidence, screening, diagnosis, management, impact on 
health outside (T2 DM) and during pregnancy (T2 DM and GDM) on maternal and foetal 
health and wellbeing and their pregnancy outcomes. Some articles also covered both 
conditions, particularly when discussed within the context of pregnancy. The sheer volume 
of articles found meant that it was impossible to include all relevant article so only the 
most pertinent were included. 
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The results on omega 3 fatty acid in pregnancy was also substantial (n=4157) but when 
screened within the context of pregnant women with T2 DM and GDM, very little 
literature was found deemed appropriate (n=78). This meant that references within this 
thesis were primarily of data on supplementation of pregnant women without diabetes. 
Also, no trials were found on comprehensively evaluating maternal and foetal outcomes 
(as identified under study design and methods). Rather, specific aspects of pregnancy 
outcomes measures such as pre-eclampsia, birth weight and IUGR were evaluated after 
fish oil supplementation. Other articles were found on the prevention of T2 DM and GDM 
and were used as supporting evidence within this thesis.  
Finding literature on pregnant women’s engagement with HCPs was challenging. Only 1 
article was found on the primary outcome measure of client engagement with HCPs. Most 
results found were on patient engagement which described service users’ involvement in 
committees including at strategic levels in the formulation of health policies as opposed to 
the way clients/patients engaged with HPs and the services made available to them and the 
subsequent impact on their health and wellbeing, following engagement.  
When screened for appropriateness, the most relevant literature was selected and used 
(n=447) as referenced within this thesis. Other literature on areas such as research, pre-
eclampsia, obesity, health inequalities, the demographic and health profile of Newham and 
local and national policies and directives were also used as supporting evidence and 







           Flow chart 2.1: Literature screening process 
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2.3 The Evidence 
2.3.1 Overview 
Globalisation has impacted on the increasing size and diversity of the UK population with 
1 in 4 births of women born oversees (Higginbottom, 2019). Disparities exist between the 
birth outcomes of Black, Asian and Ethnicity Minority (BAME) women and those of the 
indigenous group, with adverse outcomes more common among the former group (Garcia 
et al, 2015).   
Ethnicity is a key characteristic of developing pre-existing diabetes (Type 1 & Type 2) 
(Buschur et al, 2018 & Vora, 2010) and GDM (Buschur et al, 2018; Mc Donald et al, 
2015). Risk factors of pre-existing diabetes and GDM are the same and they also share 
same metabolic abnormalities (insulin resistance and hyperinsulinemia (Ben Slama, 1997). 
Women with these conditions have poorer birth outcomes than women without the 
condition (Abu-Heija et al, 2017). This poses a huge challenge for HCPs. Planning and 
delivering services that are culturally specific in and within the various ethnic groups, to 
optimise maternal and foetal outcomes are critical (Higginbottom, 2019). An adequate and 
effective screening programme for GDM and an effective management strategy for this 
condition and T2 DM throughout pregnancy and the immediate postnatal period should 
form the nucleus of all service planning.   
The experience of pregnancy and childbirth is very complex and multidimensional. 
Various emotions are experienced, but pregnancy is primarily a time of happiness for most 
women, their partners, family members and friends. Women’s hope is for ‘everything to go 
well’ for them and their babies from booking and throughout to the postnatal period and 
beyond. HCPs need to provide the bedrock on which that positivity can thrive through 
adequate and appropriate information provision and individualised woman-centred care 
and support. Women can then feel empowered to positively engage with the services 
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available to them to enhance their pregnancy health and pregnancy outcomes (National 
Midwifery Review, 2016 & WHO, 2015).  
Previous reductionist paradigm that the foetus is not affected by its environment is eroding 
as new evidence on epigenetics (Kluny & Dillard, 2014) and foetal origins hypotheses 
(Barker, 2007) emerge. For example, maternal stress can adversely impact on the foetus 
and can have long-term consequences (Kluny & Dillard, 2014).  Likewise, it is postulated 
that coronary heart disease and T2 DM may originate from maternal nutrition during intra-
uterine development (Barker, 2007). Paul (2010) in her work on foetal origins of adult 
disease supports these views.  
Similarly, maternal nutrition determines the intrauterine environment (foetal programming) 
and is critical for maternal and foetal well being (Myatt & Powell, 2010), placental transfer 
of long chain polyunsaturated fatty acids (Larque et al, 2011), foetal growth and neural 
development (Innis, 2007; Crawford, 1993 & Crawford et al, 1993), pregnancy outcomes 
(Salvig & Lamonth, 2011) and the long-term health of the offspring (McNarara & Carlson, 
2006).  Nevertheless, as fatty acids cannot be synthesised by the body, they need to be 
ingested in the maternal diet through foods and/or supplements. Previous work has shown 
that through a physiological mechanism, an appropriate balance exists between AA and 
DHA which can be beneficial for cell membrane stability and function (Ghebremeskel et 
al, 1999). This is an important phenomenon since a balance of both AA and DHA is 
required for adequate supplementation in pregnancy (Monique et al, 2000).  Combined, 
current data suggest that LCPUFAs in pregnancy is critical for optimal maternal and foetal 
health, and possibly their pregnancy outcome. As limited work is done on women 
supplemented with fatty acids in diabetic pregnancies, further work of this phenomenon is 
needed to explore the impact on maternal and foetal outcomes in a deprived borough like 
Newham, where no previous work has been done and where pregnant women can present 
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with various co-morbidities, which may or may not be related to DM. More detailed 





2.3.2.1 Diabetes Mellitus (DM) 
2.3.2.1.1 Prevalence globally and in UK  
The global prevalence and incidence of diabetes mellitus (DM) have met epidemic 
proportions. In 2014, the number of people living with diabetes had risen from 100 million 
to 422 million and that increase was more rapid in middle- and lower-income countries. 
Among adults age 18 and over, there was an increase from 4.5% to 8.7% {(World Health 
Organisation (WHO) (2018)}. In 2011, the estimated prevalence of diabetes globally was 
366 million and it was forecasted to affect 642 million by 2040 (Diabetes UK, 2019).  
In the UK, the prevalence in 2012 was 5.8 % of the population and this figure had 
increased to 6.0 % in 2013 and 6.2 % in 2014.  More recently, this number has doubled to 
3.9 million, which when added to the near million undiagnosed T2 diabetics who are 
unknowingly living with the condition, this equates to 4.8 million (Diabetes UK, 2020). Of 
this total 8 per cent has T1DM and the remaining 90 per cent has T2DM (Diabetes UK, 







2.3.2.1.2 Prevalence of diabetes in pregnancy 
Diabetes is the most common pre-existing medical disorder complicating pregnancy in the 
United Kingdom (UK) (Diabetes UK, 2014). In the UK, approximately 700,000 women 
give birth each year and up to 5% of these women have either pre-existing diabetes or 
GDM. Of the women who have diabetes during pregnancy, approximately 5% have T2 
diabetes and 87% have GDM which may not resolve after pregnancy (NICE, 2015). 
Since 1989, the St. Vincent declaration stated as a five-year goal that the ‘outcome of the 
diabetic pregnancy should approximate that of the non-diabetic pregnancy’ (Balen, 2007). 
Changes in management strategies in areas of pre-conceptual, antenatal and neonatal care 
were acclaimed to that achievement, as combined, they were believed to contribute to the 
reduction in the morbidity and mortality rates of infants of diabetic mothers.  However, 
despite the notion that care delivered within a multi-disciplinary context is paramount to 
reduce adverse outcomes (NICE, 2015), all high-risk pregnancies, including those with 
abnormal blood glucose levels, continue to pose significant challenges to health care 
professionals.   
Consequently, management of the pregnant diabetic women is continuously an evolving 
process, which takes into account the aetiology of the disease, one’s demographic, socio-
economic and lifestyle factors which include adequate nutrition.  Also, the political bias of 
one’s environment at local and national levels can be influential. Therefore, health care 







2.3.2.1.3 Definition and Concept  
Diabetes Mellitus (DM) is ‘a metabolic disorder of multiple aetiology characterised by 
chronic hyperglycaemia with disturbances in carbohydrate, fat and protein metabolism 
resulting from deficiencies in insulin secretion, insulin action, or a combination of both’ 
(WHO, 1999).  DM occurs when normal glucose metabolism becomes impaired. The 
pancreas does not produce enough insulin that the body needs or when the body is unable 
to effectively utilize the insulin produced by the pancreas (WHO, 2018). This defect in 
insulin secretion is ‘caused by autoimmune destruction of the beta cells of the pancreas, 
insulin action due to insulin resistance, or both’. Insulin resistance is the inability of the 
body to respond to and utilise available insulin (Matthews, 2008).  
 
2.3.2.1.4 Signs and symptoms 
The signs and symptoms of diabetes (Table 2.1) vary considerably in the rate of onset, the 
severity of the condition and the type of diabetes (Holt, 2009).  T1 DM can present acutely 
with individuals being unwell and ketoacidosis without recognising initial symptoms or 
subacutely with polyuria, weight loss, thirst and polydipsia (Meeking, 2011). T2 DM has a 
latent, asymptomatic period of sub-clinical stages and remains undiagnosed for many years 
(Ramchandran, 2014; Meeking, 2011). Symptoms for T2 DM can include thirst, polyuria, 
fatigue and blurred vision and individuals can present with skin infections, cellulitis, 
genital candidiasis or urinary tract infection and / or microvascular and macrovascular 





2.3.2.1.5 Cost to the National Health Service (NHS) 
 DM is a huge public health concern. Data recently synthesized by Diabetes UK has shown 
that DM places a significant burden on the UK society and specifically the NHS. The NHS 
spends approximately £10 billion annually on the disease and of that total, 80% is spent 
treating diabetic related complications and accounted for 1:6 hospital inpatients’ 
admissions. At the time of diagnosis of T2 DM, one-third of individuals have suffered a 
microvascular complication. Complications included 530 myocardial infarctions and 175 
amputations, weekly. Additionally, nearly 40% of people living with DM have some form 
of psychological ill-health. Despite these complications, 57% and 42% individuals with 
Type 1 and T2 diabetes, respectively, do not attend all their annual diabetes review 
























   
 
      Table 2.2 Micro- and macrovascular complications of diabetes 
Micovascular complications Presentation 
Retinopathy Visual impairment or a chance 
discovery 
Nephropathy Proteinuria, hypertension or 
nephrotic syndrome 
Neuropathy Painful sensory peripheral 
neuropathy, mononeropathy, carpel 
tunnel syndrome, amyotrophy or 
foot ulceration 
Macrovascular complications Presentation 
Coronary Angina or myocardial infarction 
Cerebral Stroke, transient ischaemic attacks  
Peripheral Intermittent claudication, rest pain, 
ischaemic leg 







The diagnosis of DM is made on either a fasting blood glucose of ≥7.0mmol/l and / or two-
hour blood glucose of ≥11.1mmol/l after using the World Health Organisation (WHO) 
screening tool of 75g oral glucose load. With signs and symptoms of diabetes (as listed 
above), a random blood glucose level of ≥11.1mmol/l was also be used to make a 
diagnosis of diabetes. Additionally, in 2011 WHO declared that HBA1c can also be used 
for the diagnosis of the condition, but this group was excluded from this study. Glucose 
levels ≥48mmol/l (6.5%) confirms a diagnosis of DM, although it is stated that values 
below this value does not exclude diabetes. Nevertheless, more scientific evidence is 
needed to make that diagnosis (Diabetes UK, 2015; WHO, 2011). Alternatively, many 
complications of the disease have been known to present with detrimental effects of 
hyperglycaemia with specific micro-vascular (diabetic retinopathy, nephropathy and 
neuropathy) and macro-vascular (coronary heart disease, peripheral heart disease and 
stroke) diseases (Fowler, 2008) which often led to diagnosis of the disorder (NICE, 2008).   
 
2.3.2.1.7 Types of Diabetes Mellitus 
Various factors have influenced the classification of diabetes which has changed over time. 
As the aetiology of the disease became better understood, it became more difficult to 
categorise diabetes (Todd, 2010). T1 DM was renamed from insulin dependent diabetes 
mellitus (IDDM) which was previously referred to as juvenile diabetes.  Similarly, T2 DM 
was redefining from non-insulin dependent diabetes mellitus (NIDDM) previously called 
mature onset diabetes. Gestational diabetes mellitus (GDM) which is diabetes detected 
during pregnancy following screening of women with risk factors (NICE, 2015) will be 
explored further in chapters 5 & 6. Additionally, other classifications of glucose regulation 
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which are less common and less understood exist (American Diabetes Association, 2010 & 
2015; 2008) (Table 2.3). Categorizing an individual into a diabetes type depends on the 
circumstances at the time of diagnosis and therefore many diabetic individuals do not fit 
solely into a single type (American Diabetes Association, 2010). The Expert Committee on 
Diagnosis and Classification of Diabetes Mellitus has recognised individuals who fit into 
two groups whose plasma glucose levels are above normal values but not high enough to 
be classified as having diabetes. These are impaired fasting glucose (IFG) (fasting plasma 
glucose between 6.1 – 6.9 mmol/l) and impaired glucose intolerance (IGT) (2-hour value 
of OGTT, ≥7.8 – 11.0 mmol/l) which are often referred to as pre-diabetes (Expert 
Committee on Diagnosis and Classification of Diabetes Mellitus, 1997). 
Below, a brief overview of T1 DM will be provided for an umbrella view of DM but T2 






























2.3.2.1.7.1 Type 1 Diabetes Mellitus (T1 DM) 
2.3.2.1.7.1.1 Prevalence 
In 2015, approximately 542,000 children were living with T1 DM worldwide and regional 
differences exist. That figure was forecasted to increase when adults living with the 
condition were added. In the UK, the incidence is approximately 10% of all people 
diagnosed (Diabetes UK, 2016).  
 
2.3.2.1.7.1.2 Risk factors 
Numerous studies have shown a link between T1 DM and familial (Stefan et al, 2014) and 
environmental (Gillespie et al, 2004; Kaila et al, 2003 & Metcalf et al, 2001) factors and 
viral infections (Rodriguez-Calvo & von Herrath, 2015), but the latter remains debatable 
(Shaheen et al, 2020, Scobie and Samaras, 2010 & Petzold et al, 2015).  
 
2.3.2.1.7.1.3 Aetiology  
Type 1 DM is a metabolic condition in which the beta cells of the pancreas produce no 
insulin. The rate of destruction varies between individuals but tend to be rapid in infants 
and children and slower among adults (Zimmer et al, 1994). Beta cell destruction is 
marked by production of antibodies. Over ninety per cent of the beta cells destruction 
would have occurred before signs and symptoms of T1 DM are manifested. This type of 
diabetes is more common among children and young adults, but as the architecture of T1 
DM becomes better understood, this type can be detected in a wider spectrum of ages 
(American Diabetes Association, 2003). Individuals with T1 DM will require daily insulin 




2.3.2.1.7.2 Type 2 Diabetes Mellitus  
2.3.2.1.7.2.1 Prevalence 
Type 2 diabetes mellitus (T2 DM) has met epidemic proportions, particularly in 
developing countries where approximately 80% of diabetics live (Nanditha, et al, 2016). 
Worldwide (WHO, 2018) and nationally (ONS, 2019), T2 DM is the most common form 
of diabetes. In the UK, the prevalence is between 90-95% (ONS, 2019), estimated to be 1:6 
(6% of the population). There are nearing one million individuals unknowingly living with 
undiagnosed T2 DM (Diabetes UK, 2019), which can have an impact on the prevalence 
and incidence of the disease. 
 
2.3.2.1.7.2.2 Risk factors 
Risk factors of DM (Box 2.1) can be complex and varied. With the proliferation in the 
prevalence and incidence, promotional work increases to raise awareness of the risk 






                            Box 2.1: Risk factors of type 2 diabetes mellitus 
 
2.3.2.1.7.2.3 Age 
The prevalence of diabetes increases with age.  In the UK, one in twenty individuals over 
the age of sixty-five years has diabetes compared to one in five in the eighty-five years and 
over age group (DOH, 2002). Recent figures by Diabetes UK (2015) have shown a similar 
trend. People in the most deprived areas of the UK are 1.5 times more likely than the 
average to have DM, whatever the age (DOH, 2002). 
 
2.3.2.1.7.2.4 Ethnicity  
Significant inequalities exist in the risk of developing T2 DM which is more prevalent 
among the less affluent population (Nanditha et al, 2016; DOH, 2002).  A prevalence study 
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has shown a higher incidence of T2 DM among South Asians than among their Caucasian 
counterparts (Akhter et al, 1996). T2 DM among South Asians is estimated to be more than 
150% between 2000 and 2035. Age, urbanisation and lifestyle factors were described as 
major determinants with adverse intra-uterine environment and subsequent epigenetic 
changes labelled as contributory factors (Nanditha et al, 2016). South Asians 
(Bangladeshis, Pakistanis and Indians) are the largest ethnic groups in urban locations in 
the UK (Khuti et al, 2009), and T2 DM is 6 times more common among this group (Khuti 
et al, 2009; Akhter et al, 1996) and up to three times more common in Afro-Caribbeans, 
compared to the indigenous population (Akhter et al, 1996).   
Individuals in South Asian ethnic groups develop diabetes earlier and with lower BMIs 
(He at al, 2001 & Deurenberg et al, 1998). It is hypothesised that evolutionary changes are 
believed to be responsible for this. Traditionally, consumption of foods high in 
carbohydrates among these ethnic groups was considered necessary for dealing with 
difficult nutritional provisions and arid conditions in which they or their fore parents lived. 
This in turn developed a high efficiency in the metabolism of carbohydrates. However, as 
individuals from these ethnic groups become westernised; habits have changed to a more 
sedentary lifestyle with the consumption of high-sugar, high-fat foods and processed foods. 
The beta cells then become unable to cope with the dietary changes, resulting in 
hyperglycaemia and the diagnosis of T2 DM (Holt, 2009). The change in lifestyle is 
presumably seen as symbols of positive achievements. However, generalisation should be 
avoided because dietary preferences among ethnic groups can be diverse. 
A similar phenomenon is that the risk of diabetes in adult life is highest among those who 
were exposed to intra-uterine under nutrition and subsequent exposure to an affluent diet 
resulting in a metabolic challenging environment and increased rates of T2 DM among 
individuals in Asia and the Pacific (Li et al, 2010). 
40 
 
2.3.2.1.7.2.5 Obesity and sedentary lifestyle 
 In the UK, approximately twenty-five per cent of the female population are obese and 
thirty-two percent are overweight (National Obesity Observatory, 2012). Individuals with 
T2 DM are often obese or overweight (Holt & Kumar, 2015; Meeking, 2011). T2 DM is 
often described as a lifestyle disease because environmental factors like sedentary lifestyle 
and increasing weight are inextricably linked to the development of the disease state 
(Boffetta et al, 2011). Approximately, 75-80% of individuals with T2 DM are obese. For 
every 1kg increase in body weight, there is a 9% relative risk of developing T2 DM 
(Mokdad et al, 2000).  T2 DM and obesity result in insulin resistance (Ben Slama, 1997). 
The infiltration of fat cells into the pancreatic islet cells exacerbates the effects of insulin 
resistance. This results in premature and rapid decline in the function of the beta cells in 
maintaining an increased insulin output (Haslam & James, 2005).  
Boffetta et al (2011) in a cross-sectional study found a strong correlation between BMI and 
prevalence of DM among Asians by age, country and other risk factors. Genetics also has a 
strong link to T2 DM; stronger than that of T1 DM (Scobie & Samaras, 2010).  An 
epidemiological study among the Pima Indians has shown an increased risk of obesity and 
T2 DM in offspring exposed to maternal obesity and diabetes (Ma et al, 2015; Pettitt et al, 
2004).  Socio-economic factors are determinants of health and well-being (Psaltopoulou et 
al, 2017). Low educational attainment, absence of wealth and living in low-income areas 
and countries are believed to be predictors of weight gain and obesity (Cohen et al, 2013; 
Kunst et al, 1998). Independent of BMI, central obesity is strongly associated with the risk 
of developing DM. However, the debate continues as to whether obesity is a problem of 
the lower- middle- or higher income households and countries (Dinsa et al, 2012).  
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As diabetes and obesity reach worldwide epidemic proportions, the concept of insulin 
resistance and its impact on health are gaining more prominence to inform health policy 
(Wilcox, 2005). Other metabolic risk factors of raised blood pressure and hyperlipidaemia 
are derivatives of hyperinsulinaemia developed from insulin resistance (Broom, 2006). 




T2 DM is more common in the middle- to older-aged individuals but it is becoming more 
common among younger children (Haslam & James, 2005), notable in younger adults ≤ 40 
years (Dabelea et al, 2009). This shift is attributed to a worldwide obesity epidemic 
(Boffetta et al, 2011) resulting in the dramatic increase in obesity in children and 
adolescents over recent decades (Tilenius, 2018 & Hammond et al, 2005).   
The onset of T2 DM is very subtle in nature, in that, a person can unknowingly have the 
condition for a considerable length of time before they experience symptoms (as described 
earlier) and the diagnosis being made (Holt & Kumar, 2015).  
 
2.3.2.1.7.2.7 Complications of T2 DM  
The complications of T2 DM can be debilitating and life-threatening. Table 2.2 has 
outlined the micro- and macro-vascular complications of T2 DM. These complications can 
worsen if blood glucose levels are not well-controlled. Retinopathy can lead to blindness, 
nephropathy to renal failure and neuropathy to leg and foot ulcers, limb amputation and 
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sexual dysfunction/impotence. Cardiovascular disease and strokes are also common among 
diabetics (Meeking, 2011).  
Cardiovascular disease is among the long-term complications of T2 DM (Vora, 2010) and 
is more common among Asians (Jalal et al, 2019). This disease type can be inherited 
(Scobie & Samaras, 2010) but can be mitigated by lifestyle factors like healthy eating and 
exercise. Diabetes is one of the leading causes of deaths. Globally, in 2016, an estimated 
1.6 million deaths were attributed to diabetes (WHO, 2018). In the UK, 24000 deaths have 
been reported as associated with diabetes (Diabetes UK, 2019).  
  
2.3.2.1.7.3 Gestational diabetes mellitus (GDM) 
2.3.2.1.7.3.1 Definition and concept 
Gestational diabetes mellitus is ‘any degree of glucose intolerance first diagnosed during 
pregnancy, regardless of the gestation and whether or not medication is used for treatment 
and the condition persists following pregnancy’ (Metzer et al, 1998; Buchanan & Xiang, 
2010). GDM develops at any time, but most commonly during the second and third 
trimester (Pickup & Williams, 1991).  This intolerance is of varying degrees of severity. 
This definition of GDM applies regardless of the management option and whether or not 
the condition persists after pregnancy and/or if the glucose intolerance was undetected 
prior to the pregnancy.  So, a renowned problem of GDM is to clarify if this condition is 
only a clinical sign or a distinct clinical entity – with implications for the mother and the 





2.3.2.1.7.3.2 Prevalence and incidence of GDM 
The prevalence and incidence of GDM varies between populations.  The true prevalence of 
GDM is unknown but its prevalence is increasing worldwide (Wan et al, 2019; Guariguata 
et al, 2014). The incidence of the condition is increasing in parallel with the increase in 
rates of obesity, physical inactivity and pregnancy in older women (Hunt & Schuller, 2007, 
NICE, 2015; Assaf-Balut et al, 2016, Farrar et al, 2016). This prevalence has further 
increased with the use of new diagnostic criteria (Moses et al, 2011) and universal 
screening which can increase the prevalence fourfold (Chamberlain et al, 2015).  
The current estimate of GDM is between 13% and 30% (Wong et al, 2017) but is 
dependent on the population studied and the diagnostic method used (Zhu & Zhang, 2016). 
Reported prevalence are India 27.5%, Sri Lanka 9.9%, Bangladesh 9.8% (Guariguata et al, 
2014), Canada 8-18%, (Bhattacharyya et al, 2008) with the highest believed to be in South 
East Asia.  Hirst et al (2012) reported a prevalence of 6.8-10.4% in China and in 2006 
China was classified as the second highest in the world (Enquobahrie et al, 2015). Saudi 
Arabia is 12.5% and 3.8% by WHO criteria and American Diabetes Association criteria, 
respectively (Al Rowaily & Abolfotouh, 2010).  
Previously, a large multi-ethnic study conducted by Dornhorst et al (1992) has shown a 
higher incidence of GDM in the non-indigenous population, with a relative risk of 3.1 for 
blacks, 7.6 for South East Asians and 11.3 for women from the Indian subcontinent.  A 
retrospective study by Akhter et al (1996) among Pakistani women living in Karachi 
showed an incidence of 3.3%. Also, GDM was more likely in pregnancies of Tunisian 
women older than 35 years for reasons such as obesity (Ben Slama, 1997).  GDM was 
evidenced in most of the patients studied by Ben Slama et al (1997), after the 20
th
 week of 
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gestation.  But early diagnosis was made in 20% of that group and might be suggestive of 
pre-gravid undiagnosed types 2 diabetics.  
More recently in the USA, the prevalence is believed to range between 1 and 14% of all 
pregnancies, depending on the population studied and the screening tests used. This 
equates to 7% of all pregnancies (Wang et al, 2015). In the UK, diabetes affects 5% of all 
pregnancies with 87.5% having GDM (National Institute of Health and Care Excellence 
(NICE, 2015). In 2008, this figure equated to approximately 3.5% (National Collaborating 
Centre for Women and Children’s Health, 2008), suggestive that a common trend is that 
most diabetic pregnancies are GDMs and that that trend is increasing.  
 
2.3.2.1.7.3.3 Aetiology 
Pregnant women develop GDM when the body cannot produce enough insulin to meet the 
extra need of pregnancy (Diabetes UK, 2014). GDM occurs when insulin secretion fails to 
compensate for the elevated insulin resistance as gestation advances (Horie et al, 2015).  
GDM arises during pregnancy; usually in the second or third trimester. A correlation exists 
between GDM detected at late gestation and changes in the placental function. Changes are 
noted in the utero-placental circulatory system whereby there is increased intervillous 
diffusion causing a mismatch due to distancing of the immature villi and placental size 
perfusion. Subsequently, the foetus may be exposed to chronic/acute changes in gas and 
nutrients resulting in a change of function of the placenta from being ‘foetus protector’ to a 
potential source of adverse outcome. It is therefore not surprising that placentas from GDM 
pregnancies can differ from the non-diabetic pregnancies by an increased foetal placental 





2.3.2.1.7.3.4 Risk factors 
The most recognised risks factors of GDM are previous large babies (equal to or greater 
than 4500 grams), previous history of GDM, family history of diabetes, obesity (BMI 
≥30kg/m
2
), ethnic origin especially of the South Asian, Black Caribbean and Middle East 
groups (Box 2.2).  
Early detection through screening is of great importance because early intervention is 
necessary to reduce the maternal and foetal morbidity associated with the condition. 
 
Box 2.2: Risk factors of gestational diabetes mellitus 
 BMI above 30 kg/m2 
 previous gestational diabetes 
 previous macrosomic baby weighing ≥4.5 kg  
 family history of diabetes (first degree relative with diabetes)  
 minority ethnic family origin with a high prevalence of diabetes 
 
 
2.3.2.1.7.3.5 Screening and diagnosis 
The need for screening at risk women for GDM has been highlighted by early researcher 
like O’Sullivan et al (1973) and since then the criteria has evolved over the years. In 2008, 
the UK National Clinical guidelines have recommended that all women are screened by 
assessment of specific risk factors at their first pregnancy appointment. Any pregnant 
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woman (not previously identified as having type 2 diabetes) with one or more risk 
factors should be offered an Oral Glucose Tolerance Test (OGTT) between 24- and 28-
weeks gestation (Farrar et al, 2015). OGTT involves a fasting blood test followed by a 
glucose drink then two hours later another blood sample is taken. Diagnosis is made when 
either the fasting plasma glucose level is ≥5.6mmol/litre or if the blood level reading after 
analysis is ≥7.8mmol/litre on the hour blood glucose test (NICE, 2015). NICE (2015) 
supports this screening practice and has identified the risk factors as outlined in Box 2.2. 
However, screening practices for GDM vary between health institutions (Kennedy, 2017) 
countries, regions and year (Zhu & Zhang, 2016). Following the Hyperglycaemia and 
Adverse Pregnancy Outcome (HAPO) study, recommendations were made by the 
International Association for Diabetes and Pregnancy Study Group (IADPSG) to address 
the inconsistencies (Kennedy, 2017).  
Historically, as seen in the North of England which has high levels of deprivation with a 
significant number of births of women of South Asian origin and a fifth of White British 
women being obese, only women with risk factors were offered an OGTT at 26-28 weeks 
gestation. However, blanket screening was introduced, whereby all pregnant women were 
screened at 26-28 weeks of pregnancy after a study conducted in that area highlighted a 
rising number of infant mortality due to poor health of pregnant women in that city 
(Hospital in North of England, 2012).  
The screening approaches for GDM are universal or routine screening for all pregnant 
women or selective screening for women with risk factors or a combination of both. 
Universal screening should detect most high-risk women, while selective screening adopts 
a more specific focus on high-risk women only to detect the condition (Zhu & Zhang, 
2016). Hence, the latter is deemed more cost-effective (Berger & Sermer, 2009) but may 
not detect approximately 40% of cases (Ostlund & Hanson, 2003), particularly among 
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women deemed ‘low-risk’ as women with GDM are usually asymptomatic and may not 
have associated risk factors (Kennedy, 2017).  
Based on World Health Organisation (WHO) 75g of glucose was used for the OGTT test 
in the North of England study for women between 26-28 weeks of pregnancy. The fasting 
plasma glucose level for diagnosis was ≥6.1mmol/litre or two-hour glucose ≥7.8mmol/litre 
(WHO, 1999). The results of the study showed that the proportion diagnosed with GDM 
increased almost fourfold after the introduction of the policy of offering a diagnostic 
OGTT to all women compared to selectively offering the test. The proportion of women 
having severe hyperglycaemia doubled following the change in policy (Farrah et al, 2015). 
Another finding was that offering universal OGTT was linked to a reduction of admissions 
to the neonatal unit for the whole obstetric population amongst those diagnosed with 
GDM. There were similarities in the rates of Elb's palsy and fractures before and after the 
policy change. Regardless, the rates of these conditions were exceptionally low, and the 
ratio estimates had very wide confidence intervals which included any association from a 
marked reduction to a marked increase in risk (Farrar et al, 2015). 
The benefits of offering universal testing and treatment of cases were also weighed against 
the cost of the service and the possible adverse effects to the woman herself. The criteria 
for the GDM diagnosis did not change during the study period, though it was evident that 
before the introduction of universal testing three women were tested and each of them was 
diagnosed with GDM, whereas with the introduction of universal screening, each of the ten 
women tested positively for GDM. This meant that if it was possible to increase the uptake 
of testing with the universal invitation, the difference was likely to increase. Similarly, this 
difference was likely to increase with the uptake of testing with universal screening (Farrah 
et al, 2015). 
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Conclusion of the study suggests that offering all women an OGTT was associated with 
increased identification of women with GDM and severe hyperglycaemia and neonatal 
benefits were evident for those diagnosed with GDM. However, there were no differences 
in neonatal outcomes in the obstetric population. It was therefore not surprising that 6% 
was identified as having GDM when OGTT was offered to all women and GDM diagnosis 
made based on the WHO criteria (NICE, 2008). 
 
2.3.3 Complications of T2 DM & GDM: maternal and foetal/neonatal   
2.3.3.1 Effects on mother, foetus & neonate 
Normal pregnancies are non-pathological events characterised by multiple complex 
hormonal adaptations to ensure a continuous supply of essential metabolites to ensure the 
growth and development of the foetus (Zeng et al, 2017). Glucose in adequate amounts is 
supplied to the growing foetus without causing hyperglycaemia and creating a risk 
environment (Antonio Negrato et al, 2012). Hyperglycaemia, a common feature of 
diabetes, is an indication of uncontrolled diabetes. Poorly controlled diabetes, particularly 
pre-conceptually (CEMACH, 2007) and during the first trimester of pregnancy (Knock et 
al, 1997 & Steel, 1990) are associated with an increased risk of obstetric and neonatal 
complications, morbidity and mortality (Easmin et al, 2015; Garcia-Vargus et al, 2012; 
CEMACH, 2007; Ben Slama et al, 1997; Hod, 1996). Hence, pregnancies complicated 
with T2 DM and GDM are considered high risk. Generally, pregnancy outcomes of women 
with diabetes are poorer than that of women without diabetes (CEMACH, 2007).  
A plethora of evidence has shown an association between GDM (Hosseini, et al, 2018; 
Kennedy, 2017; Gabbay-Benziv & Baschat, 2015; et al, 2014) and DM (Antonio Negrato 
et al, 2012; CEMACH, 2007) and increased risks for the mother, foetus and neonate. The 
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landmark HAPO 2008 study has confirmed this association with GDMs (Kennedy, 2017) 
and for the pre-gestational diabetics (type 1 & 2), the findings of CEMACH 2002-2003 
Diabetes Programme unmasked the public health issue concerning pregnancy outcomes 
within these groups (CEMACH, 2007). Better screening and antenatal surveillance, 
including pre-pregnancy care, particularly for pre-existing diabetics (NICE, 2015), the 
introduction of insulin (Ben Slama et al, 1997) and a better understanding of the 
conditions, have the potential for improved management of pregnant diabetic mothers and 
the achievement of a more positive maternal, foetal and perinatal outcome (Nishikawa et 
al, 2017; CEMACH, 2007).  
 
2.3.3.1.1 Morbidity / Mortality 
Diabetes in pregnancy can have immediate or long-term effects to the mother, the 
developing foetus and the neonate.  A hyperglycaemic environment is responsible for not 
only significant short-term morbidity in the foetus and the neonate but an increased risk of 
developing diabetes and other chronic, non-communicable diseases in adulthood life 
(Mitanchez et al, 2015 & Hod, 1996). Congenital malformations, stillbirth, macrosomia, 
birth injury and postnatal adaptations (such as hypoglycaemia) are more common in babies 
born to mothers with diabetes. To the mother, miscarriage, pre-eclampsia, preterm labour 
and injuries during labour are common CEMACH report (2007). These complications are 
not exclusive to those with pre-existing diabetes, but some are found to be associated with 
GDM (Horvath et al, 2019; Garcia-Vargus et al, 2012). Women with GDM are prone to 
prenatal mortality and development of future diabetes. In the UK, thirty per cent (30%) of 




2.3.3.1.1.1 Foetal loss 
Foetal loss can be categorised into three main groups: those who spontaneously abort for 
unknown reasons or possibly diabetes-related problems, those who opt for a termination 
for reasons of foetal abnormalities and otherwise, and thirdly, those who continue the 
pregnancy but experience a late loss prior to or following delivery.  The losses can occur at 
any time, but the first two seems more common in the first trimester and the latter during 
the last trimester.  Congenital abnormality is one of the reasons for spontaneous foetal loss 
(Pickup & Williams, 1991). The magnitude of the increased risk of late foetal loss was 
reported to have increased to approximately fourfold in perinatal death and a fivefold 
increase in stillbirths (Casson et al, 1997). 
The increased risk of stillbirth, in diabetic pregnancies is well documented.  Although 
stillbirth rates for these pregnancies have decreased due to screening, treatment and 
antenatal surveillance of these mothers, about 4% of all stillbirths remain attributable to 
diabetes, and diabetic pregnancies continue to be at risk of prenatal mortality (Weissgerber 
& Mudd, 2015). Overall, increasing age is associated with adverse pregnancy outcome and 
the risk of stillbirth is increased after thirty-five (35) years even after exclusion of 
conditions like hypertension and diabetes (Ben Slama et al, 1997).   
The incidence of pregnancy loss has had a rapid declined since the introduction of insulin 
during the 20
th
 century (Ben Slama et al, 1997) and is considered the medicine of choice 






2.3.3.1.1.2 Congenital Malformations 
The reduction of perinatal mortality in pregnancies complicated with pre-existing diabetes 
mellitus remain one of the most common measures used to qualify the success of a 
pregnancy outcome. Yet, the risk of having an infant with congenital abnormality remains 
significantly high in diabetic pregnancies (Reece & Homko, 2000; Carta et al, 1997; Hod, 
1996). Tight glycaemic control in the early weeks of pregnancy, facilitated by good blood 
glucose control from the pre-conceptual period can reduce the incidence of congenital 
abnormality in infants born to women with pre-existing diabetes (Steel, 1990). Prevention 
of malformation was first recognised in offspring of diabetic rats which achieved good 
glucose control during organogenesis (Ericksson et al, 1984). Also, as the teratogenic 
process of the diabetic pregnancy is multi-factorial (Albert Reece, 1996), similar outcome 
may be achieved in a hyperglycaemic state, provided that restoration of normalisation of 
free radicals and EFAs/phospholipid deficiency state are rectified through dietary 
supplementation with polyunsaturated fatty acids, myoinositol or antioxidants (Reece at al, 
1996 & Albert Reece, 1996).  
The incidence of congenital malformation varies between clinical populations (Carta et al, 
1997) and ethnic groups (Garcia et al, 2015; Kheder, 1992). Congenital malformation 
increased with age and affected 2.7% of Tunisian pregnancies of women ≥40 years 
(Kheder, 1992). Also, raised HBA1c values are associated with a significant increase in 
congenital malformations and foetal macrosomia (Visser & de Valk, 2015). 
The rates submitted to the Office for Neonatal Statistics remains under-reported and may 
result in surveillance bias. The Diabetes Control and Complications Trial reported a 
prevalence of 4.7% among controls, compared to only 1.1% among the children of women 
in the intervention group. This may explain why in a randomised controlled trial with well-
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motivated, self-selected diabetic women who received intensive treatment before 
pregnancy, the prevalence of congenital malformation in infants was similar to that of non-
diabetic women (NICE, 2008). 
Pregnancy outcomes for women with T1 DM and T2 DM are similar (NICE, 2015). In 
Casson et al (1997) study, five per cent (5%) of infants born to women with pre-existing 
Type 1 diabetes had a 10-fold greater risk of congenital abnormality and a five-fold risk of 
having a stillbirth.  The prevalence of malformation in Casson, et al (1997) study was 
similar to that in comparable studies.  Of the seven deaths noted, exclusive of miscarriages 
and stillbirths that totalled 19% (87), all except one of those infants had congenital 
abnormality. No difference of congenital malformations was observed between Type 2 
diabetics and those with GDM (Ben Slama et al, 1997). Also, no incidence was reported in 
GDM pregnancies in Pima Indians (Pettit et al, 1980). Botta (1997) in her study showed 
that the percentage of malformation in offspring of Type 2 diabetic mothers was higher 
than of women with Type 1 diabetes, despite the former having had better metabolic 
control. However, it is important to note that oral hypoglycaemic drugs were used by the 
former group during their pregnancies unlike more intensive treatment in the latter group.  
 
2.3.3.1.1.3 Macrosomia 
The definition of macrosomia, like many issues related to ‘diabetes in pregnancy’, remains 
controversial and is an area for further debate. Whatever that definition, it refers to birth-
weight that approximates 4000g and over, irrespective of the sex of the baby (Jardim et al, 
1997).   
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Macrosomia may be due to an increase maternal body mass index, increased body weight 
gain during pregnancy, absence of adequate placentation and cardiovascular complications 
(Visser & de Valk, 2015).  
Macrosomia is also correlated to time of insulination (Ben Slama et al, 1997). Early 
insulination is highly significant in the reduction of macrosomia in GDMs. Compared to 
the non-GDM woman, women with GDM have a higher incidence of macrosomia, 
regardless of receiving treatment to manage their condition and when corrections were 
made for gestational ages at birth (Jensen et al, 2000). However, the incidence of 
macrosomia between GDMs and Type 2s is similar (Cundy & McBride, 1993).  
Additionally, intensive insulin regimen significantly decreased macrosomia rate in GDM 
pregnancies from 29% to 10% but monitoring of fasting and pre-meal glycaemia had no 
impact on preventing macrosomia (Langer et al, 1994). In Casson et al (1997) study, only 
13.7% (43/344) of the study sample weighed less than the median birth weight for 
gestational age of the referenced cohort.  Hence, the result has indicated that infant 
macrosomia remains a problem in diabetic pregnancies.   
 
2.3.3.1.1.4 Intrauterine growth restriction (IUGR) and Pre-eclampsia 
Pre-eclampsia and IUGR can have detrimental effects on the mother and the foetus. These 
complications are associated with reduced placental perfusion (Dessi et al, 2015). 
Consequently, when a woman presents with either one of these conditions in pregnancy, 
both are monitored particularly as pre-eclampsia is a major cause of IUGR, pre-term births 
and perinatal deaths (Sibai et al, 2005). Similarly, IUGR is associated with stillbirth, 
neonatal death and perinatal morbidity which include cerebral palsy (Jacobson et al, 2008; 
Kady & Gardosi, 2004 & Barker et al, 1993). Additionally, abnormal placentation is a 
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causal effect of pre-eclampsia (Dessi et al, 2015) with congenital abnormities, infections 
and drug and substance misuse identified as causal effects of IUGR (Figueras & Gardosi, 
2010).  
Much controversy remains about the definition of IUGR, but more accepting is that a baby 
with an estimated foetal weight below the 10
th
 customised centile has an increased risk of 
mortality and morbidity even without an abnormal artery Doppler (Figueras et al, 2008). 
Pre-eclampsia is characterised by hypertension and proteinuria and tend to occur after 20 
weeks gestation (Lopez-Jaramillo, 2018). Adequate nutrition is essential in the prevention 
of pre-eclampsia. Deficiency in EFAs and other nutrients which include calcium, proteins 
and vitamins are believed to play a key part in the development of pre-eclampsia 
(Vasiljevic et al, 1996). Also, increasing maternal age (Phipps et al, 2016) and/or being 
over-weight/obese (Levine et al, 2000) increase a woman’s risk of developing pre-
eclampsia. Pre-eclampsia is more common among women with diabetes compared to non-
diabetics and the incidence and severity of the condition increases with the severity of the 
diabetes (Garner et al, 1990). 
IUGR and pre-eclampsia, when combined with GDM, where metabolic and blood vessels 
adaptations to pregnancy are sub-optimal, the morbidity and mortality on mother and baby 
can be detrimental (Dessi et al, 2015; Gabbay-Benziv et al, 2015). Placental blood 
perfusion can worsen resulting in failure to respond adequately to hormones such as insulin 
leading to hyperglycaemia. Subsequently, the effects cannot only have immediate 
consequences to the health of the mother and baby but may also impact on their future 
health (Dessi et al, 2015; Gabbay -Benziv et al, 2015). As the effects of T2 DM can be 
worse or in some cases similar to women with GDM, one can conclude that the incidence 
and severity of IUGR and pre-eclampsia can be equally measured for the type 2’s.  
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Early detection and management are critical to improve maternal and foetal outcomes and 
reduce long-term morbidity which includes cardiovascular, respiratory, central nervous 
system, renal and hepatic diseases which are more common to women diagnosed early 
with pre-eclampsia compared to women diagnosed late (Lisonkova et al, 2014). 
 
2.3.3.1.1.5 Gestational Ages at Birth  
Compared to non-diabetic women, the offspring of GDM women tend to be delivered at an 
earlier gestational age (Jensen et al, 2000). In Jenson’s study, there was also a trend 
towards a more pre-term delivery in the GDM group although not statistically significant. 
In a Tunisian study, pre-maturity rate was 24% (Zanina, 1985) and trend was similar in 
Ben Slama et al’s (1997) study. In Ben Slama et al (1997) study, no case of pre-maturity 
was observed in women whose mean fasting glycaemia was <5.5mmols whereas it 
concerned 33% of women whose mean fasting glycaemia exceeded 6.6mmols and that was 
highly significant. Prematurity rate was 9% for Type 1 diabetic mothers and 14% for 
mothers with GDM. The mean gestational age at delivery was 38 +/- 2.3 weeks for Type 1 
diabetics and 38.6 +/- 1.5 weeks for GDMs (Ben Slama et al, 1997).   
The overall incidence of pre-term delivery in Akhter et al’s (1996) study was 19.1% 
(10.6% in excellent control, 19.1% in moderate and 35.2% poorly controlled) and that was 
highly significant. Therefore, there was a greater significance with the poorly controlled 
group’s control. Early gestational delivery was more common in the GDM group 





2.3.3.1.1.6 Mode of delivery  
Jang et al (1997) in their study reported a significantly increased incidence of caesarean 
section in the GDM group, despite good blood glucose control during pregnancy. In a 
prospective study carried out by Sermer et al (1995), increasing carbohydrate intolerance 
was found to be associated with higher incidence of caesarean section rates even though 
the incidence of macrosomia was reduced with treatment. In Naylor et al (1996) study, the 
caesarean section rate remained high in the sub-group with GDM. 
A Tunisian study by Zanina (1985) found rates of caesarean section at 22% while the study 
by Ben Slama et al (1997) had an increased rate at 48%. Caesarean section delivery rates 
of 32.9% for the GDM group compared to 21.0% in non-GDM were reported by Jensen et 
al (2000).  In other studies, the caesarean section delivery rate was 62% (Hawthorne et al, 
1993) and 25.9% (Akhter et al, 1996). In the former study, nineteen pre-term labour started 
spontaneously (Hawthorne et al, 1993). In Jensen et al (2000) study 61% of GDMs 
compared with 24% of non-GDM were induced. Regardless, foetal outcomes and the 
frequency of various obstetric complications were reported as the same in GDM and non-
GDM groups (Lucas et al, 1993).   
 
2.3.3.1.1.7 Admission to SCBU 
SCBU admission rate of infants born to women with diabetes are higher compared to 
infants of non-diabetic women. In Jensen et al (2000) study, 46% GDM and 12% Non-
GDM were admitted to SCBU for reasons like hypoglycaemia and jaundice. In another 
study, 46.2% of babies delivered by GDM mothers were admitted to the neonatal unit 
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compared with 11.9% of non-diabetic women (Ben Slama et al, 1997). Of those, nine per 
cent (9%) infants received intensive neonatal care. 
 
2.3.4 Management of women with T2 diabetes and GDM 
2.3.4.1 Overview 
GDM and T2 DM share the same risk factors and metabolic abnormalities (insulin 
resistance and hyperinsulinemia) (Ben Slama, 1997). Therefore, their management would 
be similar depending on the severity of the conditions. For the GDMs, gestational age at 
diagnosis would be highly significant whereas for the type 2’s, medical management on 
confirmation of pregnancy would indicate where an individual is on the treatment 
spectrum. Whatever the diabetes type, a positive pregnancy outcome can be determined by 
an individual’s commitment, motivation and self-empowerment. Potential risks can also be 
minimised with high dose folic acid (5mgs daily), optimal glycaemic control combined 
with close monitoring of mother and baby during the antenatal period (CEMACH, 2008). 
 
2.3.4.2 Structured education  
Pregnancy complications are in part directly or indirectly related to some degree of 
metabolic control, regardless of the type of diabetes. Reducing complications to a 
minimum requires that women have near to normoglycaemia during pregnancy. This can 
be achieved through the joint effort of the specialist team and women themselves.   
Diabetologic education which involves the provision of adequate knowledge, skills and 




Various health educational/promotional strategies need to be in place to effectively manage 
women with pre-existing diabetes from the pre-conceptual period and throughout 
pregnancy. The Diabetes National Service Framework has recommended structured 
education programmes for all diabetics and the DESMOND trial has shown the benefits of 
such programmes for newly diagnosed Type 2s (Davies et al, 2007). 
Women with GDM will benefit from similar programmes from screening to the postnatal 
period and beyond. All health professionals working with diabetic women should be able 
to support women to go through the various stages of pregnancy from the pre-pregnancy 
stage feeling confident and empowered to effectively manage their condition and maintain 
a healthy lifestyle.   
Adequate screening and having an appropriate referral system in place following diagnosis 
of GDM is crucial to the management strategies to be employed, to optimise maternal and 
foetal outcomes (NICE, 2015). For known diabetic women, it is postulated that pre-
conceptual care followed by rigorous management throughout pregnancy until the 
postnatal period are believed to be the most appropriate measures/strategies to improve the 
pregnancy outcome of both mother and baby (Casson et al, 1997).  Appropriate dietary 
advice and/or intensive self-home blood glucose monitoring and frequent adjustments of 
insulin doses are also believed to be important requirements to achieve a positive 
pregnancy outcome.  Additionally, early and appropriate referral of all clients with 
abnormal blood glucose levels to a multi-disciplinary team (MDT) clinic is considered 
paramount and essential to reduce the perceived risks associated with maternal and foetal 
morbidity and mortality (Pickup & Williams, 1991, NICE, 2015). This MDT approach is 
also required for women diagnosed with GDM to obtain tight control of their diabetes and 
promote positive outcomes for mothers and their babies (NICE, 2015).  
59 
 
NICE guidelines further recommend that all women of child-bearing age with a history of 
previous GDM should be empowered through education on lifestyle factors during 
pregnancy and upon discharge to plan for their future pregnancies. Women should be 
advised on spacing their pregnancies and how best to lead their lives through healthy 
eating and exercise to prevent the disease transcending into T2 DM (NICE, 2015). 
Although the advice is similar on spacing their family, women with overt diabetes are 
usually advised to aim to complete their family while young because as they get older, the 
morbidity associated with diabetes can increase and/or become more severe and can 
complicate future pregnancies.   
 
2.3.4.3 Oral and insulin therapy 
Diet and lifestyle modification are usually the first line treatment for women with GDM 
and if this fails in controlling blood glucose levels, oral and/or insulin therapy is used. 
Women with T2 DM and starting pregnancy on oral medication would often be started on 
insulin therapy and a more intensive regimen is started for those already on insulin 
(Antonio Negrato et al, 2012).  
Insulin therapy is the gold standard for treatment and prevention of hyperglycaemia during 
pregnancy, when lifestyle measures have not maintained glycaemic control. 
Hypoglycaemic agents such as metformin and glyburide are safe and acceptable 
alternatives. Metformin crosses the placenta but compared to the benefits of reducing 
neonatal and maternal hypoglycaemia, there are no serious concerns around tetrogenesis. 
Compared to metformin, glibenclamide is better tolerated and more effective in lowering 
blood glucose in women with GDM resulting in lower treatment failure rates than 
metformin. However, metformin remains the drug of choice as glibenclamide is believed to 
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be associated with higher rates of pre-eclampsia, neonatal jaundice, longer stay in the 
neonatal care unit, macrosomia and hypoglycaemia (Kaira et al, 2015). 
2.3.4.4 Ultrasound scans 
Serial scans for the detection of foetal structural abnormalities are recommended. This 
should include foetal umbilical artery Doppler before 38 weeks. In women with insulin-
treated diabetes who are receiving steroids for foetal lung maturation, additional insulin 
should be given according to an agreed local protocol and should be monitored closely 
with scans (NICE, 2008 & 2015 & Albert-Reece et al, 1994). 
 
2.3.5 Maternal nutrition and placental function 
Rapid physiological changes occur in pregnancy from the time of conception until birth. 
Nutritional requirements increase during pregnancy (Blumfield et. al, 2013) and 
micronutrients and macronutrients need to be tailored to individual needs to optimise 
maternal and foetal outcomes (Mousa et al, 2019). Increasingly, maternal nutrition from 
preconception and throughout to lactation is shown to be critical to foetus survival (Ji et al, 
2017) growth and development (Ji et al, 2017; Palmer, 2011) and the homeostatic 
pathways of the offspring (Palmer, 2011).  Maternal nutrition determines the intrauterine 
environment – a phenomenon referred to as ‘foetal programming’, indicating that the long-
term health of the infant is determined by the internal environment in which the foetus has 
developed (Ji et al, 2017; Myatt & Powell, 2010; Wu et al, 2004). Therefore, good 
maternal nutrition from conception and throughout is vital to have a positive impact on 
pregnancy outcome and future health of the newborn. Pregnancy outcome can be deemed 
successful when the wellbeing of both mother and baby are optimal. Effective synergy 
between the maternal, placental and foetal systems is critical for this success which can be 
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facilitated through good maternal health (Myatt & Powell, 2010). Therefore, maternal 
over-nutrition & under-nutrition can be detrimental to the developing foetus (Figure 2.1) 
(Herring et al, 2017; Wu et al, 2004).  
 
 
            
                                      Figure 2.1 Spectrum of nutritional adequacy 
 
 
2.3.5.1 Placental transfer of nutrients 
The foetus receives its nutrition from the mother via the placenta. Placental function 
depends on the nutritional wellbeing of the mother and subsequently, its supply to the 
foetus. Substances required by the foetus are selected by the placenta and complex 
nutrients are broken down into compounds which can be utilised by the foetus. Proteins are 
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transferred as amino acids, carbohydrates as glucose and fats as fatty acids. Placental 
capacity increases as pregnancy advances and its size is determined by maternal nutrition 
(Bell & Ehrhardt, 2013). Therefore, size can impact on placental function and any 
reduction in the placental foetal blood flow can lead to conditions like intra-uterine growth 
retardation (IUGR) (Wu et al, 2004). Consequently, adequate maternal nutrition is critical 
to maternal and foetal wellbeing, particularly as some epigenetic events, modified by diet 
can impact more than one generation (Danielewicz et al, 2017).  
 
2.3.5.2 Metabolic changes in non-diabetic and diabetic pregnancies  
Maternal metabolism changes significantly during pregnancy. The key changes of lipid 
metabolism during pregnancy are increase in maternal fat deposits and hyperlipidemia 
(Herrera & Ortega-Senovilla, 2014), characterised by a rise in plasma triacylglycerols in 
response to an increase in maternal energy requirement (Hummel et al, 1976). Multiple 
adaptations occur to ensure a continuous supply of essential metabolites (glucose and 
amino acids) for the growth and development of the foetus (Zeng et al, 2017) and meeting 
the increased physiological demands of the woman during pregnancy, labour and lactation 
(Tucker Blackburn, 2013). Total metabolism increases 30% higher than in the non-
pregnant woman (Hamzah, 2015).  Early pregnancy (up to 20 weeks) is described as the 
anabolic state and is marked by an increase in maternal fat stores and accelerated placental 
growth (Tucker-Blackburn, 2013).  
Maternal protein nutrition plays a critical part in improving embryonic survival, growth 
and development, foetal programming and alteration in foetal genes expression. Low levels 
can result in embryonic losses, intrauterine growth retardation (IUGR) and reduced post-
delivery growth due to the absence of specific amino acids responsible for cell metabolism 
and function. Embryonic death and IUGR are also caused by an increase in maternal 
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nutritional protein due to amino acid excesses and toxicity derived from amino acids 
catabolism (Herring et al, 2018). Total concentration of protein decreases by 
approximately 0.1g/dl during pregnancy due to increased utilisation and excretion 
(Hamzah, 2015).  Approximately 900g of new protein is synthesised by the mother, foetus 
and the placenta (Tucker Blackburn, 2013). 
Maternal carbohydrate is metabolised into glucose which is also critical for maternal and 
foetal wellbeing. Insulin is necessary for regulation of these processes and the activity of 
the beta cells increase during early pregnancy (Zeng et al, 2017). Hyperinsulinemia during 
the first two trimesters of pregnancy is deemed responsible for promoting maternal 
lipogenesis and fat deposition (Zeng et al, 2017). Approximately 3-4 kilograms of fats are 
stored in the abdomen wall, breasts, hips and thighs (Hamzah, 2015).   
Placental growth is overtaken by foetal growth in the second trimester. In response, the 
placenta starts producing anti-insulin hormones (oestrogen, cortisol, progesterone and 
human placental lactogen). As pregnancy progresses, there is a progressive decline in 
maternal insulin sensitivity (insulin resistance) (Sivan et al, 1999; Buchanan, 1990), 
increasing to 45-70% by the 3
rd
 trimester (Kuhl, 1991). This triggers a cessation of fat 
accretion and an increase in adipose lipolysis, hepatic gluconeogenesis and ketogenesis 
(Catalano et al, 2006; Boaden, 1996), which the foetus utilises in later pregnancy. To 
compensate, two- to three-fold insulin secretion occurs (Cousins, 1991).  
However, if beta cells are defective, women may present with hyperglycaemia in early 
pregnancy (possible undiagnosed T2 diabetes), and/or GDM may manifest in late 
pregnancy (Boaden, 1996). This adaptive mechanism is ineffective in diabetic pregnancies 
where maternal insulin resistance and defect in beta cell reserves and function already 
exist. Consequently, due to hyperglycaemia, maternal and foetal outcomes may be 




2.3.5.3 Long chain polyunsaturated fatty acids (LCPUFAs) supply in pregnancy 
Long chain polyunsaturated fatty acids (LCPUFA) are essential fatty acids (EFAs) and 
include linoleic acid (LA) (omega 6) and alpha-linoleic acid (ALA) (omega 3) (Leaf, 
1992). The major metabolites of LA and ALA are arachidonic acids (AA) and 
docosahexaenoic acids (DHA), respectively. Like DHA, eicosapentaenoic acids (EPA) are 
the most important metabolites of ALA. Omega 3 and omega 6 fatty acids are required for 
the growth and development of many organs, particularly the brain and eyes. Other 
physiological functions include transportation of oxygen, energy storage, cell membrane 
function, and regulation of cell proliferation (Innis & Friesen, 2008). Also, some markers 
of inflammation have been associated with anti-inflammatory action with omega 3 fatty 
acid supplementation and a possible link to maternal-foetal fatty acid transfer (Simopoulos, 
2002 & Calder, 2002).  The role of LCPUFAs, particularly AA and DHA in relations to 
pregnancy health and outcomes has received great interest in recent decades, particularly in 
areas of neuro-visual development (Crawford et al, 1989; Leaf et al, 1992; Colletta et al, 
2010) and in optimising the health of pregnancies complicated with diabetes (Min et al, 
2016, Min et al, 2014 & Thomas, 2005; Ghebremeskel, 2004; Ghebremeskel, 1998).   
 
2.3.5.3.1 Foetal and neonatal supply of essential fatty acids (EFAs)  
From conception, EFAs (AA and DHA) foetal demands are high because they are needed 
for incorporation into the lipids of proliferating membranes (Lauritzen et al, 2001). AA is 
supplied mainly for foetal growth and development and DHA for development and 
function of the nervous system (Lauritzen et al, 2001)), which includes the eyes and 
particularly the brain which has accelerated growth during the second trimester (Colletta et 




The foetus and neonate can synthesize AA & DHA (Poisson et al, 1993) but at possibly too 
slow a rate to match its demand (Koletzko et al, 1996). The foetus depends on the mother 
for optimal supply of these nutrients (AA & DHA) due to its limited ability of synthesising 
these fatty acids. It is estimated that the foetus accumulates about 70 mg/day of omega-3 
fatty acids; both AA & DHA but mainly the latter (Clandinin et al 1980, Martinez 1992).  
 
LCPUFAs mainly AA, DHA, eicosapentaenoic acids form 10-15% of the volume of the 
cell membrane. Any reduction of this amount may lead to conditions related to prematurity 
(Crawford, 1993 a & b), low birth weight and neurological impairment (Connor et al, 1992 
& Crawford et al, 1976). Gestational length and foetal growth trajectory may also be 
affected (Myatt & Powell, 2010). AA and DHA increase three-fold in human cerebellum 
and cerebrum in latter pregnancy and the immediate postnatal period (birth to week 12) 
(Clandinin et al, 1980). Therefore, reduction of AA at full term (Leaf et al, 1992) and up to 
the first few weeks following birth, may suggest that maternal supply of fatty acids is 
critical for optimal foetal and the neonatal wellbeing (Koletzko et al, 1996). 
 
2.3.5.3.2 Maternal supply of EFAs  
Compared to the non-pregnant woman, pregnant women have lower levels of blood and 
tissue fatty acids (Ghebremeskel et al, 2000). From week 10 of pregnancy, there is a 
marked decline in maternal levels of AA & DHA (Otto et al, 1999 & Min et al, 2000). 
Increased parity (Al et al, 1997) and lactation (Otto et al, 1999 & Min et al, 2000) are 
associated with depleted stores of AA & DHA. 
Maternal supplementation is necessary because AA & DHA are higher in the foetus than in 
the maternal circulation. Like other nutrients, AA & DHA are selectively transferred from 
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the mother to the foetus via the placenta (Haggarty et al, 1997). Therefore, the placenta 
needs to have an adequate supply of these nutrients for uptake, particularly in the latter 
stage of pregnancy when the foetal demand increases. Any deficiency may compromise 
pregnancy outcomes (Min & Crawford, 2004). At times of high foetal demand, AA & 
DHA are met by maternal stores leading to depletion in the maternal stores (Otto et al, 
1999). Therefore, EFAs must be eaten by pregnant mothers through foods or supplements 
because they cannot be synthesized by the body (Bell et al, 1997; Min & Crawford, 2004). 
Foods rich in omega 3 are fish (such as salmon, tuna, mackerel & sardines) nuts and seeds 
(such as walnuts, chia seeds & almonds) and plant oils (such as flaxseed oil). Pulses, 
poultry, green leaves and vegetables are some foods rich in omega 6 (Bourre, 2005).  
 
2.3.5.3.3 LCPUFAs supply in diabetic pregnancies 
Pre-gestational T2 DM (Hadden et al, 2003; Balsells et al, 2000 & Cundy et al, 2000) and 
GDM (Wu, 2018 & Sweeting et al, 2016) are associated with increased risk of perinatal 
and maternal morbidity. These metabolic conditions can affect maternal LCPUFAs status 
and this in turn can have an adverse impact on the supply of these fatty acids to the foetus 
(Crawford, 2004).  
Experimental studies on diabetes have shown that the enzymes involved in the regulation 
and synthesis of LCPUFAs are impaired. In other words, diabetes impairs the activity of 
delta-6 and delta-5 desaturases – enzymes necessary for synthesis of AA and DHA 
(Brenner et al, 2000; Poisson et al, 1992; El Boustani et al, 1989).  
In non-diabetic pregnancies, DHA is taken up preferentially by the placenta and transferred 
from the maternal to foetal circulation resulting in an increased supply in venous cord 
blood levels in the foetus compared to the mother (Innis, 1991). In diabetic pregnancies 
this process of DHA transfer becomes affected (Min et al, 2005a; Thomas et al, 2005; 
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Wijendran et al, 2000). Compared to women without diabetes, previous studies have found 
that AA and DHA were significantly lower in the red blood cells membranes of women 
with GDM (Min et al, 2016, Thomas et al, 2005) and T2 DM (Min, et al, 2014; Min et al, 
2004 & 2005a, Min, 2006) and in the plasma and red blood cell of their children (Min, et 
al, 2014; Thomas et al, 2005; Min 2005a & 2005b).  
Also, infants born to mothers with T2 DM and GDM have shorter attention span and motor 
function (Ornoy et al, 1999), low cognitive performance (Levy-Shiff et al, 2002 & Hod et 
al, 1999) and a higher risk of language impairment compared to women without diabetes, 
(Dionne et al, 2008)  
Insulin therapy has the corrective ability by normalising fatty acids distribution in the cell 
membranes through enhancement of the activity of delta-6 and delta-5 desaturases or by 
improving the incorporation of LCPUFAs (Shin et al 1995; Poisson, 1989 & Poisson et al, 
1992). Although this impairment may be corrected by insulin therapy, its effect on 
maternal and foetal pregnancy outcome remains unknown and would be explored within 
this study.  
Strong evidence exists to support supplementation with LCPUFAs to enhance both 
maternal and foetal well-being in women whose pregnancies are complicated with diabetes 
(Min et al, 2016; Min, et al, 2014; Gould et al, 2013; Thomas et al, 2005; Ghebremeskel et 
al, 2004; Ghebremeskel et al, 1998).  
 
2.3.6 Omega-3 fatty acids and pregnancy outcomes (maternal and foetal) 
The search the impact of omega-3 fatty acid supplementation on pregnancy outcomes has 
yielded very little that was relevant to answer the research enquiries in Phases 3 and 4 
because the pregnancy outcome studies were done on women without diabetes. Although 
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pregnancy outcomes of women with T2 DM and GDM have long been studied, a possible 
explanation for this was the management complexities which these conditions present may 
have deterred researchers from conducting studies which added another management 
dimension to an already challenging situation. Also, pregnancy outcome data was from 
observational studies and RCTs were on specific aspects of pregnancy, for example pre-
eclampsia (Chen et al, 2015) and preterm birth (Olsen, 2000). Consequently, no systematic 
reviews or meta-analysis were found on the pregnancy outcomes of women with T2 DM 
and GDM after supplementation with omega-3 fatty acids. Phases 3 and 4 of this study 
hope to fill this gap. 
An early review by Olsen et al (1986) indicated that supplementation with omega-3 fatty 
acid during pregnancy may increase foetal birth weight by prolonging gestational age. A 
RCT later followed to assess the efficacy of supplementation in the reduction of 
preeclampsia, preterm birth and IUGR. Conclusions were that fish oil supplementation 
reduced the risk of preterm birth but had no effect on preeclampsia and IUGR (Olsen et al, 
2000).  A Cochrane review conducted by Makrides et al (2006) showed a consistent small 
increase in mean gestational length but no significant effect in preventing preeclampsia 
following fish oils supplementation.  
Two reviews from the Cochrane Library on fish oil supplementation in T2 DM outside 
pregnancy have demonstrated that supplementation had no effect of glycaemic control in 
T2 diabetics but lowered triglyceride and may raise LDL cholesterol particularly in 
hypertriglyceridemic patients on higher doses of fish oils (Farmer et al, 2007 & Hartweg et 
al, 2009).  
No reviews were found on postpartum diabetic status of women with GDM after fish oils 
supplementation but a recent meta-analysis on omega-3 fatty acid supplementation during 
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second and third trimesters has shown no effect on the reduction of developing GDM 
(Chen et al, 2015) and this was supported by a systematic review conducted by Saccone et 
al (2016). Also, a RCT conducted by Wu et al (2012) showed no relationship between 
omega-3 fatty acids and fish/seafood intake nor eicosapentaenoic (EPA) and DHA in the 
reduction of T2 DM although a modestly lower risk with alpha-linolenic acid (ALA) was 
suggested. More recently, a systematic review conducted by Ostadrahimi et al, (2016) has 
purported that enough evidence did not exist to confirm whether or not omega-3 fatty acid 
should be routinely used in pregnancy to prevent or treat diabetes; indicating that further 
research is needed.   
Another systematic review and meta-analysis of RCTs conducted by Saccone et al (2015) 
has concluded that in women with a previous history of IUGR and uneventful singleton 
pregnancy, fish oil supplementation during pregnancy does not prevent the recurrence of 
IUGR. Saccone et al (2016) in a subsequent systematic review found that there was 
slightly improved serum-creative protein concentrates in pregnant women who received 
omega-3 fatty acid, and reduced incidence of hyperbilirubinemia and hospital admission in 
the newborn. Regardless, they concluded that there was not enough evidence to 
recommend routine supplementation of omega-3 fatty acid in pregnancy since 
supplementation had no effect on the prevention of pre-eclampsia (PE), GDM, preterm 
birth, small for gestational age infants, neonatal development and postpartum depression. 
More research was suggested as there was a significant reduction in perinatal death in 
women who started taking omega-3 fatty acid ≤ 20 weeks gestation. Similarly, a meta-
analysis has shown that there was no effect on the reduction of PE, pregnancy induced 
hypertension (PIH) and GDM (Chen et al, 2015).  
The most recent systematic reviews conducted by Middleton et al (2018) on the use of 
omega 3 fatty acid during pregnancy has found reduced incidence of preterm birth (<37 
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weeks), very preterm birth (<34 weeks), low birth weight babies and a possible increased 
incidence of prolonging pregnancy beyond 42 weeks, reduction of sick babies and neonatal 
intensive care admission. There was no difference in induction of labour for postmaturity 
and postnatal depression.  In child development and growth, very few differences existed. 
Conclusion from that study was that very little or no difference existed between the 
supplemented and non-supplemented groups. That has raised the question on whether an 
increased dosage could be more beneficial in the reduction of pre-term birth, low birth 
weight babies and prolonging pregnancies. The need for more empirical studies was 
suggested to establish if and how outcomes may vary between indifferent populations of 
women with different increasing doses of omega-3 fatty acid during pregnancy. Having 
reviewed the overall guidance on fish oil consumption in pregnancy, Taylor et al (2018) 
have found great variations and have suggested that to achieve impact, guidelines need to 
be clear and memorable and presented in visual format, supported by technology for the 
logging of fish oil consumption in real time.  
Regardless, conclusions from reviews by Saccone et al, (2016), Ostadrahimi et al, (2016), 
Middleton et al, (2018) and others which are also of the same ilk have indicated that there 
is not enough evidence to support or refute the use of fish oil supplementation in 
pregnancy. This study hopes to contribute to answering the research questions around fish 
oil supplementation in pregnancies complicated with T2 DM and GDM.   
 
2.3.7 Client engagement  
Adequate nutrition and exercise form the cornerstone for effective diabetes management 
and these lifestyle measures are critical for optimising glycaemic control for the reduction 
of cardiovascular risk (Holt & Kumar, 2015) and pregnancy related maternal and foetal 
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diabetes complications (NICE, 2015). Effective management can be facilitated through 
adequate engagement with the services that are available to pregnant women coupled with 
professional help and support from HCPs (NICE, 2015).  
 
In deprived boroughs like Newham, diabetic women could have been starting their 
pregnancy in poor nutritional health. By women participating in the nutritional trial, they 
would have had additional advice on healthy eating and could have benefited from fish oils 
consumed and the likely benefits which supplementation offered. Combined, these factors 
could have enhanced women’s nutritional health, possibly resulting in optimal maternal 
and foetal outcomes. Therefore, it was necessary to obtain existing quality data to have a 
better understanding of the socio-cultural and economic factors that facilitate engagement. 
That information was critical for the success of the RCTs (Phases 3 & 4) in areas of client 
recruitment and follow-up care provision. 
 
For decades, research evidence has highlighted ethnic health inequalities in areas like 
nutrition and chronic illnesses such as diabetes and pregnancy outcomes. Complex socio-
economic and political factors may in part, be responsible for this. Lack of investment in 
researching the health needs of women from ethnic minority groups may also have 
contributed to this inequality and may have denied this group which may have the greater 
capacity to benefit from being researched (Sheikh, 2006).      
Empirical evidence published between 2006 and 2016 in a systematic review on Black, 
Asian and Minority Ethnic (BAME) patient and public involvement in social research and 
found that ethnic minority patients’ involvement usually stopped at the study design phase 
and rarely progressed to the data analysis and interpretation phases (Dawson et al, 2018). 
Ethnic minority patients’ involvement throughout the research cycle can generate new 
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learning and a broader research interest which can be influential among and within their 
cultural groups, resulting in better research engagement.   
Pregnancy is ideal for addressing the complex and challenging needs of ethnic minorities 
(Aquino et al, 2014) and promote positive engagement with HCPs. Current trend is that 
increasingly, a higher proportion of pregnant women are seeing midwives as their first 
contact when pregnancy is confirmed (Care Quality Commission, 2018). Therefore, 
midwives are in a privileged position to ‘get it right from the start’ by making that first 
contact a very positive one and using it to form the building blocks on which to form 
meaningful, trustworthy, enriched and lasting relationships. Such relationships can thrive 
by keeping women positively engaged with the services available while encouraging them 
to make informed choices that would make their pregnancy experience a positive and 
lasting one. This requires that women are provided with adequate and appropriate 
information about the services that are available to them and through support and guidance, 
gain the confidence to access those services and be engaged in their personalised woman-
centred care plans in meeting the requirements of NICE (2015) and ‘Better Births’ 
(National Maternity Review, 2016).  
 
2.3.7.1 Policy strategies: equity in care provision and delivery 
Local and national guidance have evolved to improve general health and well-being and 
maternal and foetal outcomes among disadvantaged women. Management of the pregnant 
diabetic women is continuously an evolving process, which takes into account one’s 
environment, culture, socio-economic and nutritional factors. The political bias of one’s 
environment at local and national levels is also crucial. 
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Since 1989, the St. Vincent declaration by the World Health Organisation stated as a five-
year goal that the ‘outcome of the diabetic pregnancy should approximate that of the non-
diabetic pregnancy’. Changes in management strategies in areas of pre-conceptual, 
antenatal throughout to include neonatal care were acclaimed to that achievement, as 
combined, they were believed to contribute to the reduction in the morbidity and mortality 
rates of infants of diabetic mothers.  However, despite the notion that care delivered within 
a multi-disciplinary context is perceived to be paramount to reduce adverse outcomes, all 
high-risk pregnancies, including those with abnormal blood glucose levels, continue to 
pose a significant challenge to HCPs.  
Quality maternity care service and provision remain at the heart of the NHS which is 
constantly striving for improvement (Care Quality Commission, 2018). Local governments 
through strategic planning have similar goals to promote the wellbeing of their local 
population. In pursuit of achieving that objective, Changing Childbirth was launched over 
two decades ago and the quality of maternity care and pregnancy outcomes had improved. 
More recently, as part of the NHS Five Years Forward View, NHS England in 2015 
announced a major review of the maternity service. In response to this, the National 
Maternity Review Report ‘Better Births’ was published a year later with focus on 
becoming ‘safer, more personalised, kinder, professional and more family friendly; where 
every woman has access to information to enable her to make decisions about her care; and 
where she and her baby can access support that is centred around their individual needs 
and circumstances’ (National Maternity Review, 2016).  
The Care Quality Commission survey (2017) on women’s experiences of the maternity 
service reported small incremental improvements in all aspects of care including the 
postnatal period. Obstetric and midwifery teams were then tasked with ensuring that 
systems were in place and services were provided in such a way as to encourage pregnant 
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women to positively engage with HCPs and that services should be constantly evolving to 
meet the changing needs of women (Care Quality Commission, 2018). 
By the end of the First World War, life expectancy in the UK increased by 1 year every 4 
years but by 2010, that rate slowly decreased. Socio-economic factors contributed to the 
decline which was manifested through inequalities in health. This has led to the Marmot 
Review which was published as ‘Fair Society, Healthy Lives’. That review found striking 
differences in health between people living in wealthier and deprived communities. Central 
to that review was the recognition that a child could be disadvantaged before birth and that 
accumulates throughout that child’s life. For equity, recommendations were made to 
address the social determinants of health which included education, housing, income, 
social isolation and disability. A framework of action embedded within six policy 
objectives (Table 2.4) was presented for action by national and local governments, but 
primarily the latter (Marmot et al, 2010). 
                  Table 2.4: Marmot review 6 policy objectives 
Nos. Policy objectives 
1 Giving every child the best start in life 
2 Enabling all children, young people and adults to maximise 
their capabilities and have control over their lives 
3 Creating fair employment and good work for all 
4 Ensuring a healthy standard of living for all 
5 Creating and developing sustainable places and 
communities 
6 Strengthening the role and impact of ill-health prevention 
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Ten years on and the review has shown that things have become worse, especially for 
women. The health gap has become wider between the wealthy and deprived (Dixon, 
2020). Compared to our European counterparts, the UK has poorer outcomes in some areas 
and women from disadvantaged backgrounds are more likely to have the worse outcomes 
(Marmot, 2019). We await the report on ‘Better Births’ which aimed to address some of 
those shortcomings within its 5 years plan by providing more personalised and safer care 
for women and their babies while reducing inequalities and improving birth outcomes 
(National Maternity Review, 2016). The recent Ockendon report (2020) has shown that we 
still have a long way to go in achieving safe midwifery care but we remain hopeful.  
A woman’s pregnancy experience stretches beyond social interactions between her and her 
baby’s life but to the lives of family members, friends, their wider social network and their 
life-long interaction with health services and their providers. This in turn can determine the 
immediate and long-term health and well-being of households, the wider population and 
cost implications for the NHS and local governments (Care Quality Commission, 2018).  
Further result of the literature search to support the phenomenon of client engagement can 












2.4 The Borough of Newham 
2.4.1 Population profile 
2.4.1.1 Sex, age and ethnic distribution 
The borough of Newham has a population of approximately 353,134 (ONS, 2019). In 
2019, forty-seven percent (47%) were females with (68%) of the population between ages 
18-64 and 24.4% ≤18 years. Ethnic distribution was Asians (45.2%), Whites (27.7%), 
Blacks (17.7%) and other ethnic groups (9.3%) (Newham London, 2020).  
This ethnic mix presents many challenges for health care service providers especially as 
Newham has one of the highest birth rates in the country which is primarily from a 
younger population (Newham London, 2015). The average age of an individual living in 
Newham is 31 with a median of 29 (Newham Census Demographics United Kingdom, 
2011).  
2.4.1.2 Religion 
Religious groups within the borough were Christians 40%, Muslims 8.8%. Hindu 2.1%, 
Sikh, 9.5% had no religion, 6.4% stated no religion and 1.2% belonged to other religious 
groups (Newham Census Demographics United Kingdom, 2011). 
 
2.4.1.3 Language  
Two percent (2%; 863,000) of the population across England and Wales either spoke little 
or no English as shown in 2011 census. This figure reduced to 1% in most local authorities 
except in areas like Brent, Tower Hamlets and Newham where there was a substantial 
increase to 8% - 9% of the population (ONS, 2015). The diversity of the borough means 
that over 200 languages and dialects spoken in the borough which explains the increase. In 
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2017, 59% of the Newham population did not speak English as their first language. People 
living in the borough who spoke English were 41%, followed by Bengali (13%), Urdu 
(6%), Gujarati (5%), Punjabi (3%), Portuguese (2%), Hindi (2%), Somali (2%), Polish 
(2%) and other European languages (13%) (Ipsos MORI Social Research Institute, 2018). 
The population in Newham is constantly mobile and has become more Asians and moving 
into the borough  as seen in the shift of languages spoken in previous data where people 
living in the borough were English-speaking (59%), Bengali (7.4%), Urdu (4.4%), Gujarati 
(3.3%), Lithuanian (2.7%), Tamil (2.3%), Polish (2.0%), Punjabi (1.8%), Romanian 
(1.6%) and Portuguese (1.4%) (Newham Council Communication, 2006).  
 
2.4.1.4 Language and Health 
Data collected from the 2011 census has shown a correlation between non-proficiency in 
language and poor health. Only 65% of those who were not proficient in English enjoyed 
good health compared to 88% of those who spoke English well. Also, access and 
utilization of the available services can also be affected by non-proficiency in English 
(Newham Council Communication, 2006).  
 
2.4.1.5 Language and Employment  
In the 2011 census, non-proficiency in English was linked to unemployment.  Employed 
non-proficient females were 34% compared to 58% who were proficient at speaking 






2.4.1.6 Prevalence of diabetes  
Approximately 10% of the adult population (26,500) are diagnosed with Type 2 diabetes 
mellitus (T2 DM). Newham has a very diverse population which has contributed to this 
high prevalence (NCCG, 2017a; NCCG, 2017b). This has impacted on the number of 
GDMs locally and subsequently, the future prevalence of T2 DM since up to 50% of 
GDMs will be diagnosed with overt diabetes within ten years (Wu et al, 2016). 
Consequently, the obstetric / midwifery challenges are varied and include diabetes in 
pregnancy. 
 
2.4.1.7 Birth rate   
The population of the UK at mid-2018 was estimated to be approximately 66.4 million 
(66,435,550) – an increase by 395,000 (0.6%); a similar increase to the previous year. The 
number of births occurring in that year was 744,000 a decrease by 2% (1800.00) compared 
to the previous year and the lowest since 2006. In mid-2012, birth rate peaked by 813,000 
but has subsequently decreased by 69.000 (Office of National Statistics, 2018a).  In 2015, 
the birth rate in Newham was the 4
th
 highest in UK and second highest in London (Aston-
Mansfield, 2017). In that year, there were 6226 live births (Aston-Mansfield, 2017) but by 
2016 crude live birth rate was 18.7 per 1000 (Clark, 2018). Overall, most births were to 
women between 25 – 29 years (Public Health England, 2013).  
 
2.4.1.8 Healthy life expectancy (HLE)  
In the UK, life expectancy in 2017 for males was 79.2 years and 82.9 for females. These 
figures have remained unchanged in England (between 2014 – 2016) unlike other parts of 
the UK (Office of National Statistics, 2018b). Historically, the HLE of borough of 
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Newham is low compared to other local authorities and in 2015-2017 it remained low at 
60.7 for females and 65.3 for males (Office of National Statistics, 2018c) indicating that a 
woman living within the borough has poorer health compared to national average. Recent 
data has shown a fall in life expectancy in women living in deprived areas in England 
compared to those in wealthier areas of the country, but this is in contrast to those living in 
more deprived areas like Newham (Office of National Statistics, 2018c).     
 
2.5 Summary 
 ‘Diabetes’ and ‘diabetes in pregnancy’ are not new ‘illnesses’.  Yet, they continue to pose 
challenges to HCPs for many years. In the quest for HPs to address these challenges, 
references are continually made to early empirical evidence for strong clinical decision 
making. It is therefore not surprising that much early work, like that performed by 
O’Sullivan (1973) on ‘screening for GDM’ is still used by many practitioners to inform 
practice.  Similar studies are still being used by researchers as a basis from which to work 
when conducting relevant studies. More recently, the International Association of Diabetes 
and Pregnancy Study Group (IADPSG) study (IADPSG Consensus Panel, 2010)  is used as 
the benchmark for screening, supported by NICE guidance (2015) while pregnancy 
outcome of this group is benchmarked on the Hyperglycaemia and Adverse Pregnancy 
Outcomes (HAPO) (HAPO Study Cooperative Research Group, 2008). The lack of 
consistency probably explains why confusion still exists around the screening criteria for 
GDM and other issues related to diabetes in pregnancy and the need for future research 
using these benchmarks.  
The search revealed that there was lack of clarity on the screening criteria for GDM. NICE 
had provided guidance that women with a previous history of GDM should be screened 
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early after booking and if the result was normal, at 24-28 weeks gestation. However, it 
remains uncertain whether in boroughs like Newham with a highly diverse population and 
a high prevalence and incidence of diabetes, whether women with other risk factors like 
family history and raised BMI are screened too late. From the evidence, there is a strong 
association with these risk factors and the development of GDM. Therefore, it was 
pertinent to question whether other risk factors other than a previous history of GDM were 
responsible for the early detection of GDM and to evaluate the impact of early (≤24 weeks 
gestation) and late (≥24 weeks gestation) diagnosis of GDM on maternal and foetal 
outcomes.  
The results of the literature search have shown that pregnancy outcomes of women with T2 
DM and GDM to be sub-optimal when compared to women without diabetes. Therefore, it 
would be worthwhile to explore whether fish oil supplementation had any impact on 
maternal and foetal outcomes, particularly as previous evidence has shown that most 
pregnant women do not meet the UK recommended dose of at least 2-3 portions of fish 
weekly with at least 1 portion of oily fish. Fish oil supplementation may therefore be 
beneficial to meet this shortfall and improve maternal and foetal health and outcomes and 
was therefore worth exploring.  
Prior to embarking on the RCT, it was necessary to establish what factors impacted on a 
woman’s decision on whether to engage with HCPs. It was intended that the results of that 
question would have helped to facilitate a successful RCT. No high quality data was found 
on client engagement with HPs within the midwifery fraternity and on pregnancy outcomes 
of women with T2 DM and GDM after supplementation with fish oils. Regardless, these 
predictors were used to assess maternal and foetal health and evaluate their pregnancy 
outcomes using the themes generated and identified below. Consequently, data generated 




Various themes were derived from the literature search and will soon follow. The research 
paradigms adopted will also be described.  
 
 
2.6 The philosophical framework and research paradigms adopted  
2.6.1 Thematic approach  
A thematic approach is the utilization of recurring ideas and thoughts to guide the research 
under study. When applied to the analysis of research, themes are recurring regularities 
emerging from analyses of previous studies which help to structure the analysis and 
findings of one’s research study (Blaxter et al, 1997). 
Having explored the literature various themes were reoccurring, For example, on 
‘outcomes of diabetic pregnancies’, foetal loss, congenital abnormalities, macrosomia, low 
birth weight infants, preterm birth, IUGR, hypertensive disorders (PIH, PE, eclampsia), 
time and mode of delivery and admission to SCBU were common reoccurring themes. It 
followed naturally that the best line of research enquiry was one of replication, thereby 
focusing on similar maternal and foetal outcomes based on those themes previously 
highlighted and discussed, and to establish how findings from this study compared with 
previous data. As no previous research has been done on the local SADC, utilising existing 
themes enabled me to draw on the work of other researchers to support or refute my own 
arguments and draw conclusions based on the findings derived from each phase of this 
study (Blaxter et al, 1997). It was simply a case of not ‘re-inventing the wheel’.  
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The objective of scientific and academic writing is clear communication (Reardon-Castles, 
1987). A thematic approach was deemed an appropriate analytic framework to provide 
adequate contextualization for this study. It has afforded structure in the way the research 
was conducted, written and findings reported by adding clarity, and hopefully it would 
provide clear communication for the reader. The research paradigms adopted follows. 
 
2.6.2 Research paradigms 
Midwifery care is constantly evolving. Various initiatives have been launched from 
Changing Childbirth in 1993, the National Midwifery Review (2016) throughout to present 
day Ockendon report (Ockendon, 2020); all with the focus on safety and the provision of 
the best possible individualised care to women. Quality care has its foundation from 
evidence-based midwifery research which informs strong clinical decision making. 
Midwifery research follows a systematic line of inquiry to answer questions generated 
from problems faced in clinical practice as I have described in the personal interest section 
in chapter 1 under ‘justification’. Various constructions and interpretations of reality exist 
within midwifery. These are characterised by the unique way of working within the 
discipline and conceptualisation of all related phenomena. It is from that philosophical 
framework that research questions are generated and the methodological approach of any 
study is driven as I have demonstrated in chapters 1 and 3, respectfully.  
Research paradigms more associated with nursing are Positivist (Empiricist) and 
Naturalistic (Interpretivist / Constructivist / Post-positivist). Commonly used nursing / 
midwifery research methods are qualitative and quantitative in design and are characterised 
by ontological and epistemological differences to understand and conduct research 
(Gortner 1993, Parahoo 1997, Sapsford & Abbott 1992, & Polgar & Thomas 2000). 
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The construct of the qualitative design meant that this approach was adopted for 
experimental chapter 1 (chapter 4). This chapter explored the factors which influenced 
pregnant women’s decision to engage with HPs on the nutritional study. This design 
allowed for an interactive, subjective and systematic approach to describe women’s views 
on engagement gave meaning to those experiences by establishing the rationale for their 
decision. A non-reductionist approach was conducted to explore women’s reality in 
thoughts, beliefs, behaviours, expectations and perceptions (Foss & Ellefsen, 2001, Polgar 
& Thomas 2000 & Halcomb, 2021).  Through questioning, it was imperative to allow 
women to explain their reasons for engaging or not engaging and to gather as much 
information as possible on women’s reality in their responses after which the data was 
categorised for analysis. By allowing women to share their reality, a true conceptualisation 
of the influential factors to client engagement with HCPs could have been captured and 
shared. As the data is subjective and open to interpretation, it is associated with the 
Naturalistic/Interpretivist paradigm (Schalk–Thomas, 1990 & Halcomb, 2021).   
The quantitative design was adopted for chapters 5, 6 & 7 where relationships were 
examined; cause and effect evaluated or test for effectiveness conducted (Halcomb, 2021 
& Reaves, 1992). For example, in chapters 6 & 7, the effect of omega-3 and omega-6 on 
the health and wellbeing and pregnancy outcomes of women with GDM and T2 DM, 
respectively, were examined. This design lends itself to the reductionist paradigm where 
the research concept is broken down into parts to be studied to provide concise data after 
evaluation (Halcomb, 2021). It afforded measurability of the phenomena studied using 
numerical data which was coded and evaluated in a systematic way with the SPSS 
statistical analysis tool. Consequently, a more accurate account of the findings was 
presented within these chapters. This design emerges from the Positivist paradigm which 
places value on objectivity, rationale, prediction and control (Halcomb, 2021). Also, the 
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quantitative design was used for evaluation of the maternal and foetal outcomes in all 
experimental chapters. The quantitative and qualitative issues under inquiry were coded 
according to themes. This afforded clarity in data collection and analysis, the results 
obtained and the discussion of the issues raised throughout (Foss & Ellefsen, 2001).  





















The aims of the research programme were to investigate (1) Socio-cultural and economic 
factors which influence engagement of pregnant women with health care professionals; (2) 
Comparative pregnancy outcomes and postnatal health of women diagnosed with 
gestational diabetes mellitus (GDM) in early, and mid to late, gestations periods and (3) 
The effect of omega-3 fatty acid supplementation on the outcome of pregnancy in women 
with type 2 diabetes and GDM and the postnatal health of women with GDM.  
 
2.8 Specific aims: 
 
1. Diabetic (n=594) and non-diabetic (n=243) pregnant women aged 17 to 45 were 
recruited during antenatal appointments or home visits in the first, second and third 
(up to 32 weeks gestation) trimesters. Detailed demographic, socio-cultural and 
economic data and the interactions of the women with health care professionals 
were collected using a questionnaire developed for the study.  
2. Pregnant women diagnosed with GDM before 24 (n=212) and after 24 (n=226) 
weeks of gestation were recruited after diagnosis and up to 32 weeks gestation. 
Demographic, socio-cultural, economic and clinical, obstetric data were 
meticulously collected from hospital records and from the participants with the use 
of a questionnaire.    
3. One hundred fifty (n=149) women diagnosed with gestational diabetes were 
randomised and given DHA (n=75) or high oleic acid sunflower seed oil placebo 
(n=74) supplement until delivery. Comprehensive data was collected on diabetes 
management regimen, pregnancy complications (preeclampsia, miscarriage, 
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preterm labour, etc.), foetal outcome (prematurity, macrosomia, low birth weight, 
neonatal admission to special care baby unit, etc.) and postnatal glycaemic status. 
Also, detailed demographic, socio-cultural and economic information was gathered 
with a questionnaire designed for the study.   
4. Pregnant women with type 2 diabetes (n=96) were recruited during their antenatal 
visits in the first trimester. They were randomised into two groups and given DHA 
(n=47) or high oleic acid sunflower seed oil placebo (n=49) capsules until delivery. 
Similarly, their matching controls (non-diabetics) (n=89) were also recruited in the 
first trimester on their maternity booking appointments or on antenatal clinic visits, 
and randomised and given DHA (n=40) and placebo (n=49). Demographic, socio-
cultural, economic and maternal and foetal outcomes were collected and 
documented rigorously, using a questionnaire designed for the study.   
 
This literature review provided context for the following chapters. Chapter 3 which 
follows describes the design of the study which involves the materials and 


















Chapter 3:  
 














3.1 Chapter overview    
 
Chapter 3 builds on chapter 2 and provides the overall conduct of the study. In this chapter 
I have described the study design/method which included the study participants’ selection 
process for all phases of the study, the definitions specific for this study, the study 
intervention, and monitoring and data collection processes, and the ethical considerations 
(e.g. informed consent) and approval obtained for the study. The statistical analysis tool 
used is also described. 
I was responsible for co-ordinating all aspects of the study from set-up to study close-out. 
My role also involved training support staff {staff midwife x 1 (full-time) and 
administrative staff x 1 (full-time)} on the conduct of the study using the study protocol 
with local guidelines. Supervision was provided throughout the research process. I actively 
led on screening for eligibility, recruitment, consenting and follow-up of women. I was 
single-handedly responsible for data collection and evaluation. The supporting midwife 
focused mainly on recruitment while administrative duties were conducted mainly by the 
administrator with my help and support. However, this was a multi-disciplinary study 
which was supervised by staff (Professor and Doctor) from London Metropolitan 
University and local Professor and Obstetrician, and combined these senior and 
experienced staff provided me with the supervision and support that I needed to 







3.2 Study participants 
3.2.1 Inclusion criteria 
This was a double-blind placebo-controlled, randomised, nutritional trial which was 
conducted between 2007 & 2016 within the borough of Newham; an inner city area of 
London with predominantly a young and mobile population which is highly diverse and of 
mainly Afro-Caribbean and South Asian ethnic groups.  
Singleton pregnant women who were non-diabetics or had either T2 DM or GDM and ages 
between 17 and 45 were recruited at Newham University Hospital (NUH). Ages were 
grouped loosely based on the Office of National Statistics age grouping, the fertile periods 
in a woman’s life and for ease of data analysis. Eligible type 2 diabetics and their matching 
healthy controls (non-diabetics) were recruited <17 weeks. All women with GDM were 
recruited up to 32 weeks gestation. Non-diabetic women were offered an oral glucose 
tolerance test (OGTT) at 28 weeks gestation to exclude GDM (flow chart 1.1).  
After assessing for eligibility and prior to meeting to discuss the study in detail, a letter of 
invitation (appendix 3.1) and a small patient information leaflet (PIL) (appendix 3.2) were 
posted to clients with their antenatal appointment letters. PILs were posted routinely with 
booking appointment letters for pre-gestational diabetics and with the invitation letter to 
the GDES, for those with GDM. For the healthy controls, PILs were given when first 
approached by the researchers. Therefore, most women would have already received the 
PIL in the post prior to their first meeting with the researcher/s. The PIL was translated 
into five different languages (Bengali, Somali, Urdu, Punjabi and Tamil) and therefore the 
appropriate PIL was given. A sample of the leaflet in Bengali language (appendix 3.3) and 
the order form are enclosed (appendix 3.4). The main PIL (appendix 3.5) was given to each 
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woman on first meeting. For detailed discussion of the study and subsequent recruitment, 
all women were given the choice of home or antenatal appointments (usually ≥ 1 week), at 
which time the study was explained in detail while giving women and/or their family 
members the opportunity to ask questions and address any concerns.  
Non-diabetic women (healthy controls) were referred from the maternity booking centre 
and routine antenatal clinics while diabetic (T2 DM & GDM) women were from the 
specialist multi-disciplinary antenatal diabetes clinic (SADC) where all women with 
diabetes in pregnancy were cared for by a multi-disciplinary team comprising of a lead 
Obstetrician and Diabetologist and their supporting colleagues of similar and lower grades, 
Diabetes specialist midwives (DSM) and nurses (DSN) and a dedicated dietitian.  Women 
with GDM were also referred from the weekly gestational diabetes education sessions 
(GDES) which were run by specialist staff {DSMs (including the researcher), a DSN and 
dedicated dietitian}. 
After the initial meeting, women who showed interest were offered a follow-up 
appointment on their subsequent antenatal visit/s to the hospital or in their homes. Several 
episodes of communication and visits were often necessary to initiate recruitment but these 
were guided by women’s informed choice on whether they were to be followed-up. 
Although time consuming, it was necessary primarily for clients’ informed decision 
making to be respected and was critical to promote client engagement, compliance and 
continuation on the study. Follow-up appointments with family members and/or their 
friends were encouraged, offering women the choice to be supported and their decisions 
respected.  
Women recruited were T2 diabetics (n=136), GDMs (n=458) and non-diabetic women 
(n=243). All subjects (n=837) were included in the first arm of the study (chapter 4) (Phase 
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1) (Graph 4.1) while only women who had a diagnosis of GDM on OGTT (n=438) (Phase 
2) and women with a diagnosis of GDM and consented to the nutritional arm of the study 
(n=149) (Figure 6.1) were included in Phase 2 (chapter 5) and Phase 3 (chapter 6), 
respectively. Subjects with pre-gestational T2 DM (n=96) and consented to participate in 
the nutritional arm of the study were matched with consenting women without diabetes 
(n=88) and included in the final arm of the study as indicated in chapter 7 (Phase 4) 
(Figure 7.1) (Flow chart 1.1 & Figure 3.1.).  
Pre-gestational diabetics with T2 DM were referred to the SADC from their general 
practitioners (GPs), outreach diabetic clinics and some women self-referred. Women 
diagnosed with GDM were referred to the GDES within one to two weeks of diagnosis 
with the condition. Please refer to ‘clinical pathway’ in section 3.8 for further information 










Figure 3.1 Distribution of subjects  
 
 
3.2.2 Exclusion criteria  
Women diagnosed with GDM on random blood glucose and HBA1c were excluded from 
the study to reduce variations in screening regimen and conflict when evaluating outcomes 
measures. Also, these tests were not considered robust enough to make a confirmed 
diagnosis of GDM. Women were excluded if they were pregnant with more than one 
foetus, had known major foetal abnormalities in the index pregnancy, and chronic medical 
conditions such as sickle cell, kidney and heart diseases and HIV/AIDS. Women were also 
excluded if they were planning to receive tocolytic or corticosteroids therapy, taking 
omega 3 supplements, allergic to fish and/or fish products and those who were vegetarians 
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had a choice of whether or not they wanted to be included into the study. After re-
evaluation, women with T1 DM (n=19) were excluded from the analysis as recruitment of 
subjects within this group was small and could have affected credible statistical analyses. 
 
3.3 Screening and diagnosis 
Local screening and diagnostic criteria were broadly based on NICE 2008 guidance and 
the European Association for the Study of Diabetes (EASD) criteria (1979). 
 
3.3.1 Gestational Diabetes Mellitus (GDM) 
Women who were deemed high risk had a random blood glucose at booking and an OGTT 
at 16 weeks (or soon after booking appointment, if a late booker) and at 28 weeks 
gestation, if that early result was normal. Risk factors of GDM were a previous history 
GDM, macrosomia (birth weight of ≥4 kilograms), previous unexplained stillbirth and a 
family history of diabetes (first degree relative with Type 1 or Type 2 diabetes), maternal 
age ≥40 and either overweight or obese (BMI ≥30 kg/m
2
).  Non-indigenous women were 
also considered to be in the high-risk category as currently specified in NICE (2015) 
guidance, but at the time of conducting the study, ethnicity was not a risk factor for 
screening; yet it was used when evaluating all outcome measures.  
Diagnosis of GDM was made with a fasting glucose concentration of ≥6.1mmol/l and /or a 
2-hour value ≥7.8mmol/l after 75g glucose challenge. An OGTT was regarded as the gold 
standard for screening for diabetes. The test involved overnight fast followed by taking 
blood at 0 and 120 minutes with a glucose load of 75 grams of glucose given to the woman 
after taking the blood samples. Women who were diagnosed with GDM and who met the 




3.3.2 Type 2 diabetes mellitus (T2 DM) 
At Newham, a diagnosis of T2 DM was made on either a fasting blood glucose of 
≥7.0mmol/l and / or two-hour blood glucose of ≥11.1mmol/l after using the WHO 
screening tool of 75g oral glucose load. With symptoms of diabetes, a random blood 
glucose level of ≥11.1mmol/l was also used to make a diagnosis of T2 DM. Women with 
T2 DM were included in the study regardless of how the diagnosis was made but that 
diagnosis should have been made pre-pregnancy. 
 
3.3.3 Glycaeted haemoglobin (HBA1c) and blood glucose levels 
HBA1c measures glycaeted haemoglobin which identifies average plasma glucose 
concentrate in one’s blood. HBA1c test results provide an overview of blood glucose 
control or lack of it, when used in conjunction with blood glucose (BG) readings and an 
individual’s state of health and well-being. Target value during pregnancy was 
43mmol/mol (6.1%) (NICE, 2008 & 2015) and measured 4-weekly according to local 
policy to provide an estimate of glycaemic control. As pregnancy progresses, HBA1c 
values are usually low due to increased erythropoietin and the decreased lifespan of the red 
blood cells to 90 days (from 120 days) (Lurie & Mamet, 2000). HBA1c drops between 12-
16 weeks gestation, drops even further between 20-24 weeks (Hanson et al, 1983 & Lind 
& Cheyne, 1979) and increases during the third trimester (Phelps et al, 1983). 





3.3.4 Self blood glucose monitoring 
All women with T2 DM & GDM were taught self blood glucose monitoring (SBGM) and 
asked to record their blood glucose readings in a diary four times daily; on waking (pre-
breakfast) and 2 hours post meals (breakfast, lunch & dinner). Normal BG values pre-
meals were 4.0 mmol/l – 6.0 mmol/l and 4.0 mmol/l - 7.7 mmol/l 2-hours post-meals 
(NICE, 2008) unlike current target values of 4.0 mmol/l – 5.5 mmol/l and 4.0 mmol/l – 7.7 
mmol/l, respectively, as recommended by NICE (2015).   
 
3.3.5 Definition of Overweight and Obesity  
The World Health Organisation’s definition for overweight and obesity were adopted for 
this study, regardless of ethnicity. Overweight is classified as a body mass index (BMI) 
≥25 – 29.9 kg/m
2 
and obese and BMI ≥30 kg/m
2
. According to local hospital protocol, 
women with BMI>30 kg/m
2 
were referred to a dietician for lifestyle advice on healthy 
eating and exercise. 
 
3.4 Data collection  
Written informed consent forms designed for the study (appendix 3.6) and based on the 
principles of the Declaration of Helsinki and ethically approved (appendix 1.2) were 
obtained prior to data collection. Detailed demographic, socio-cultural, economic and 
clinical information were obtained from subjects during one-to-one interviews at the time 
of recruitment. Questionnaires designed for the study (appendices 3.7 & 3.8) were used for 
data collection. Questionnaires were developed based on discussion with investigators and 
stakeholders eg. obstetricians, diabetologists, midwives, nutritionists and researchers and 
they were piloted and modified.  
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Maternal outcome measures included pregnancy complications, early (miscarriages) or late 
(stillbirth) pregnancy loss and neonatal death. Data on hypertensive disorders in pregnancy 
(pre-eclampsia / eclampsia, or systolic blood pressure ≥140 mmHg and diastolic blood 
pressure ≥90 mmHg), onset of labour (induction of labour, spontaneous vaginal delivery & 
elective caesarean section), mode of delivery (vaginal, assisted / instrumental or caesarean 
section) and postpartum glycaemic status were also collected. Other outcome measures 
included ante-partum haemorrhage, postpartum haemorrhage, cholestasis, anaemia, ante-
partum thrombocytopenia and non-alcoholic fatty liver but due to their small numbers, 
they were grouped together as ‘other pregnancy complications’. Clinical data included 
maternal diabetes status, and glycaemic treatment and control.  
Foetal/ neonatal outcomes included birth maturity (extremely preterm <28weeks, very 
preterm 28-31weeks, moderate preterm 32-36weeks, term 37-40 weeks & post-maturity 
≥41weeks), Apgar scores (1 minute, 5 minutes & 10 minutes), low birth weight (birth 
weight ≤2499grams), macrosomia (birth weight ≥4500grams), intra-uterine growth 
restriction (confirmed on ultrasound - maternal age and ethnicity - and gestational age 
specific birth weight <90
th
 centile), congenital abnormality, admission to special care baby 
unit, reasons for admission (hypoglycaemia, respiratory distress syndrome, prematurity, 
suspected infection and poor feeding/jaundice) and stillbirth and neonatal death.  
Confounding factors included maternal characteristics of age, marital status, ethnicity, 
religion, ability to speak English, body mass index (BMI) and parity. Socio-economic 
factors of employment status of subjects and partners and pre-existing medical conditions 
and obstetric complications developed in the index pregnancy were also collected.  
Predictors of pregnancy outcomes were factors which influenced women’s decision to 
engage or not to engage with HCPs (experimental chapter 1), risk factors for early 
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detection of GDM and the gestational ages at time of diagnosis of GDM (experimental 
chapter 2), and omega-3 and omega-6 fatty acids supplementation or placebo intake in 
women with GDM (experimental chapter 3) and T2 DM (experimental chapters 4) and 
establish how these have impacted on maternal and foetal outcomes (as outlined earlier). 
Baseline data which included socio-demographic, medical and obstetric data were taken at 
the time of recruitment of women for all phases of the study, using the fore-mentioned 
questionnaires (appendices 3.7 & 3.8).  For the index pregnancy, obstetric data was 
collected prospectively from subjects through questioning and examination of women’s 
maternity hand-held records, the hospital case notes and electronic patient records (EPR). 
The EPR system was also used to collect supporting clinical obstetric (past and current), 
medical (past and current) history and biochemical (eg. haematology and OGTT) 
measurements.  
Follow up of subjects and timing of data collection varied. They were study-phase-specific. 
For subjects in Phase 1 (chapter 4) and Phase 2 (chapter 5), additional data on maternal and 
foetal health and pregnancy outcome were extracted following delivery. Following 
baseline data collected for subjects in Phases 4 (chapter 6) and 5 (chapter 7), all subjects 
received a courtesy call one week after recruitment to assess how they were having started 
the study and taking the supplements and any relevant data was collected at that time. 
Thereafter, subjects were followed up 3-monthly from the date of recruitment until the 
postnatal period. At 28 gestational weeks, non-diabetic women (only) attended for an 
OGTT to exclude GDM and all women were reviewed at 34-36 weeks (when they attended 
for a scan for a sub-study). Postnatal OGTT results were collected following the tests 
which were offered 6-8 weeks after delivery, for women in Phases 2 (chapter 5) and 3 
(chapter 6) of the study.  Intervals for data collection were at recruitment and on follow-up 
visits as indicated in flow chart 1.1.  
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Data collected was categorised and labelled into variables and coded for analysis. For 
example, study groups ‘Control-T2 DM and T2 DM’ (experimental chapter 4) and 
gestational ages at time of diagnosis of GDM {< 24 weeks (early) and ≥ 24 weeks (late)} 
(experimental chapter 2) were used with the view of testing the hypotheses and achieving 
the research aim/s. As detailed below in the ethical approval and informed consent 
sections, the services of health advocates / translators employed and approved by the Trust 
were utilised for interviews and data collection from women who spoke little or no 
English.  
 
3.5 Ethical approval and informed consent  
Application for ethical approval for this study was sought by collaborators from the 
London Metropolitan University. Ethical approval was granted by the East London and the 
City HA Local Research Ethics Committee 3 (REC reference number 06/Q0605/89) and 
registered with ISRCTN Register (REC reference no. ISRCTN68997518) (appendix 3.9). 
Local approval was also granted from the hospital (appendix 3.10) which provided 
insurance cover for the study (appendix 11). The principles of the Declaration of Helsinki 
and Good Clinical Practice were applied throughout and formed the basis for written 
informed consent from participants. Informed consent forms, PILs and questionnaires were 
approved by the ethics committee. PILs were translated in five commonly spoken 
languages (Tamil, Punjabi, Bengali, Urdu, and Somali) within the borough. Non-English 
speaking women were supported by health advocates (translators) employed by the Trust 
(Newham University Hospital Trust) and were complemented by ‘language line’ which 
was an external translation services approved by the Trust. All investigators, researchers 
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and subjects were blinded to the allocation of supplements during recruitment and 
unblinding occurred only after the completion of the study.  
The supplements used within this study are licensed and on sale in health shops, 
supermarkets and chemists in the UK and other countries. Women were informed of this 
and advised to report any possible side effects. Checks were also made one week after 
recruitment and on follow-up appointments as indicated above in flow chart 1.1.  A 
dedicated mobile telephone number linked to myself was given to women for use at 
anytime of the day including out of hours.   
 
3.6 Intervention and blinding 
After recruitment, women were randomly assigned to either treatment or placebo group. 
The treatment group received two gelatine capsules a day containing DHA enriched 
formula totalling 600mg DHA and 200mg AA from the time of recruitment until delivery.  
For the same period, the control (placebo) groups received two gelatine capsules 
containing mainly oleic acid (721 mg) for daily use. Capsules for both groups were 
encapsulated in identical oblong soft gelatin (75 mg in size) and to prevent oxidation, 10g 
of vitamin E (d-alpha tocopherol) per gram polyunsaturated fatty acids was added to each 
capsule. Allocation of supplements was as outlined in the supplement protocol (appendix 
3.12). To maintain the quality of the supplements, they were stored in a cool and dry 
cupboard, away from direct sunlight.  Daily temperature checks were done at varied times 
during the day to ensure that the temperature remained within the guided range of 4-20 
degrees to monitor the stability of the supplements. In adherence to research governance, 
the cupboard, was kept locked at all times and was accessible only by the research team.  
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Supplements were provided by Equazen/Vifor Pharma Ltd. (Glattbrugg, Switzerland) 
which was responsible for randomisation generated through a random code. Only the Data 
Manager knew the randomisation codes which were assigned in batches of nine bottles per 
subject and distributed three bottles at a time which was planned around routine antenatal 
follow-up appointments. Unblinding of allocation was made available to investigators, 
researchers and subjects after data analysis.  
Non-diabetic women received dietary advice on healthy eating in pregnancy, initially by 
the booking midwife and this was reinforced by research staff on recruitment. All T2 
diabetic women received more targeted individualised advice and a supporting healthy 
eating advice sheet (appendix 3.13) was given at booking and they were monitored 
throughout till delivery. For this group (T2 DM) one-to-one consultation with the 
dedicated dietitian in the SADC continued based on individual need, if blood sugar levels 
were unstable. Women diagnosed with GDM received similar dietetic input as women with 
T2 DM from the point of diagnosis of the condition and education received on their visit to 
the GDES and throughout till delivery.   
Contemporaneous records of the supplements were kept to ensure the correct code 
allocation to subjects on recruitment and on follow-up visits. Each subject was allocated an 
individual distribution record sheet and all supplements dispensed were logged on an 
electronic spreadsheet. That rigorous process allowed for ease and accuracy of distribution 






3.7 Compliance  
3.7.1 Self blood glucose monitoring 
As previously mentioned, target values for blood glucose values pre-breakfast and post 
meals were 4.0-6.0mmol/l and 4.0-7.7mmol/l, respectively. Women’s blood glucose levels 
(BGLs) were reviewed individually and holistically with their activity/exercise, diet and 
the general health and wellbeing of women and their babies. Lifestyle advice on healthy 
eating and exercise were provided by a dedicated dietician for pregnant diabetic women 
and by the DSN & DSM. For women with unstable BGLs, they received dietetics input 
throughout pregnancy until delivery; based on need. Lifestyle advice was reassessed and 
individual care plans put in place. Where necessary, women were re-taught SBGM. A 
diary was given to each woman to record their glucose readings which were reviewed on 
each antenatal visit. A weekly telephone clinic run by a DSN for women considered high 
risk with unstable BGLs also proved beneficial.  
 
3.7.2 Supplements  
Compliance was monitored on follow-up visits, through courtesy calls and keeping 
comprehensive records of supplements taken. Regular phone calls (including out-of-office 
hours) were made, and follow-up visits were at the hospital and/or home visits. Following 
the initial dispensing of the supplements at recruitment, women were given further supply 
at 3 months and 6 months (from the date of recruitment) and monitoring also occurred at 
those times. Supplements were discontinued at delivery.  
Women were encouraged to bring their supplement bottles (including empties) on their 
follow-up appointments and a count was made and documented. For those who did not 
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bring their bottles, a home visit was done, or women were asked to provide via text or 
telephone call, a count of the sealed bottles and the remainder of supplements in the bottle 
in use.  
Food diaries were given to women for completion, but the return rate of the completed 
forms was low, and the quality of the returned forms was poor. Consequently, the decision 
was made to omit data from food diaries from the analysis.  
 
3.8 Clinical pathway  
3.3.1 Overview 
All pregnant women with diabetes (GDM and T2 DM) were monitored in the combined 
specialist antenatal diabetic clinic (SADC) throughout until delivery by a specialist 
multidisciplinary team as previously described. Women were given access to the direct line 
for the specialist team and bleep numbers for the DSM and DSN were also made available 
to them with the view of optimising BGLs at the earliest opportunity to minimise any 
likely adverse events. Teaching was provided for women to become informed about 
diabetes on pregnancy and pregnancy on diabetes. Also, women were provided with 
relevant information on care provision within the SADC to enable them to engage with the 
specialist team and make informed decisions about their care.  
Follow up appointments were dependent of diabetes type, BG control and maternal and 
foetal and health and wellbeing. A weekly telephone clinic service was also provided to 
review the BGLs of all women who were extremely ‘high risk’ and/or who caused 




3.8.2 Pregnant diabetic and non-diabetic women 
Women were referred by their GPs to NUH maternity department for booking soon after a 
pregnancy diagnosis was made. Some women also self-referred. The aim was to book all 
women before 10 weeks gestation. Early booking was necessary to collect information on 
current and past medical, clinical and non-clinical information for early identification of 
risk factors, to effectively plan women’s care and increase the likelihood of positive 
maternal and foetal outcomes (NICE, 2016).  Follow up appointments were then planned 
and women and their babies monitored during antenatal visits with blood tests, physical 
examinations and scans. All diabetic women were followed up in the SADC and non-
diabetic women in routine antenatal clinics or in specialised clinics for conditions like 
hypertension. The non-diabetic women for this study were recruited from the maternity 
booking centre and routine antenatal clinics. 
 
3.8.3 Pregnant women with GDM 
At booking, women with risk factors of GDM were offered an OGTT at 16 and/or 28 
weeks gestation. Once a diagnosis of GDM was made as outlined above, women were 
offered an appointment within 1-2 weeks period to attend the GDM education session 
which adopted a multidisciplinary approach with a diabetes specialist midwife (DSM), 
diabetes specialist nurse (DSN) and a dietician, and in keeping with NICE (2015) 
recommendations; the national body by which the SADC is governed.   
GDM and its potential risks to mother and baby were explained. Teaching on lifestyle 
factors of healthy eating and exercise were discussed within the context of women 
managing their diabetes and the vital role those factors play in optimising maternal and 
104 
 
their foetal health and wellbeing. Education was supported by a healthy eating leaflet for 
reference (appendix 5). Women were advised to walking for at least 20-30 minutes daily as 
physical exercise during pregnancy have shown benefits in improving glycaemic control 
and in preventing and treating complications during pregnancy such as GDM and obesity 
(Filhol et al, 2014).  
Women were taught self blood glucose monitoring (SBGM) on a 1:1 basis to empower 
them to take control of their health and well-being. They were advised to monitor blood 
glucose levels (BGLs) four times daily; on waking (pre-breakfast) and 2 hours post 
breakfast, lunch and dinner and they were advised to contact the specialist team if their 
reading were outside the normal ranges (4.0mmol/l – 6.0mmol/l on fasting and 4.0mmol/l 
– 7.7mmol/l 2-hours post meals). Local values were formulated based on NICE (2008) 
recommendations and with consideration given to the local clientele. The acceptable 
normal ranges of BGLs and the interval between food consumption and testing remain 
historical debatable issues.  
At the end of each teaching session, individuals were given the opportunity to evaluate 
their results within the context of the normal ranges and advice was given on the actions 
necessary when results were abnormal. Additional practical help was provided at the end 
of each session to women who expressed anxieties around SBGM.  
Teaching sessions were opened to partners, family members and/ or friends to enable them 
to provide support to the newly diagnosed women with GDM, at a time which can be most 
daunting and stressful. Also, the wider family circle would have received the teaching and 
should have benefited personally and be better able to support women to successfully 




Women with GDM were offered a follow up appointment in the SADC a week after 
attendance to the education session and were reviewed on an average of 2-3 weeks 
intervals and weekly if BGLs were unstable. SBGM was stopped during the immediate 
postnatal period provided that their BGLs were stable. SBGM continued if their BGLs 
were out of range and women were reviewed on their follow-up appointments 6-8 weeks 
later by members of the diabetes MDT. 
 
3.8.4 Pregnant women with T2DM 
Pregnant women with T2 DM were given the earliest appointment once the pregnancy was 
confirmed. On the first appointment in the multidisciplinary specialist SADC, women were 
seen by a Consultant Diabetologist who reviewed their blood glucose readings and a plan 
put in place for future follow-up appointments. On the initial appointment, women were 
also reviewed by an Obstetrician with whom a Diabetologist would have conferred prior to 
devising an individualised plan of care. This was deemed necessary to embrace the 
multidisciplinary approach to care to achieve to perceived benefits of this notion and in 
keeping with recommendations from NICE (2008 & 2015) and local guidelines.   
Women with T2 DM were taught SBGM prior to being referred to the SADC and their 
skills were re-assessed by the DSMs or DSNs on arrival to the clinic. Any issues related to 
SBGM were addressed and clients were monitored through review of their BGLs and 
questioning during 1-2 weekly antenatal clinic appointments. Women were also 
encouraged to call the specialist midwives/nurses if BGLs were out of range and/or they 
had any concerns with SBGM, and where issues were raised, one to one teaching ensued. 
Women with T2 DM continued SBGM beyond discharge from hospital as that activity 




Pharmacotherapy (oral anti-diabetic medication and/or insulin therapy) was commonly 
used in the management of glycaemic control for women with T2 DM, pre-pregnancy and 
during pregnancy. Women with GDM and whose BGLs were not controlled by lifestyle 
modification during the antenatal period, also received similar treatment. Oral 
pharmacological agent was metformin which was considered the effective non-insulin drug 
of choice during pregnancy. An individualised sliding scale regimen was provided for the 
intra-partum period for all women on medication.  
Post-delivery, anti-diabetic medication was stopped for all women with GDM and their 
diabetes control was reviewed. A six to eight weeks OGTT was offered, and lifestyle 
modification behaviour was encouraged. Women with abnormal BGLs at this stage were 
followed up in the outreach diabetes clinics and those with normal results were to have 
annual diabetes review; arranged by their GPs. Women with T2 DM were returned to their 
pre-pregnancy medication regimen, unless otherwise indicated. Also, they were followed-
up in the outreach diabetes clinic within six to eight weeks.   
 
3.10 Statistical Analysis 
Methods used to analyse the data will be described in each chapter, but independent 
variables were used to assess their impact/effect on women’s participation or lack of 
participation in research, early and late diagnosis of GDM and maternal and foetal 
outcomes with and without supplementation with omega 3 fatty acids, throughout to the 
postnatal period. Variables included women’s ages, booking BMI, ethnicity, religion, 
employment status, their ability to speak English, gravida/parity, gestation at time of 
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approach, chronic medical history, and pregnancy complications developed. HBA1c levels 
at recruitment and pre-delivery and anti-diabetes treatment (pre- and during pregnancy) 
were recorded. Occupation was classified using the Registrar General Social Class Scale 
(1911-present).   
Pearson’s Chi square analyses were used to establish any relationship between the 
confounding variables and predictors. For example, to establish the relationship between 
lack of engagement and pregnancy outcomes, the Pearson’s Chi square crosstabulation test 
was used. Also, Chi square test was used to evaluate any differences in pregnancy outcome 
data.  
Independent T-test analyses were performed to compare identified predictors with 
confounding factors and predictors and pregnancy outcomes.  The independent samples T-
test was used to assess whether the means of those in the active and placebo groups differ 
in terms of birth weight and Apgar scores, in keeping with McCormick et al (2015) model 
on hypothesis testing. Based on theory of variance as outlined by (McCormick et al, 2015), 
the assumption made was that birth weight and Apgar scores which are continuous 
dependent variables, are normally distributed and of similar variations within the active 
and supplemented groups (homogeneity of variance). Therefore, the Independent T-test is 
deemed appropriate for use in testing whether the means of women who received fish oils 
and placebo differ in their babies’ weight and Apgar scores at 1, 5 and 10 minutes.  
Anova test of homogeneity of variance was used to test if there were differences between 
the fish oils and placebo groups with e.g., birth weight and Apgar scores were statistically 




IBM SPSS for Windows (version 25) (IBM Corporation, Armonk NY, USA) was used to 
perform all statistical analyses. Statistical significance was defined as p<0.05. 
In each chapter, the statistical analyses relevant to those chapters will be discussed further. 
 
The following chapter 4 has examined the factors that influence a pregnant woman’s 
decision on whether or not to engage with HCPs on the nutritional study and the impact 
















Chapter 4:  
 
Factors that influence 
engagement of pregnant women 
with health professionals: impact 







4.1 Chapter overview    
In this chapter, I have explored the factors which influenced women’s decision on whether 
or not to engage with HCPs and the impact of their decision on maternal and foetal 
outcomes.  To do this, women with T2 DM, GDM and without diabetes were approached 
by random selection and offered the opportunity to take part in the nutritional study and 
information on their decision, socio-cultural, economic and clinical data collected using 
questionnaires (appendices 3.7 & 3.8).  This chapter is the first phase of the study and laid 
the foundation for chapters 5 – 7 (Phases 2-4), particularly around subjects’ selection and 




4.2.1 Concept of engagement / non- engagement  
Engagement is defined as “actions individuals take to obtain the greatest benefit from the 
health care services available to them” (Gruman et al, 2010 p 351). Engagement and non-
engagement are terms use mainly within this first phase of the study. Lack of engagement 
and non-engagement mean the same and are used interchangeably within this study. 
Women were described as non-engaged when they didn’t show interest or ask questions 
about the study even though the PILs would have been offered in their spoken language 
and non-English speaking women would have been supported by health advocates on their 
initial meetings. Non-engagement extended to include when women declined accepting the 
PIL, offered no response when approached by researchers who were HCPs, declined 
hearing about the study and declined participation. Lack of engagement was measured by 
women declining to become part of the study when first approached or after being 
followed up. A positive level of engagement described when women showed interest in the 
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study and was later recruited after providing written informed consent, irrespective of the 
number of encounters with HCPs. Partial engagement referred to the ‘considerers’ who 
showed interest and were given time to decide whether or not they wanted to become part 
of the study. Final outcome refers to the final decision made by women whether they 
engaged or not engaged with HCPs, regardless of whether or not they showed interest 
and/or were followed up.  
 
4.2.2 Health inequality and access 
The experience of pregnancy and childbirth is very complex and multidimensional. Local 
health authorities are tasked with making the journey along the trajectory from the 
antenatal period to the postnatal period as pleasant and risk-free as possible. The quantity 
and quality of resources invested along this pathway to reduce the mortality and morbidity 
associated with pregnancy and childbirth vary depending on where in the world women are 
cared for and by whom.  
Globally, approximately 289,000 deaths occurred in 2013, a 49% decrease from 1990 
(WHO, 2014). Disparities exist between the developing countries and the Western world in 
the maternal mortality ratio (MMR). For example, in 2015, the rate in the Philippines was 
114:100,000 compared to 12:100,000 in countries like the UK (WHO, 2015). Disparities 
also exist among BAME women who tend to have poorer birth outcomes compared to their 
White counterparts (Garcia et al, 2015). Additionally, as DM is more prevalent among this 
group (Diabetes UK, 2020 & 2016), and pregnant diabetics have poorer birth outcomes 
compared to non-diabetic women (Hosseini, et al, 2018; Kennedy, 2017; Gabbay-Benziv 
& Baschat, 2015; Antonio Negrato et al, 2012 & CEMACH, 2007), BAME women with 
diabetes would be severely disadvantaged in terms of their birth outcomes. Regardless, to 
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reduce this disparity, women can benefit from health care if they have considerable 
knowledge and are motivated to actively engage with the care available to them (Gruman 
et al, 2010).  
Only 58% of women can access prenatal care worldwide (UNICEF, 2017). This is 
postulated to be due to ‘proximity to services, transportation cost, availability of skills, 
knowledge of availability services, knowing when to seek care, underlying gender 
inequality and cultural hierarchy that can affect decision making’, which individually or 
combined can result in morbidity and/or mortality (Public Health England, 2017).  
In the UK, the national drive is to reduce the Maternity Mortality Ratio and this can be 
achieved by services tailored to meet the needs of its local populations and women 
engaging with HCPs involved in their care and accessing care in a timely fashion. This is 
based on a philosophy of putting women, their babies and their families at the centre of 
care planning and delivery (National Maternity Service Review, 2016 & NICE, 2016).  
 
4.2.3 Maternity service provision: Newham University Hospital (NUH) 
Almost 50% of the population of Newham in East London are female with nearing 70% 
between ages 18-64, as previously shown in chapter 2 (section 2.4.1) and combined these 
factors have impacted on the high birth rate within the borough. The ethnic distribution is 
vast with the indigenous group being in the minority (Newham London, 2015 & 2020). 
Asians remain the dominant cultural group (Newham London, 2015 & 2020) but the 
population is still rapidly changing with the arrival of Europeans now residing in the area 
and with an explosion of regeneration projects which started prior to and continued since 
London 2012 Olympics (ONS, 2019). Deprivation and cultural diversity result in complex 
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medical and social issues and a high incidence of morbidity and co-morbidities (O’Driscol 
2018, Dawson et al 2018, Jayaweera 2010, Cumberlegde 2015 & DOH 2013}, possibly the 
cause of Newham having one of the highest death rates in London (ONS, 2017).   
In pregnancy, women can present with complex health needs comprising of pre-existing 
conditions like hypertension while others are diagnosed during (gestational diabetes 
mellitus - GDM) and/or after pregnancy (postnatal depression).  Individually or combined, 
these can have adverse effects on women’s and their babies’ health and pose a huge 
challenge for healthcare policy makers to provide equitable access for all (Szczepura, 
2005). Therefore, it is paramount that care services embrace the notion of a multi-
dimensional, multi-faceted and all-encompassing approach to ensure that holistic high care 
quality care is available for local pregnant women to reduce potential morbidity and 
mortality.  
The local midwifery services embrace this framework which incorporates specialist 
midwifery provision in areas, for example, mental health, diabetes and when caring for 
teenage and vulnerable women. The primary aim of these services is to promote 
engagement of women with specialist HCPs for help and support, through an accessible 
service with continuity of care for their client groups and to optimize the quality of care 
provided.  
Additionally, Newham has one of the highest annual birth rates compared to other UK 
hospitals (Aston Mansfield Community investment Unit, 2017 & ONS, 2015) and this has 
formed the cornerstone for the recent rebuild of the maternity wards and facilities 
following consultation with the local community and stakeholders in order to develop 
services that match the needs of its local service users. Other new and improved services 
include community birthing centre facilities, a low-risk birthing unit, and a 24-hours 
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telephone helpline. Women can also self-refer for booking and access the 24-hours 
assessment unit. On one hand, the availability of these services to meet the needs of local 
women is good but on the other hand, women need to engage with the services made 
available to them, for those services to become meaningful.  
 
4.2.4 Possible reasons for non-engagement: local and national measures taken  
Despite the availability of local services, women are not adequately engaging, and this is 
believed to be due to traditional ways in which health service is delivered {Blunt, 2014; 
National Institute for Clinical Excellence (NICE), 2014a} and possibly, structural and 
population characteristics (NICE, 2014b). Positive and negative women’s experience at the 
reception desk may have similar impact on their engagement with HCPs throughout their 
pregnancy journey. In recognition of this shortfall, some work through patients and public 
engagement programs has commenced to encourage active engagement in the decision-
making around the tendering and procurement of services (Newham Clinical 
Commissioning Group, 2017). NICE (2014b) has provided guidance on the use of 
community engagement for care delivery. In 2016, ‘Better Birth’ was launched by the 
National Maternity Service Review to reduce variations of quality of care and encourage 
women to be partners in care planning. Based on this notion, local needs can be tailored 
and delivered with local women being at the nucleus to promote equity in accessing 
services.  
A cross sectional analysis of routine data was conducted at the local hospital to evaluate 
the initiation of engagement with maternity services for antenatal care. Conclusions were 
that late engagement was predominantly among non-Whites who were born outside the UK 
and were non-English speaking. Women of Afro-Caribbean origin were more likely to 
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engage with services late compared to their White counterpart. Other factors included high 
parity, maternal age younger than 20 and living in temporary accommodation (Cresswell et 
al, 2013).  
Despite this information, the scientific evidence remains outstanding for the Newham 
specific needs on the core factors responsible for engagement and/or lack of it, particularly 
as Newham is more research active. One may argue that it is futile having the best high-
quality resources if (a) disconnect exists between service providers and users it purports to 
embrace and (b) a lack of understanding exists as to why that it.  
Therefore, only by addressing the problem through research, the factors responsible for the 
lack of uptake of services can be effectively addressed and maternity services restructured 
to form the bedrock for engagement with local pregnant women who can then benefit 
significantly from the services available to them. Subsequently, potential morbidity and 
mortality can be reduced. A plethora of evidence has demonstrated a strong link between 
deprivation and adverse nutritional health (Marmot, 2019; Marmot, 2012; Marmot, 2005) 
and pregnancy outcomes (Min et al, 2016). With deprivation being significantly high in the 
borough of Newham, this study provided women with the opportunity to improve their 












The aim of this phase of the study is to investigate: -  
Socio-economic, cultural, religious and demographical factors which hinder effective 
engagement of pregnant women with health professionals in the London Borough of 
Newham. It was therefore necessary to: - 
 Establish the level of engagement of local women with HCPs. 
 Elucidate factors which may influence or hinder effective engagement with HCPs.   
 Evaluate possible ramifications of patients’ lack of engagement on maternal and 
foetal outcomes.   
4.4 Subjects and Methods 
This was an observational cross-sectional study of pregnant women who were willing to 
participate or not participate in a nutritional study. Women were ages between 17 and 45 
and booked at Newham hospital. They were randomly approached at the hospital’s 
specialist antenatal diabetes clinic (SADC), gestational diabetes education sessions 
(GDESs), and routine maternity booking and antenatal clinics and offered the opportunity 
to improve their nutritional health.  
All subjects approached were included in this phase of the study. Women with T2 DM and 
their matching comparisons without diabetes were recruited before 17 weeks gestation 
while women with gestational diabetes mellitus (GDM) were recruited when the diagnosis 
was made and up to 32 weeks gestation. Women without diabetes were also recruited up to 
32 weeks gestation (Figure 4.1).  
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A questionnaire designed for the study (appendix 3.8) was used for data collection on 
reasons given by women for their engagement or non-engagement with HCPs on the 
nutritional study. Other information collected included women’s ages, ethnicity, religion, 
employment status, ability to speak English, parity, gestation at time of approach, past and 
present medical and/or obstetric history and/or complications and whether or not women 
had support with their decision on engagement or lack of engagement with HCPs. Please 
refer to chapter 3 for further details.  
 
4.5 Statistical Analysis  
As mentioned in the Subjects and Methods Chapter (3), the IBM SPSS Statistics for 
Windows (Version 25) analysis framework was used. The levels of measurements used for 
this chapter were nominal and categorical data. The number of cases which appeared in 
each category was counted to either accept or nullify the hypotheses and descriptive 
statistics were used to establish frequencies in data, for example, to establish how many 
women were in the different study groups and engaged when first approached and after 
follow-up. Data are reported as mean and standard deviation (mean ± SD). Two different 
unpaired samples were compared and therefore the independent T test was used, for 
example, to test the statistical mean between birth weight, gestational ages at delivery and 
levels of engagement.  
The Chi-square (cross tabulation), Pearson’s correlation test for independent samples was 
used to analyse any pattern of observed frequencies which may suggest a correlation 
between variables tested (Foster 2001 & Kinnear & Gray 2008), for example, whether 
there was an association between marital status and engagement and engagement and 





4.6.1 Characteristics of subjects 
4.6.1.1 Study subjects distribution 
Of the total number of subjects studied (n=837), women diagnosed with GDM was 458 
(55%) while healthy controls and T2 diabetics were 243 (29%) and 136 (16%) respectively 
(Graph 4.1). Overall, the level of engagement within these groups was 120 (33%) controls, 
151 (42%) GDMs and 90 (25%) T2 diabetics.   
 
4.6.1.1.1 Age, marital status, parity, BMI and folic acid use 
Baseline characteristics of the participants are provided in Table 4.1. Most engaged 
pregnant women (n=370) were married (n=326, 88%) (p < 0.001) with a mean age of 31 
years and between 21- 40 years (n=339, 92%) (p < 0.002). Mean BMI was 28.51kg/m
2
 
with 131 (35%) and 139 (38.0%) being overweight and obese, respectively while 86 (23%) 
were of normal weight (p < 0.939). Mean parity was 2.08 with similar distribution of 
women being first time mothers (n=127, 34%) and those having had 2 - 4 children (n=129, 
34%). Of all women studied, 50% (429) used folic acid during pregnancy and 72% (256) 
users were among those who engaged.  
4.6.1.1.2 Ethnicity, Language & Religion 
Two hundred and one (54.3%) of engaged women were Asians, 113 (31.0%) were Afro-
Caribbeans and 55 (15%) were Whites (p < .002). Two hundred and eighty-one (70%) 
were English-speaking (p < .001). Most women were Muslims (n=182, 58%), followed by 
Christians (n=149, 33%) and Hindus & Sikhs (n=29, 9%) (p < .002) (Table 4.1). 
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4.6.1.1.3 Employment status:  engagement and ethnicity  
Most women were unemployed (n=204, 41%); very few occupied managerial positions (n 
= 39, 10%) and for the remaining who worked (n=127, 29%), they were in the middle to 
lower economic groups (p = .026). Most partners did routine manual jobs (n=134, 36%) 
while 62 (17%) were managers and the remaining (n=174, 24% each) equally distributed 
between intermediate jobs and the unemployed (Table 4.1).  
Combined, patients in the managerial / intermediate occupations, and those who were 
either students, unemployed or had routine / manual jobs were 17 (31%) / 38 (69%) 
Whites, 42 (37%) / 71 (63%) Afro-Caribbeans and 39 (19%) / 162 (81%) Asians, 
respectively, for the engaged 17 (31%) / 38 (70%) Whites, 42 (37% / 71 (63%) Afro-
Caribbeans and 39 (19%) / 162 (81%) Asians (p < .000). Respectively, for the non-
engaged, there were 15 (30%) / 28 (70%) Whites, 28 (27%) / 75 (73%) Afro-Caribbeans 
and 57 (19%) / 250 (81%) Asians (p < .000).  For the partners, combined in professional 
jobs and for those who were either lower paid jobs and the unemployed were 11 (20%) / 44 
(80%) Whites, 46 (41%) / 67 (59%) Afro-Caribbeans and 86 (44%) / 109 (54%) Asians, 
respectively (p < 008). For the non-engaged, there were 11 (22%) / 39 (78.0) Whites, 29 
(28%) / 74 (72%) Afro-Caribbeans and 19 (39%) / 188 (61%) Asians (p < .001), 
respectively, combined in professional jobs and for those who were either lower paid jobs 

























Table 4.1: Characteristics of participants 
  
Levels of engagement on 1st approach  
Final levels of engagement after follow-
up 
        
 











No. of Subjects (n)  226 310 255 
 
370 460 
 Age, (years) (mean 31.0) n (%) 




       ≤ 21 6 (24.0)  10 (40.0) 9 (36.0)
 
12 (45.2) 14 (53.8)
        21 – 30 99 (28.3) 140 (40.0) 111 (31.7) 
 
158 (43.2) 208 (56.8 
 
       31 – 40 
109 
(29.0) 142 (37.8) 125 (33.2) 
 
181 (45.5) 218 (54.6) 
        ≥ 40 12 (30.0) 18 (45.0) 10 (25.0) 
 
19 (48.7) 20 (51.3) 
 Body mass index (BMI) 
(kg/m2), (mean 28.51) n (%) 




       Underweight (<18.5) 5 (27.8) 8 (44.4) 5 (27.8)
 
8 (42.1) 11 (57.9) 
        Normal weight (18.5-24.9) 53 (26.6) 83 (41.7) 63 (31.7) 
 
86 (43.4) 112 (56.6) 
        Over weight (25.0-29.9) 79 (30.2) 88 (33.6) 95 (36.3) 
 
131 (46.1) 153 (53.9) 
        Obese (≥30) 84 (28.8) 115 (39.4) 93 (31.8) 
 
139 (45.0) 170 (55.0) 
 Marital status, n (%) 




       Married  
191
(26.1) 296 (40.4) 245 (33.5) 
 
326 (42.3) 445 (57.7) 
        Single 33 (58.9) 13 (23.2) 10 (17.9) 
 
42 (75.0) 14 (25.0) 
 Ethnicity, n (%) 




       All Whites 41 (40.6) 36 (35.6) 24 (23.8)
 
55 (52.4) 50 (47.6)
        Afro-Caribbeans 74 (35.7 78 (37.7) 55 (26.6) 
 
113 (52.3) 103 (47.7) 
 
       Asians 
110 
(22.8) 196 (40.7) 176 (36.5) 
 
201 (39.6) 307 (60.4) 
 Religion, n (%) 




       Hindu & Sikh 23 (31.5) 31 (42.5) 19 (26.0)
 
29 (38.2) 47 (61.8)
        Muslim  90 (20.5) 182 (41.5) 167 (38.0) 
 
182 (39.4) 280 (60.6) 
 
       Christian 
106 
(42.1) 85 (33.7) 61 (24.2) 
 
149 (56.9) 113 (43.1) 
 Language, n (%) 




       English 
180
(32.3) 207 (37.2) 170 (30.5) 
 
281 (48.4) 300 (51.6) 
        Non-English 46 (19.7) 103 (44.0) 85 (36.3) 
 
89 (35.7) 160 (64.3) 
 Parity, (mean 2.08) n (%) 




       No previous child 72 (25.6) 117 (41.6) 92 (32.7)
 
127 (43.2) 167 (56.8)
        1 child 65 (33.0) 73 (37.1) 59 (29.9) 
 
97 (47.1) 109 (52.9) 
        2-4 children 81 (29.1) 107 (38.5) 90 (32.4) 
 
129 (43.6) 167 (56.4) 
        ≥ 5 children 7 (20.6) 13 (38.2) 14 (41.2) 
 
16 (48.5) 17 (51.5) 
 Employment status - 
Subjects, n (%) 




       Managerial & professional 26 (33.3) 24 (30.8) 28 (35.9)
 
39 (50.6) 38 (49.4)
        Intermediate 40 (33.9) 44 (37.3) 34 (28.8) 
 
59 (48.8) 62 (51.2) 
        Routine & Manual 46 (35.7) 44 (34.1) 39 (30.2) 
 
68 (53.1) 60 (46.9) 
        Unemployed, student, not 
classified / stated 
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(24.5) 198 (42.5) 154 (33.0) 
 
204 (40.5) 300 (59.5) 
 Employment status - 
Partners, n (%) 




       Managerial & professional 35 (25.9) 50 (37.0) 50 (37.0)
 
62 (44) 79 (56)
        Intermediate 53 (33.3) 50 (31.4) 56 (35.2) 
 
87 (52.1 80 (47.9) 
        Routine & Manual 82 (31.3) 104 (39.7) 76 (29.0) 
 
134 (47.9) 146 (52.1) 
        Unemployed, student, not 
classified / stated 56 (23.8) 106 (45.1) 73 (31.1) 
 
87 (36) 155 (64) 
 Folic acid use, n (%) 
      
.000 (1)
       Yes 
    
257 (60.5) 168 (39.5) 
        No  
    
102 (27.6) 267 (72.4) 
 Support present when 
engagement decision made, n 
(%) 
      
.000 (2) 
       Alone  
    
67 (91.8) 6 (8.2) 
        Husband and/or relative 
    
196 (77.2) 58 (22.8) 
        Unknown 
    










Employment status (Patients) Whites Afro-Caribbean Asians 
P value / standard
deviation (df) 
Engaged, n (%)  55 113 201 .000 (6) 
       Managerial & professional 5 (12.8) 24 (61.5) 10 (25.6) 
        Intermediate 12 (20.3) 18 (30.5) 29 (49.2) 
        Routine & Manual 13 (19.1) 17 (25.0) 38 (55.9) 
        Unemployed, student, not classified /          
stated 25 (12.3) 54 (26.6) 124 (61.1) 
 Non-Engaged, n % 50 103 307 .000 (6) 
       Managerial & professional 6 (15.8) 10 (26.3) 22 (57.9) 
        Intermediate 9 (14.5) 18 (29.0) 35 (56.5) 
        Routine & Manual 14 (23.3) 19 (31.7) 27 (45.0) 
        Unemployed, student, not classified / stated 21 (7.0) 56 (18.7) 223 (74.3) 
 
     Employment status (Partners) 
    Engaged, n (%)  55 113 201 .008 (6) 
       Managerial & professional 7 (11.3) 19 (30.6) 30 (58.1) 
        Intermediate 4 (4.6) 27 (31.0) 56 (64.4) 
        Routine & Manual 29 (21.6) 34 (25.4) 71 (53.0 
        Unemployed, student, not classified /          
stated 15 (17.5) 33 (38.4) 38 (44.2) 
 Non-Engaged, n % 50 103 307 .001 (6)
       Managerial & professional 4 (5.1) 9 (11.4) 66 (83.5) 
        Intermediate 7 (8.8) 20 (25.0) 53 (66.3) 
        Routine & Manual 22 (15.1) 25 (17.1) 99 (67.8) 
        Unemployed, student, not classified / stated 17 (11.0) 49 (31.6) 89 (57.4) 
  
 
4.6.2 Engagement at first and final meetings  
The level of engagement on first and final meetings was similar, regardless of demographic 
profiling. Of all women studied, approximately a third (n = 229, 29%) consented when first 
approached while 255 (32%) agreed to be followed up to participate in the nutritional arm 
of the study.  Of those considerers, 14 (5.6%) were lost to follow-up and 12 (4.8%) 
exceeded the gestational age and were therefore no longer eligible to making a decision on 
whether or not to engage. Approximately two-thirds (n = 140, 61%) engaged when they 
were followed up totalling an overall recruitment of 370 (43.2%) and non-engagement 460 
(53.7%) (Tables 4.1 & 4.2). Sixty-seven (18%) women were alone and 196 (53%) received 
social support when the decision was made whether or not to engage (p < .000).  
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The reasons given for women’s lack of engagement are outlined in figure 4.1. These 
reasons were varied and included no research interest 90 (22.6 %), time constraints 39 
(9.8%) and family members influence 41(10.3%). That level of persuasion was apparent 
among the ‘considers’ (n = 255), as 140 (55%) wanted ‘more time’ to make a decision 
while the remaining 115 (45%) stated that they needed to discuss the study with their 
husbands and/or family members prior to making that decision.  
There was some reluctance to disclose the reasons for lack of engagement and this 
accounted for nearly a third (n = 121, 30.3%) of non-participants. For women who 
engaged, the likely benefits to their baby were the main reason given as can be surmised in 
Box 4.1. Other reasons were religious, altruistic (wanting to do good for others) and use of 
little of their time.   

























 ‘If it can be good for my wife and baby’ 
 ‘Anything that might help me and my baby …and help others’ 
 
 ‘Maybe I will have some good out of it’ 
 
 Only if it’s Halal 
 
 ‘Sounds good …..although other children did not have it’ 
 
 ‘Sounds great but I need to discuss it with my husband / family first’   
 
 ‘My family is a doctor (overseas) so let me discuss it and I will let you know’  
 
 ‘Want the best for baby’ 
 
 ‘If it can help others’ 
 
 ‘I’ve got too much on ……but I will…..benefit to baby’ 
 
 ‘If I don’t have to take time off work …I will’   
 
 ‘I don’t like taking tablets….. but I’ll try…help baby’ 
 
 ‘I hate taking tablets. But if it can be good for my baby…’ 
 ‘Only if it is free’ 
 
 ‘Only if it doesn’t take too much of my time’ 
 





4.6.3 Factors which impact on engagement / lack of engagement 
The implications of demographic and socio-economic factors and the impact of these on 
engagement and folic acid use in pregnancy were examined.  
 
4.6.3.1 Demographic and socio-economic factors on engagement 
4.6.3.1.1 Age: 
Engagement was similar in all age groups with a slight increase among those ages forty 
and above (Table 4.1). The difference was p < 0.875. 
4.6.3.1.2 Marital Status: 
Seventy-five percent (75%) of singletons engaged compared to forty-two percent (42%) of 
those who were married (Table 4.1). The difference was p <0.001. 
4.6.3.1.3 Language: 
Forty-eight percent of women who spoke English engaged compared to thirty-six percent 
(36%) of those who did not speak English (Table 4.1). The difference was p < 0.001. 
4.6.3.1.4 Ethnicity: 
Approximately half Whites and Afro-Caribbean engaged (52%) compared to Asians (40%) 
(Table 4.1). The difference was p < .002. 
4.6.3.1.5 BMI:  





Of the Christians approached, fifty-seven percent (57%) engaged compared to Muslims 
and Hindus & Sikhs among whom there was no difference in engagement (39%) (Table 
4.1). The difference was p < 0.001. 
4.6.3.1.7 Parity: 
Engagement was similar whatever a woman’s parity although there was a slight increase 
among multiparous women and those with one previous child (Table 4.1). The difference 
was (p < 0.783).  
4.6.3.1.8 Employment status: Women 
Professionals and those with managerial and intermediate jobs had 51% and 49% level of 
engagement, respectively, compared to those who had routine and manual jobs (54%). 
Students and the unemployed demonstrated a lower level of engagement (41%) (Table 
4.1). The difference was p < 0.026.  
4.6.3.1.9 Employment status: Partners 
Similarly, women of partners who were students or unemployed had a lower level of 
engagement (36%) compared to those who had intermediate occupations (52%), 
professionals (44%) and manual workers (48%) (Table 4.1). A difference of p < 0.006 
existed.  
4.6.3.1.10 Support received 
Engagement was higher among those who were alone (92%) compared to those whose 




4.6.3.2 Demographic and socio-economic factors and folic acid use 
4.6.3.2.1 Marital status: 
Folic acid use was higher among singletons (65%) compared to married women (51%) 
(Table 4.1). The difference was p < 0.050. 
4.6.3.2.2 Language: 
The use of folic acid among English-speaking women was fifty-seven percent (57%) 
compared to those who did not speak the language (40%) (Table 4.1). The difference was 
p < 0.0001. 
4.6.3.2.3 Ethnicity: 
Folic acid use among the Whites, Afro-Caribbeans, and East Asians was similar (56-57%) 
unlike the South Asians (50%) (Table 4.1). The difference was p < 0.472. 
4.6.3.2.4 BMI:  
In the various BMI categories, folic acid use was underweight 47%, normal 53.5%, 
overweight 56.2% and obese 49.7% (Table 4.1). The difference was p < 0.436.   
4.6.3.2.5 Religion: 
Muslims had a forty-seven percent (47%) uptake of folic acid compared to other religions 
(Table 4.1). The difference was p < 0.002. 
4.6.3.2.6 Parity:  
More than half of singletons (54.4%) and women with one previous child (57.1%) used 
folic acid compared to women with 2 – 4 children (48.0%) and those with five or more 
children (45.5%) who had under 50% usage (Table 4.1). The difference was (p < 0.155).   
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4.6.3.2.7 Employment status: 
4.6.3.2.7.1 Employment status of clients 
Women in managerial/professional and intermediate jobs had an uptake of folic acid use of 
approximately sixty (60%) compared to routine/manual (55%) and students and the 
unemployed (48%) (Table 4.1). The difference was p < 0.014. 
4.6.3.2.7.2 Employment status of client’s partners 
The use of folic acid of women whose partners were in managerial/professional jobs was 
58% compared to the unemployed (49%) (Table 4.1). The difference was p < 0.253. 
 
4.6.4 Implications of engagement / lack of engagement on maternal and 
foetal outcomes  
Pregnancy outcome data is presented in Table 4.3.  In women who engaged and did non-
engaged, 172 (47%) vs 249 (54%) developed pregnancy complications. The statistical 
difference was p < 0.001. The incidence of IUGR 14 (4%) vs 14 (3%) and hypertensive 
disorders (PIH, pre-eclamsia or eclampsia) 33 (10%) vs 34 (8%) were similar in both 
groups. On scan, detection of big babies was 22 (6%) and 49 (12%) while presumed foetal 
compromise and other pregnancy complications were 29 (9%) vs 41 (10%) and 21 (7%) vs 
66 (16%) in women who engaged and did non-engaged, respectively. Furthermore, in the 
engaged group, stillbirths 4, neonatal death 1, miscarriages 24 compared to stillbirth 1, 
miscarriages 9 and congenital abnormality I in women who did not engage. 
Premature birth was 59 / 65 in the engaged and non-engaged women (excluding stillbirths, 
miscarriages and neonatal death), respectively (p < 0.001). Of those engaged and non-
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engaged women had, 2 / 5 macrosomia and 46 / 36 low birth weight infants, respectively 
(p < 0.037). Onset of labour for women recruited and not recruited were 145 (45%) / 206 
(49%) spontaneous, 110 (34%) / 143 (34%) induced and 67 (21%) / 69 (17%) elective 
caesarean section, respectively (p < 0.283) and mode of delivery 149 (46%) / 206 (49%) 
vaginal, 17 (5%) / 29 (7%) instrumental and 156 (48%) / 183 (44%) caesarean section, 
respectively (p < 0.366). Thirty-one (10%) babies of engaged and 35 (8%) of non-engaged 
were admitted to special care baby unit (p < 0.400) (Table 4.3).  
With use of the independent sample t-test, birth weight mean = 3082.53 grams (df = 
615.06) and for those who were not recruited mean = 3187.85 grams, (df = 591.30); t (735) 
= -2.36, respectively (p < 0.019). Gestational ages at birth for those who engaged (n = 323) 
and those who did not (n = 418), mean = 37.49 grams, df = 2.58) and mean = 37.88 grams, 













Table 4.3: Impact of engagement and non-engagement on pregnancy outcomes  
 Levels of engagement  P value  /  (df) 
Pregnancy outcome measures Engaged Non-Engaged  
Pregnancy complications, n (%) 370 460 .001 (7) 
None 198 (61.9) 211 (49.9)  
IUGR by scan 14 (4.4) 14 (3.3)  
Big baby by scan 22 (6.9) 49 (11.6)  
Congenital abnormality 0 (0.0) 1 (0.2)  
Malpresentation 3 (0.9) 7 (1.7)  
PIH, Pre-eclampsia or Eclampsia 33 (10.3) 34 (8.0)  
¤ Presumed foetal compromise 29 (9.1) 41 (9.7)  
✤Other pregnancy complications 21 (6.6) 66 (15.6)  
Onset of labour, n (%) 322 418 .283 (2) 
Spontaneous 145 (45.0) 206 (49.3)  
Induced 110 (34.2) 143 (34.2)  
Elective caesarean 67 (20.8) 69 (16.5)  
Mode of delivery, n (%) 322 418 .366 (2) 
Vaginal 149 (46.3) 206 (49.3)  
Instrumental 17 (5.3) 29 (6.9)  
Caesarean section 156 (48.4) 183 (43.8)  
Birth outcome, n (%) 347 427 .006 (5) 
Full term birth live 258 (74.4) 353 (82.7)  
Preterm birth live 59 (17.0) 63 (14.8)  
Stillbirth 4 (1.2) 1 (0.2)  
Neonatal death 1 (0.3) 0 (0.0)  
Miscarriages 24 (6.9) 9 (2.1)  
Medical TOP 1 (0.3) 1 (0.2)  
Gestational ages at birth, n (%) 347 427 .001 (2) 
Full term birth 258 (74.4) 351 (82.2)  
Preterm birth 59 (17.0) 65 (15.2)  
*Other outcomes 30 (8.6) 11 (2.6)  
Birth Weight, n (%)  319 417 .037 (2) 
Low birth weight (≤2499grams) 46 (14.4) 36 (8.6)  
Normal birth weight (2500 - 4449grams) 271 (85.0) 376 (90.2)  
Macrosomia (≥4500grams) 2 (0.6) 5 (1.2)  
Admission to Special care baby unit 
(SCBU), n (%) 
313 416 .400 (2) 
Yes 31(9.9) 35 (8.4)  
No    281 (90.1) 381 (91.6)  
*Other outcomes comprise of stillbirth, miscarriages and neonatal deaths. ¤ Presumed foetal compromise: suspicious cardiotocograph, 
spontaneous rupture of membranes, premature rupture of membranes, prolonged premature rupture of membranes, meconium-stained 
liquor and reduced amniotic fluid index. ✤Other pregnancy complications: cholestasis, anaemia, ante-partum haemorrhage, postpartum 






4.7.1 Influential factors to engagement/non-engagement  
4.7.1.1 Key factors  
The likely benefits to the baby were the main reason given for women’s engagement with 
HCPs. Pregnancy is usually a time of excitement for the woman, her friends and family 
members. However, amidst the euphoria, mothers are usually more concerns about the 
wellbeing of their babies and therefore it is not surprising that this factor was highly 
influential in their decision to engage with HCPs. Most pregnancies are usually very much 
‘wanted pregnancies’ and women would do what it takes in the best interest of their babies. 
Conversely, women declined primarily because they had no research interest, were pressed 
for time and needed family involvement in their decision making. This is in keeping with 
the evidence which has shown that non-Whites are less likely to participate in research 
(Shavers et al, 2002) and a family-centred approach to decision making being adopted by 
Asians (Hussain-Gamble et al, 2004) who formed the predominant ethnic group studied.  
 
4.7.1.2 Socio-cultural, economic and demographic factors  
4.7.1.2.1 Impact of social influences and client-focused approach on decision making 
Nearly one-third of the women approached engaged with HCPs on first meeting. The level 
of engagement after follow-up had doubled leading to an overall engagement rate of forty-
three percent. The co-ordination of women’s appointments with their antenatal follow-up 
visits and the offer of home visits would have saved women considerable time and money 
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travelling to and from appointments and may have contributed to the engagement rate 
nearing fifty per cent. Most women and their partners were either unemployed or low 
earners and money saved on transportation would have been invaluable.  
Compared to hospital visits, many more family members and friends frequently got 
involved and supported women with their decision making on home visits. Bearing in mind 
the main reasons given for delay in women’s choices were ‘time for decision making’ and 
‘discussion with husband and/or family’, the offer of home visits would have been highly 
beneficial to both parties (pregnant woman and HCP) and should be considered as an 
option to promote positive engagement of high risk women.  
As most women were married Asians who are culturally family oriented (Hussain-
Gambles et al, 2004), one can appreciate those reasons given by the ‘considerers’ and that 
further explained why a third of women studied needed time to provide a feedback on 
whether or not to engage with HCPs. In this study, ten percent husbands / family members 
openly influenced the decision about lack of engagement while fifty-three percent were 
involved in the decision-making process of all who engaged. These high numbers could 
have been derived from the fact that Asian men tend to be paternalistic, particularly 
towards non-English speaking partners. Regardless, the benefits of holistic care are well 
documented (Cumberlege, 2016) and women’s partners should be involved in all aspects 
of women’s care, be it the women’s choice for their (partner’s) involvement. Gorelic et al 
(1998) supports this holistic view of embracing the wider family circle which they purport 
to be critical to engagement since the combined efforts of individuals and their families can 






4.7.1.2.2 Language and religion  
A woman’s ability to speak English was a highly significant factor in whether or not she 
engaged. This was reflected in the results on folic acid use which has now become 
synonymous with pregnancy. It was felt that if women were willing to use folic acid for the 
potential benefits which are now established, they might be willing to engage with HCPs 
on the nutritional study. The non-English speaking women were Asian Muslims who had a 
low uptake of folic acid. This could be due to language barriers which resulted in their lack 
of understanding about folic acid and its use to reduce the risk of neural tube defect in the 
infants as recommended by NICE (2015).  An Australian epidemiological study and survey 
on refugees from sub-Saharan Africa has confirmed that language barrier, poor health 
information on how to access services have contributed to that client group not accessing 
care (Sheik-Mohammed et al, 2006), suggesting that the effect of engagement might have 
been similar.  
Locally, health advocates employed by the Trust, support non-English-speaking women, 
and the latter should have had adequate information to make an informed decision, despite 
their language difficulties. Therefore, one may argue that because some non-English-
speaking women did not want to engage, it was their informed choice to have no 
interference, leaving everything to ‘Allah’ as mentioned by some women when they 
declined engagement. A highly significant number of Christians engaged compared to the 
Muslims. As Christians tend to be predominantly non-Asians, one may conclude that help 
from partners and family members was not as important as among Asians, resulting in 





4.7.1.2.3 Time constraints  
Like religion, time constraints, cultural and personal reasons were factors highlighted for 
client’s lack of engagement. Often when individuals are approached to engage in available 
services, time constraints are usually raised and can be a deterrent. Women within the 
borough had an average of 2-4 children and this comes with huge commitments. Activities 
like the school run and managing a home full-time, particularly as many were unemployed, 
can be demanding on a woman’s time. This demand can be further challenged when ill-
health is present as women living within the borough of Newham had poorer health 
compared to the national average (Office of National Statistics, 2018c). With T2 DM and 
other chronic medical such as hypertension and cardio-vascular disease at high levels 
within the borough (Newham London, 2017), some women were possibly carers, 
particularly as many Asians tend to live with extended families and needed to fully 
embrace their roles as dutiful daughters-in-law.  
HCPs should ensure that women’s social circumstances are considered to reduce the 
frequency and length of appointments. Preparatory work should be done prior to meeting 
clients and home visits should be offered as an alternative to hospital appointments, where 
possible.  
 
4.7.1.2.4 Health behaviours  
One’s view of health and illness and the emphasis that one places on one’s health and well-
being when considering other hierarchy of needs, can be varied.  In a deprived borough 
like Newham, survival may take precedence over ‘living a healthy lifestyle’ and therefore 
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actively participating in research with the view of improving health in the future may not 
be a concept which some pregnant women may find of great interest and urgency.  
Conversely, some may have grown tired of stereotypes and engaged, and this could have 
impacted on the overall engagement rate.  
Regardless, health promotional work falls within the remit of HCPs who are duty bound to 
provide healthy life style advice and support to all pregnant women and particularly those 
deemed high risk, as women with T2 DM and GDM. Behavioural change requires self-
discipline and motivation. Motivation is a psychological construct which can be promoted 
and supported by HCPs with the appropriate psychological skills-set to effect behavioural 
change. The MAPS behavioural change technique which includes motivation, action, 
prompts and cues are believed to be effective in lifestyle behaviour change and can be 
delivered as part of clinical care by HCPs to improve health outcomes in individuals with 
diabetes (Swanson & Maltinsky, 2019).   
 
4.7.1.2.5 Employment status  
Most women and a third of their partners were either unemployed or did routine manual 
jobs. This possibly accounted for the low level of engagement among this group 
particularly as professional/managerial women and those with intermediate jobs had a high 
level of engagement compared to those who had routine and manual jobs. A health 
education survey demonstrated that South Asians contribution to the labour market varies. 
Women of Pakistani and Bangladeshi origins are less economically active and Indian men 
are more likely to be in employment compared to Pakistani men resulting in the 
employment rate being twice as high in this group compared to the local population 
(Hussain-Gambles et al, 2004).  
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In this study, there was a strong correlation between employment status and ethnicity. 
Whites and Afro-Caribbeans were more in employment unlike South Asians (Table 4.2). 
The use of folic acid was lower when they and their partners were unemployed, and this 
may be due to financial constraints; a factor which could have been a deterrent for some 
women living in a deprived borough like Newham with they and their partners being 
unemployed or in lower paid jobs. Overall, the use of folic acid during pregnancy was low 
as only half the women studied took it during pregnancy. Regardless, a high percentage of 
women who used folic acid also engaged indicating that this group of women may have 
felt generally motivated to do what was necessary to maintain good health to optimise their 
pregnancy health and particularly that of their neonates.   
 
4.7.1.2.6 Ethnic groups 
A significant difference strongly existed in the levels of engagement between ethnic groups 
whereby Whites and Blacks engaged more than women of Asians descent, despite the 
latter being the more dominant group. After the Whites, Afro-Caribbeans was the second 
largest group studied which was better at engaging. The evidence from Shavers et al 
(2002) study has, in part, supported these findings having demonstrated that Whites are 
more likely to participate in medical research when compared to people from the ethnic 
minority groups.  
A systematic review conducted to evaluate whether ethnic minorities are less likely to 
engage in research has found that the issue was that individuals from this group were less 
likely to be approached and invited to take part, but when they were, they engaged on 
similar levels as their White counterparts (Wendler et al, 2006).  Therefore, the onus is on 
HCPs and not the marginalised (Sheikh, 2006). A well coordinated collective approach 
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through networking and alliance building is critical to overcome deeply entrenched 
divisions. Likewise, understanding the causes of exclusion of the marginalised can help 
with the engagement process. Implementing participatory local structures with links to 
local and national Government can enable women to access the political stream and have a 
voice in the decision-making process (O’Driscoll, 2018).    
As most women studied were non-Whites, lack of engagement could have related to trust 
issues (Psarros, 2018). Also, some women, particularly Asians, may have needed to 
consult with husbands and family members prior to deciding and they may not have openly 
shared that with HCPs for fear of reprisal, and combined, these factors may have 
contributed to the high rate of undisclosed reasons for lack of engagement among 
approached subjects.  
 
4.7.1.2.7 Perceived discrimination 
Perceived discrimination may have existed among this group as demonstrated in a US 
study. This phenomenon which is very powerful prevented African Americans from 
accessing treatment for symptoms of cancer in a timely manner (Mullings et al, 2019). If 
patients can defer accessing health care for conditions as serious as cancer, engagement 
with pregnancy services may seem lower in the prioritisation of health needs as pregnancy 
is not an illness. Therefore, perceived discrimination could also have been a deterrent for 
reduced levels of engagement among non-Whites who are more likely to report feelings of 
discrimination (Cumberlege, 2016). There is a strong interconnectedness between poverty, 
marginalisation and political exclusion and a multifaceted approach is required to address 
this shortfall. Combined, poverty and marginalisation have led to shortfalls in an 
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individual’s livelihood, education, access to basic needs (Hedstrom and Smith, 2013) and 
these in turn can determine their access to and ability to optimise local health services. 
 
4.7.1.2.8 Historical factors 
Many myths and misunderstanding of research exist. These have caused concerns and lack 
of trust between the general public and researchers (Mills et al, 2006). Lack of motivation 
to engage may simply have been due to historical effects of bad press on research studies 
as far back as the Tuskegee Study of Untreated Syphilis (1932-1972) in USA and more 
recently the Northwick Park Hospital cancer trial (2006) in UK; both of which resulted in 
significant harm to patients who participated in those studies. Undoubtedly, some women 
approached by HCPs involved in this study would have shared some misunderstanding of 
and/or lack of trust and these factors may have contributed to non-engagement. These were 
probably women who provided no reason for non-engagement, showed no research interest 
and wanted no interference unless there was guarantee that they were having the active 
supplements.  
Motivational work is needed to regain trust in the public by promoting engagement on all 
levels. Work has begun by institutions such as National Institute for Health and Research 
and NICE on patient and public engagement, including at strategic levels, to ensure that 
services are truly patient-focused. This change of focus embraces the notion that patients 
are partners and their contributions are critical to ‘getting things right from the start’. 
Having representation of people from the public and of BAME background who ‘look like 
you’ could act as a catalyst for pregnant women of all ethnic groups to feel that they can 
trust policy makers who would want the best for them and their babies. Hopefully, as this 
work flourishes, trusting relationships can be re-built and women feel encouraged to 
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engage positively and early especially when diabetes is present, to optimise their health in 
pregnancy and subsequently their pregnancy outcomes.  
Apart from the public engagement initiatives work needs to be done within disciplines 
including maternity, to promote research as part of the package of women’s routine care as 
opposed to viewing research as an ‘additional extra’. Stakeholders and managers need to 
embrace this notion and lead from the front to drive this change in the provision of true 
woman-centred holistic care.  
 
4.7.1.2.9 Caring responsibilities 
In 2011, 5,800,246 people identified as carers nationwide. Within that same year, the 
number of reported carers in Newham was 24,604; an increase of 19% from 2001. This 
increase was higher than the national average of 11% (Newham Clinical Commissioning 
Group, 2015). This disparity is not surprising since the reported morbidity and co-
morbidities within the borough was shown to be extremely high when the Joint Strategic 
Needs Assessment was conducted (Information Centre for Health and Social Care GfK 
NOP, 2011). Furthermore, as local carers are more likely to be women (Information Centre 
for Health and Social Care GfK NOP, 2011), some non-engaged local pregnant women 
would have also been primary carers. Also, as that 2011 report demonstrated that fifty-two 
percent local carers reported that their own health needs had been compromised by caring 
for others (Newham Clinical Commissioning Group, 2015), some women studied would 
have been primary carers who suffered ill health. Some women may not have engaged for 
social reasons which accounted for 8% of non-engagers. Women’s caring duties could 
have meant them overlooking the potential benefits to their and their babies’ health by 
engaging with HCPs on the nutritional study. Pathways for information sharing between 
140 
 
primary and secondary care sectors need to be improved. Effective communication 
between HCPs needs to be increased and where necessary appropriate inter-referrals made. 
These sectors need to work more cohesively to ensure that pregnant mothers who are 
carers do not feel marginalised and get lost within the care system, but have their needs 
met and those for whom they care, as outlined in the Newham Joint Carers’ Strategy 2015 
-2018 (Newham Clinical Commissioning Group, 2015).  
 
4.7.1.2.10 Cultural and linguistic diversity 
Cultural and linguistic diversity is a real phenomenon in East London and certainly within 
Newham. In this study there was a significant difference in women who did and did not 
speak English and engaged. Cultural and language barriers may prevent pregnant women 
from engaging because women’s ability and willingness to engage with HCPs in seeking 
and understanding advice can be affected (Sheik-Mohammed et al, 2006; Harper Bulman 
et al, 2010). One’s inability to speak English can have an adverse impact on one’s health, 
likewise the perception of HCPs during pregnancy (Harper Bulman et al, 2010). 
Subsequently, this could have had an adverse impact on pregnancy outcomes and is an area 
of significance worth exploring in the future.  
A retrospective Australian study which examined whether cultural (country of birth, race 
& refugee status) and linguistic (primary language spoken & use of interpreters) diversity 
were independent predictors of maternal and foetal outcomes when at least one adverse 
event occurred, has found a reduced likelihood of an adverse pregnancy outcome of those 
born outside Australia and New Zealand and/or those who used interpreting service. Those 
findings did not support the model for having a multi-faceted / professional approach when 
caring for this group but emphasised the need for use of interpreting services. It is believed 
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that continuity of care provider was more important for areas of communication and 
compliance. Having the same interpreter as practised within Newham, may have given 
women the confidence and provided additional support and encouragement to adequately 
engage and to better communicate their needs, if or when needed (Thomas et al, 2010). 
Being surrounded by people of similar culture and religious background should instil 
confidence in individuals to make informed decisions about their care.  
Conversely, some interpreters live within the locality and may be familiar with women, 
their wider family and friends leading to some women being reluctant to disclose 
information which is critical for their care planning and delivery. Regardless, it is 
important to use the hospital approved health advocates. The use of informal interpreters 
may prevent open dialogue between women and HCPs by women withholding critical 
information (eg. domestic abuse) and not receiving appropriate counselling and support as 
a result (Harper Bulman et al, 2010). This practice should be discouraged because care 
pathways may not match the true needs of women resulting in adverse impact on 
pregnancy outcomes and the long-term maternal and foetal / neonatal well-being.   
 
4.7.1.2.11 Migrants, Gypsy, Roma and Traveller’s population and engagement/non-
engagement  
4.7.1.2.11.1 Mobile migrant population 
Newham has a very mobile population partly due to the increase of migrants within the 
locality; some of whom may not have had the necessary documents to reside in the UK. A 
recent study which looked at the experiences of migrant women accessing maternity care 
has found that among the reasons given for non-engagement were communication 
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difficulties (Shortall et al, 2015; Parry et al, 2004) and having to pay for care received 
(Shortall et al 2015, Aston 2014 & Taylor 2013). Similar findings were found in a project 
commissioned by Public Health England which evaluated factors which contributed to 
inequalities in maternal and child health of Black and ethnic minorities in low-income 
households. Access and effective use of health services were examined, and barriers 
identified included registration refusal due to migration, language and communication 
difficulties and prejudice and discrimination (Psarros, 2018). Taylor (2013) supported 
those disclosures and further stated that lack of engagement can result in some women 
avoiding antenatal care and can be forced to deliver at home or present in labour with 
complications. Also, fear of being arrested and having to provide documents for 
administrative purposes were also deterrents. Combined, those factors resulted in only 38% 
receiving care before 12 weeks gestation, and of the remaining who booked late, 34% 
booked after 20 weeks in Shortall et al, 2015’s study and that level of engagement 
contravenes NICE (2015) antenatal care guidelines. The population profile of Newham 
bears similar resemblance and similar factors could have contributed to lack of engagement 
and accounted for nearing fifty per cent of local women having developed complications 
during pregnancy. However, one needs to be careful of generalizing since an Australian 
study has found no significant correlation between refugee status and adverse pregnancy 
outcomes (Thomas et al, 2010). 
 
4.7.1.2.11.2 Gypsy, Roma and Traveller’s population 
A large Gypsy, Roma and Traveller’s population reside in Newham. This group which is 
among the most deprived in the UK (Women and Equalities Committee, 2019) takes pride 
in being tough and self-reliant (Parry et al, 2004) and these and other lifestyle factors such 
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as low educational attainment, overcrowding and caring responsibilities (Burchardt et. al, 
2018) may have prevented women from this community accessing maternity services and 
engaging with HCPs. Non-engagement may also be derived from mistrust formed from 
perceived racism, discrimination, hate and violence against women and girls in this group 
(Women and Equalities Committee, 2019).  Also, Gypsies, Roma and Travellers live 
within close communities with the characteristics of an extended family (similar to the 
Asians) and therefore good and bad experiences with HCPs will be shared (Parry et al, 
2004). This practice can determine the health care choices that are made and the level of 
engagement within this group and local maternity services, over generations. This 
community is also very private, and their way of life may not comply with the philosophy 
of positive engagement whereby women are encouraged to communicate freely and form 
strong partnerships with HCPs. Consequently, the principles of positive engagement go 
against the social and cultural norms of Gypsies, Roma and Travellers. 
 
4.7.1.2.12 Age and engagement/non-engagement  
Age was not a factor as to whether or not to engage. Nevertheless, as one advances in 
years, one tends to strive to do what one thinks is right as responsible citizens. Women 
who engaged early or on the first follow-up meeting possibly fell within this category. This 
notion could have influenced women’s decision to engage with pregnancy services 
available to demonstrate their acceptance and compliance with health advice. Also, that 
yearning could have been to exonerate oneself of being blamed should ‘things go wrong’ 
during pregnancy and/or after delivery. Therefore, as a portrayal of responsible behaviour, 
one can engage with HCPs by ‘doing what’s right by the baby’; the main reason given for 




4.7.1.2.13 Engagement/non-engagement: the unknown factors 
All previous issues raised could have contributed to lack of disclosure of the reason for 
non-engagement. Some of those issues are discussed below. 
4.7.1.2.13.1 Social influences 
Approximately a third of all women approached did not disclose their reasons for non-
engagement. Lack of coercion or women simply expressing their informed choice could 
have been among the reasons for women not engaging. Ultimately, women’s decision 
needed to be respected in keeping with research ethics as outlined in the protocol which is 
embedded in the UK policy framework for health and social care research (formerly 
Research Governance Framework) (Department of Health, 2015).  
One reason given by the ‘considerers’ was ‘time to make a decision’. Yet, some 
considerers were ‘alone’ and presumed unsupported when they made their final decision. 
The conclusion from that could have been that some women who were within that category 
may have needed time to get their husband and / or family members’ approval but that was 
not openly shared. Therefore, social influence could have been more profound than that 
stated among those being ‘alone’ when the decision on engagement or non-engagement 
was made. If that theory is true, the need for having an inclusive approach with women’s 
social support system becomes even more profound and should always be respected by 





4.7.1.2.13.2 Attributes of HCPs 
Follow-up of the ‘considerers’ involved a significantly high level of activities which were 
costly in terms of time for repetition of activities and financial (travelling) cost for home 
visits. Nevertheless, despite the extra resources required, it was clear that doggedness 
contributed positively to high levels of engagement especially when subjects were 
followed up. One may argue that successful engagement could have been further 
influenced by the interest, motivation, approachability and dedication of researchers and 
the emphasis that they placed on client engagement and the likely benefits to clients 
through research engagement. Good communication, effective listening skills, respect for 
client’s autonomy and awareness of the health related matters within the locality 
(Newham) could have individually or combined, had a positive impact on engagement and 
should form the cornerstone of any research project. In the absence of these attributes, non-
engagement among clients could escalate and may have an adverse impact on pregnancy 
outcomes.   
 
4.7.1.2.13.3 Complacency  
Complacency could have been another reason as was reflected in low folic acid use despite 
Government guidelines based on the need to reduce neural tube defects as shown in 
previous studies (NICE, 2016). For example, although there was no significant difference 
in folic acid use based on parity, the higher the parity, the less likely women were to use 
folic acid in pregnancy, and this may have contributed to only approximately 50 per cent of 
all women approached having taken it in pregnancy. After having had previous 
complications-free pregnancies, women may have internalised that they wanted ‘no 




4.7.1.2.13.4 Lack of trust  
Lack of trust, as previously explained, may have been another possible reason. Women 
communicating to HCPs that they were not trusted would not have been easy for fear of 
reprisals that the care they subsequently received would have been affected and this may 
have prevented women from disclosing a reason for non-engagement.   
 
4.7.2 Pregnancy outcomes (maternal and foetal) 
4.7.2.1 Maternal outcomes 
4.7.2.1.1 Social inequalities  
Having explored ethnic and social inequalities of women’s experiences of maternity care in 
England, it was found that single mothers, ethnic minority women and those who 
completed education earlier in their lifetime, accessed maternity care late, experienced 
complications during pregnancy and birth, had poorer pregnancy outcomes and felt less 
satisfied with some aspects of care received (Raleigh et al, 2010). In this study, it was 
highly significant that the singletons were better at engaging possibly because they do not 
feel the need to have to consult with their partners and/or family members prior to making 
a decision in the same way as Asians who historically embrace the notion of a family 
approach to decision making (Hussain-Gambles et al, 2004).  Contrary to Rayleigh’s study, 
non-engaged women had better birth outcomes and this was significant. Women within 
that group had more full term live births and less preterm births, stillbirths, miscarriages 
and low birth weight infants compared to women who engaged.  A possible explanation for 
this could be that women without diabetes were among those who were non-engaged 
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because they felt that they had uncomplicated pregnancies and were more likely to have 
had better pregnancy outcomes compared to those with diabetes (CEMACH, 2007).    
 
4.7.2.1.2 Hypertensive disorders and related conditions 
Hypertensive disorder complicates approximately 5-10% of all pregnancies and is the 
second most common cause of direct maternal deaths. Pre-eclampsia, eclampsia and 
HELLP syndrome represent different severity of the disease on the spectrum (Vest & Cho, 
2014). Combined, these hypertensive disorders accounted for 10% (engaged) and 8% (non-
engaged) of all complications in this study. Women who engaged developed less 
complications and enjoyed healthier pregnancies than those who did not engage, and this 
was highly significant. Yet, hypertensive disorders were slightly increased among those 
who engaged. 
Women with essential hypertension need early engagement and regular antenatal follow-
ups to reduce the morbidity and mortality associated with this medical condition. If not 
managed effectively, mild to moderate hypertension can develop into severe hypertension 
which can have devastating consequences for the mother and baby. Equally, foetal growth 
restriction can develop if blood pressure is too tightly controlled so a balance needs to be 
had (Nabhan & Elsedawy, 2011). 
Timely delivery of the foetus is critical in the presence of hypertensive complications (Vest 
& Cho, 2014). Hence, hypertensive disorders are among the strongest predictors of preterm 
delivery (World Health Organisation, 2012), which was 17% and 15% in the engage and 
non-engaged, respectively, and was highly significant. Other adverse effects of 
hypertensive disorders include low birth weight infants, perinatal deaths and placental 
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abruption (Nabhan & Elsedawy, 2011).  In this study, there was a higher incidence of low-
birth-weight infants in the engaged group, among which was the only case of neonatal 
death. Anaemia and placental abruption were grouped under ‘other obstetric 
complications’. As these conditions are associated with poor neonatal outcomes, it would 
have been useful to explore the impact of those conditions on pregnancy outcomes in the 
engaged and non-engaged groups.  
Hypertensive disorders are in part related to inactivity which can be manifested through 
obesity. Maternal obesity increases the risk of complications in pregnancy which includes 
gestational hypertension, pre-eclampsia and gestational diabetes (Office of National 
Statistics, 2019).  
A recent study by Domingues et al (2015) on physical activity on maternal-foetal health 
during pregnancy has shown that activity in pregnancy was extremely low, but the study 
was ongoing. Exercise intervention programmes are believed to be beneficial but a recent 
study on obese and overweight women at risk of gestational diabetes has shown no 
improvement in fasting blood glucose insulin sensitivity and birth weight, but this was 
believed to be associated with non-compliance (Oostdam et al, 2012).   
A significantly high number of women in this study were either over-weight or obese, but 
the result was insignificant. Being overweight or obesity is a precursor for increased 
incidence of hypertensive disorders (Greenstein & Wood, 2011), T2 DM (Mokdad et al, 
2000 & Boffetta et al, 2011) and GDM (Hunt & Schuller, 2007) which was high among 
this study group. The distribution of women who did and did not engage was similar. This 
was reflective of Newham’s population which is highly diverse with many Asians who 




Poverty is a derivative of socio-economic factors and a predictor of obesity (Cohen et al, 
2013) which is widespread within the borough of Newham. Women who are less 
motivated to manage their own health may not positively engage with HCPs due to socio-
economic factors including poor housing and employment in lower paid jobs. Therefore, 
optimal health may not a priority. Also, in some cultures, being obese and overweight can 
be seen as a sign of wealth, attraction to the opposite sex and fertility (Naigaga et al, 2018). 
Enabling women to look beyond this cultural view may be a challenge for HCPs in areas of 
diabetes education and management. 
 
4.7.2.1.3 Onset of labour and mode of delivery  
Engagement had no impact on onset of labour. In keeping with local policy on diabetes 
management in pregnancy, supported by NICE, 2008 & 2015 guidance, women with T2 
DM and GDMs on insulin were induced between 37 and 40 weeks of pregnancy to 
optimise the pregnancy outcomes of mothers and their babies. The rate of induction was 
similar in both groups. More non-engaged women went into spontaneous labour compared 
to the engaged but this was not significant. The homogeneity in both groups of women’s 
demographic profile of age (mean, 31 years) and BMI (mean, 28.51kg/m
2
), parity (mean, 
2.08 children) and disease type (T2 DM and GDM) were all non-significant. This coupled 
with local and national guidance on the management of women with DM in pregnancy, 
would have impacted on the similarity seen in onset of labour in each group.  
For the reasons highlighted above, homogeneity in both groups of women could also have 
impacted on mode of delivery which was not significant, but accounted for a slightly 
increased number of births by caesarean section among those who engaged. That slight 
increase may have been attributable to maternal request and/or a slightly decreased number 
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of women without DM among the engaged. The morbidity and mortality associated with a 
diabetic pregnancy are high (Assaf-Balut et al, 2016; Reece & Homko, 2000 & CEMACH, 
2007) and delivery by elective caesarean section may have also been necessary to promote 
the wellbeing of mother and baby. Cumulatively, this would have also contributed to 
almost fifty percent of all women approached in each group being delivered by caesarean 
section which may have been exacerbated by the high rate of induction.  
Approximately a quarter of women studied were primips. There was an equal distribution 
of first-time mothers and multi-parous women who were delivered by caesarean section. It 
is a preconception that failed IOL is more common among first-time mothers following 
induction. A population based cross-sectional study has shown that induction of primips 
with uncomplicated histories resulted in an increased incidence of failed spontaneous onset 
of labour and increased emergency caesarean section rate (Davey & King, 2016). 
Conversely, a recent study has shown that the induction of fist time mother at 39 weeks did 
not increase the caesarean section rate but resulted in a lower frequency (Grobman et al, 
2018).  
Women in NUH present in pregnancy with many co-morbidities increasing the likelihood 
of being induced, delivered by caesarean section and having a pre-term birth. Although the 
difference was not significant, planned caesarean section was offered to approximately 
one-fifth of all patients in the engaged group and a slightly reduced number among those 
who did not engage. A plausible explanation for this could be the high incidence of 
morbidity with which some subjects presented in early pregnancy and complications 





4.7.2.2 Foetal/Neonatal outcomes  
Engagement had no impact on foetal outcomes. Women who engaged were more likely to 
have a preterm birth and were worse for other pregnancy complications such as 
spontaneous, premature and prolonged rupture of membranes and suspicious 
cardiotocograph. Effective clinical management of high-risk women with T2 DM and 
GDM would have required that some women were delivered early and this would have 
contributed to the premature birth rate which was highly notable, and significant.  
The incidence of macrosomia was small, but it was two-fold higher for non-engagers than 
for those who engaged with HCPs. Considering that the pregnancy outcomes were better 
for the non-engaged, and pregnancy complications were worse in that group, could it be 
that most mothers within that group had heavier babies due to slightly raised BMIs, 
impacting on that marginal difference in macrosomic babies? A systematic review and 
meta-analysis conducted on maternal obesity and foetal macrosomia has found a 
correlation between both entities (Gaudet et al, 2014).  
Overall, the detection of big babies on scan was significantly high and should have resulted 
in a higher detection rate of macrosomia in both groups, with a high likelihood of being 
mainly among those who did not engage. A plausible explanation is that clinical 
management of women whose babies were confirmed as large for gestational age on scan 
were offered an early induction based on maternal and foetal health and wellbeing. 
Approximately a third of engaged and non-engaged women were induced and therefore 
based on local protocol, women detected with big babies on scan could have been among 
those induced. Subsequently, this could have impacted on the reduced detection rate of 
macrosomia but may have likely increased the incidence of large for gestational age infants 
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and premature births; the latter which was greater among women who engaged (17%) than 
the non-engaged (15%), which was significant.  
The CQC 2017 survey on women’s experience of the maternity service has reported that in 
2013 and 2015, 17% of births were premature while the remaining 93% delivered at 
maturity (37-weeks gestation) (Care Quality Commission, 2018). For this study, the overall 
preterm birth rate was 15% and above the national average of 7.8% in 2019 (Office of 
National Statistics, 2020). Preterm birth is often associated with neonatal death 
(Domingues et al, 2015) but was not indicative of the case in this study since delivery was 
at term. This woman’s inability to communicate English, process complex information 
about her care and her health prior to and during pregnancy were possible contributed to 
the cause of death.    
 
4.8 Conclusion  
The findings of this study have shown that socio-cultural, economic and demographic 
factors have impacted on a pregnant woman’s decision on whether or not to engage with 
HCPs. Strong decision-making indicators were ethnicity, marital and employment status, 
social support system and women’s ability to speak English. The likely benefits to the baby 
were the overarching reason given for positive engagement.  
Engagement with HCPs reduced complications in pregnancy but had no effect on onset of 
labour, mode of delivery and the reduced incidence of hypertensive disorders, premature 
births, macrosomia, low birth weight infants, neonates admission to SCBU. Further large 
scale trials are needed in this area.  
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Ethnic minorities from deprived areas like Newham can present with complex health issues 
which can provide substantially rich data for local research. Locally, ethnic minorities’ 
participation in research is under-reported. This might be due to the under-representation 
of this group in research due to the challenges that their involvement might pose in areas 
such as language difficulties, lack of trust and feelings of not belonging which can prevent 
women from engaging. Despite resources being limited within the NHS, HCPs need to 
embrace a holistic approach when engaging with all pregnant women, particularly those 
who are ‘high risk’ even when they may present with complex social, cultural, financial 
and challenging health needs, amidst discussion on research participation.  
For positive client engagement to become successfully embedded within the NHS culture 
and subsequently flourish, HCPs need to acknowledge that issues with non-engagement do 
not lie solely with pregnant women from ethnic minority groups. Also, HCPs need to 
examine their own prejudices through self-reflection, and this could be a positive way 
forward to provide a truly respectful and equal service to all pregnant women within our 
locality. By so doing, women may feel encouraged to positively engage with HCPs and the 
services available to them. Among and within each ethnic group there are certain nuances 
and unless service providers acknowledge, respect and embrace this notion, service 
engagement in pregnancy will continue to be problematic, possibly resulting in increased 
morbidity and mortality. 
 
This chapter has set the scene for all experimental chapters (5-7) (Phases 2-4) and has 
influenced the distribution of subjects and in each of those chapters. Particularly, for the 
RCTs conducted in chapters 6 & 7 to be successful, it was necessary to provide women 
with the information in the language that they understood, preferably face to face. 
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Supported by health advocates and PILs translated into 5 different languages, a better 
understanding of the factors which fostered engagement with HCPs were established. 
Findings from this chapter were invaluable to HCPs on the approach to take when 
recruiting and following up participants in the other phases.   
In chapter 5, predominant risk factors for the early detection of GDM were examined and 
the implications of gestational age at diagnosis on maternal and foetal outcomes. NICE’s 
recommendation on screening for GDM has also been evaluated in the context of its 
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5.1 Chapter overview    
In chapter 5, I have explored the risk factors for the early detection of GDM and evaluated 
the impact of early (≤24 weeks) and late (≥24 weeks) diagnosis on maternal and foetal 
outcomes. Women with GDM are at increased risk of sub-optimal pregnancy outcomes and 
recurrent GDM. Early identification of ‘at risk’ women can improve pregnancy outcomes 
in the index pregnancy and provide women with the education and support for proactive 




5.2.1 Gestational diabetes mellitus (GDM) 
 
5.2.1.1 Definition 
Gestational diabetes mellitus is ‘any degree of glucose intolerance first diagnosed during 
pregnancy, regardless of the gestation and whether or not medication is used for treatment 
and the condition persists following pregnancy’ (Metzer et al, 1998). GDM is further 
defined as a condition which forecasts future overt diabetes in mothers and the long-term 
metabolic health of their offspring through foetal programming effects (Krishnaveni et al, 
2010). 
 
5.2.1.2 Risk factors and aetiology 
Commonly identified risk factors of GDM are family history of diabetes, past GDM 
pregnancy, BMI ≥30kg/m
2
, previous large baby (≥4.5kg) and ethnicity particularly women 
from South Asia, Black African/Caribbean and the Middle East (NICE, 2015) as outlined 
in Box 2.2. Other risk factors include age, parity, hypertension, stillbirth and/or neonatal 
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death in previous pregnancies (Teede et al, 2011) and polycystic ovaries syndrome (PCOS) 
(Tomlinson et al, 2012 & Teede et al, 2011). 
GDM is marked by abnormal glucose metabolism and insulin resistance (Ben Slama, 
1997). In non-diabetic pregnancies, insulin resistance is marked by compensatory increases 
in insulin secretion by the pancreatic bêta cells (Richardson and Carpenter, 2007). In the 
presence of GDM, relative insulin deficiency is derived from beta cells dysfunction. GDM 
is also associated with obesity. Women starting pregnancy who are already overweight or 
obese are at high risk of developing GDM (Chu et al, 2007). Also, ethnicity may determine 
the effect of obesity on insulin resistance in pregnancy as BMI has greater insulin 
resistance in pregnancies among Asians, (Retnakaran et al, 2006). 
 
5.2.1.3 Prevalence 
The true prevalence of GDM is unknown but its prevalence is increasing worldwide (Wan 
et al, 2019; Guariguata et al, 2014). Current estimate of GDM is believed to be between 
13% and 30% (Wong et al, 2017) but is dependent on the population studied and the 
diagnostic method used. GDM affects 87.5% of all diabetic pregnancies (National Institute 
of Health and Care Excellence (NICE, 2015). 
 
5.2.1.4 Effects of GDM 
The adverse effects of GDM on foetal/neonatal and maternal health are well documented 
(Benhalima et al 2015, Dessi et al 2015, Billionet et al 2017 & Kwik et al 2007). The 
Hyperglycaemia and Adverse Pregnancy Outcome (HAPO) study is often referred to as a 
landmark study which described the adverse impact on both mothers and their babies’ 
health (HAPO Study Cooperative Research Group, 2008). Increased placental transfer of 
glucose to the foetus due to maternal hyperglycaemia results in adverse foetal and neonatal 
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outcomes which include macrosomia, small for gestational age, hypoglycaemia, congenital 
abnormality, increased admission to special care baby unit, stillbirth and neonatal death 
(Benhalima et al, 2015). Infants born to women diagnosed with GDM are at risk of 
impaired glucose regulation leading to obesity (Wu et al, 2016 & Damm, 2009), T2 DM 
(Mitanchez et al, 2015 & Wu et al, 2016) and autisms (Xiang et al, 2015). Effects related 
to the mother include preterm births, increased caesarean section rates, pre-eclampsia, 
maternal trauma and post-partum haemorrhage. Micro/macrovascular complications are 
associated with chronic hyperglycaemia (Kawahito et al, 2009). Additionally, diagnosis of 
GDM can lead to a 70% risk of developing the condition in subsequent pregnancies and T2 
DM within 10 years after delivery (Schwartz et al, 2015). Consequently, any preventative 
measures can have huge cost benefits (Hex et al, 2012). Early identification of ‘at risk’ 
women can improve pregnancy outcomes and provide women with the education and 
support for proactive behavioural changes for their long-term health and subsequent 
pregnancies. 
  
5.2.1.5 Management   
5.2.1.5.1 Overview  
 
Early intervention is critical to reduce the morbidity associated with the condition (Görig et 
al, 2015). After diagnosis, women should be referred for multi-disciplinary review where 
teaching is provided on GDM, its likely implications on maternal and foetal health in the 
immediate and long-term, importance of blood glucose control and likely treatment. 
Women should also be taught to self-monitor blood glucose and reviewed regularly in 
MDT clinic until delivery. Individualised plans of care should be implemented during 
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labour and delivery and women discharged with lifestyle advice and screened postnatally 
to establish their diabetes status (NICE, 2015).    
 
5.2.1.5.2 Strategies employed on diagnosis 
On diagnosis of GDM, women were referred to the multi-disciplinary (MDT) education 
session where the condition and potential risks to their and their babies’ health were 
explained. Dietary advice was given using the ‘Eat well plate’ (Figure 5.1) and they were 
taught self-monitoring of blood glucose levels. Advice was given to contact the specialist 
team if their blood glucose levels exceeded the targeted levels (pre-prandial ≤6mmol/l and 
2 hours post-meals <7.8mmol/l). They were also encouraged to increase their daily 
physical activity, particularly post-meals to contribute to normalising their blood glucose 
levels without emphasis on weight-loss. An appointment was given for the following week 
to attend the MDT (Obstetricians, Endocrinologist/Diabetologists, Nurse and Midwife 
specialists and dietician) clinic for antenatal diabetes review. Subsequent follow-up 
appointments were given throughout till delivery based on individual assessments of 
mothers’ and babies’ health and well-being. Individualised plans of care were implemented 
























5.2.1.5.3 Strategies employed post-delivery 
All women diagnosed with GDM were offered an OGTT 6weeks post-delivery and a 
follow-up appointment for diabetes review after that appointment in the MDT postnatal 
clinic. Women with normal results were referred to their General Practitioners (GPs) with 
advice for yearly screening. Women with abnormal results were referred to the Outpatients 
clinic for specialist care by the Endocrinologist/Diabetologist and Diabetes Nurse 
Specialist.  
Before discharge, women are encouraged to continue with healthy eating and to increase 
their level of activity to maintain a healthy lifestyle. They are also encouraged to have an 
early antenatal booking in subsequent pregnancies to enable early screening for the 
condition if overt diabetes was not confirmed 
 
5.2.1.6 Screening 
5.2.1.6.1 What is the guidance? 
There is no consensus with regards to the time of screening (Leary et al, 2010; Gilmartin et 
al, 2008 & Bottalico, 2007). However, in response to the HAPO study (HAPO Study 
Cooperative Research Group, 2008) and the need to promote standardised quality care, the 
International Association of Diabetes and Pregnancy Study Group (IADPSG) 
recommended universal screening between 24-28 weeks for pregnant women not known to 
be diabetic (IADPSG Consensus Panel, 2010), as some women may be asymptomatic 
(Cundy et al, 2014); but despite this, ambiguity remains (Benhalima et al, 
2015).  Consequently, there is ongoing and increasing debate on effective screening for 
GDM (Feghal et al, 2018; Moncrieff, 2018 & Hanna et al, 2007), but most support 
universal screening between 24- and 28-weeks gestation for women with risk factors such 
as previous history of GDM, previous macrosomic baby, obesity, family history of 
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diabetes and age 35 and above and polycystic ovaries syndrome (Standards of Medical 
Care in Diabetes - 2017 (2017).   
 
As pregnancy advances, insulin resistance increases (Catalano et al 1993). Screening at 24-
28 weeks gestation is recommended at the time of peak insulin resistance to get an accurate 
diagnosis of GDM while allowing time for intervention and management benefit (Feghal et 
al, 2018). However, due to Type 2 diabetes meeting epidemic proportions outside of 
pregnancy, women may present with undiagnosed pre-existing diabetes or may develop 
GDM below 24 weeks gestation (Feghal et al, 2018). Hence, blanket screening at the 
antenatal booking visit is recommended by some organisations. For women with risk 
factors (as previously described) the recommendation for early screening varies but more 
common is screening between 24-28 weeks (Standards of Medical Care in Diabetes - 2017 
(2017), NICE, 2015). If changes to GDM screening are to be made, the level of uncertainty 
and heterogeneity should be considered (Chamberlain et al 2015). 
  
Current NICE’s guideline (2015) recommends early testing for pregnant women with a 
previous history of GDM and repeat testing between 24-28 weeks gestation if the initial 
result was normal. Women with other risk factors should be screened between 24-28 
weeks.  
Intensive MDT management is critical once the diagnosis is made and appropriate follow-
up care is necessary post-delivery. However, the evidence suggests that communication 
between the primary and secondary sectors are fragmented resulting in fewer than fifty 
percent of women not attending for their postnatal screening. Adequate postnatal care is 
therefore ineffective, and a substantial number of women can develop T2 DM which in 




5.2.1.6.2 Demographics of the local population   
The borough of Newham has a population of approximately 353,134 (ONS, 2019). In 
2019, forty-seven percent (47%) were females with (68%) of the population between ages 
18-64 and 24.4% ≤18 years. Ethnic distribution was Asians (45.2%), Whites (27.7%), 
Blacks (17.7%) and other ethnic groups (9.3%) (Newham London, 2020). Further details 
on the Borough of Newham can be found in chapter 2 (2.4). 
 
This ethnic mix presents many challenges for health care service providers especially as 
Newham has one of the highest birth rates in the country which is primarily from a 
younger population. Gestational diabetes mellitus (GDM) poses a huge challenge for 
obstetricians and midwives. The local prevalence of GDM is unknown but is presumed 
very high as approximately 26,500 people are diagnosed with Type 2 diabetes mellitus (T2 
DM) and this is about 10% of the adult population (NCCG, 2017a).  Therefore, it is critical 
to have appropriate local and national screening guidelines which incorporate identifiable 
risk factors of GDM which will identify women who need to be screened and in a timely 
manner; considering the potential morbidity and mortality associated with the condition. 










5.3 Aims  
 
 To assess whether NICE national guideline is appropriate for screening women at 
risk of gestational diabetes with risk factors of raised BMI and first degree relatives 
with diabetes. 
 To assess whether there are any differences in maternal and foetal outcomes with 
women who are diagnosed before 24 weeks gestation and women diagnosed after 
this gestation. 
 
5.4 Research questions 
 Does adherence to the recommendations of current NICE’s guidelines on screening 
for GDM, result in delayed diagnosis and intervention in women with other risk 
factors who develop the condition early in their pregnancy?  
 Are there differences in pregnancy and post-pregnancy outcomes between early and 
late diagnosis of GDM? 
  
5.5 Hypotheses 
 Current NICE guideline on early screening for GDM is appropriate to detect 
women most at risk of developing the condition.  
 There is no difference in pregnancy and post-delivery outcomes between women 









5.6 Subjects & Methods 
 
5.6.1 Study population and design 
 
This study was conducted at Newham University Hospital on pregnant women between 
ages 17 to 45. Women diagnosed with GDM ≤ 24 weeks gestation (n=212) and ≥ 24 weeks 
gestation (n=226) were identified at the hospital’s SADC and GDESs (previously 
discussed) and were recruited during the first to third trimester at their homes or on 
antenatal visits. Data of only women with a confirmed diagnosis of GDM following an oral 
glucose tolerance test (OGTT) were included and detailed demographic, socio-cultural, 
economic and clinical data collected. Diagnosis of GDM was made when the fasting 
plasma glucose was ≥6.1mmol/litre and/or two hours ≥7.8mmol/litre (NICE, 2008). 
Women with a previous history of GDM, family history of diabetes, BMI ≥30 kg/m2, 
previous babies weighing ≥4kg, maternal age ≥40 and raised random blood glucose 
≥7.0mmol/l and <11.1mmol/l had an OGTT at 16 weeks and if negative repeated at 28 
weeks gestation. Eligible women were recruited up to 32 weeks gestation.  
 
A questionnaire (appendix 3.7) was used to collect data on (a) gestational age at the time of 
diagnosis of GDM (<24weeks gestation & > 24weeks gestation) (b) antenatal and postnatal 
OGTT results, (c) pregnancy complications (eg. hypertensive disorders and pregnancy 
loss), (b) diabetes management and (d) maternal and foetal outcomes (eg. prematurity, 
post-maturity, macrosomia and low birth weight, neonatal admission to special care baby 
unit). Detailed demographic, socio-cultural and economic data was also collected. Further 





5.7 Statistical analysis 
Data analysis was conducted using the SPSS Statistics for Windows (Version 25) analysis 
framework. Data collected were labelled, coded and inputted into the SPSS tool. The level 
of measurement was nominal data. The number of cases that appeared in each category 
was counted to either accept or nullify the hypotheses and descriptive statistics were used 
to establish frequencies in data, for example, to establish how many women were 
diagnosed before and after 24 weeks gestation. The Chi-square (cross-tabulation), 
Pearson’s correlation coefficient test for independent samples was used to analyse any 
pattern of observed frequencies which may suggest an association between variables 
tested, for example, whether there was an association between ethnicity and women 



















The demographic and clinical information of the participating subjects are outlined in 
Table 5.1. Women aged 21-30 and 31-40 diagnosed with GDM <24 weeks gestation were 
84 (40%) and 119 (56 %) and ≥24 weeks gestation 100 (44%) & 108 (48%) respectively (p 
< 0.206). The mean age was 25.9. The rate of diagnosis <24 weeks and ≥24 weeks 
gestation in Asians was 71% and 68% respectively and 26% and 23% (respectively) in 
Afro-Caribbeans (p < 0.025). GDM diagnosis <24 and ≥24 weeks were 38% & 34% 
respectively in overweight women and 42% in obese women in both screening groups (p < 
0.494). For those diagnosed <24 weeks, 20% presented having had previous chronic 
medical conditions while 14% was in the latter group (≥24 weeks gestation) (p < 0.74).  
  
Table 5.1: Demographic and medical information and gestational weeks at diagnosis  
Demographic & medical 
information 
<24 weeks of 
gestation  
≥24 weeks of 
gestation  
Totals P value 
Ages  (n=212) (n=226)                 0.206            
≤ 20 years 2 (0.9%) 5 (2.2%) 7 (1.6%)  
21-30 years 84 (39.6%) 100 (44.2%) 184 (42.0%)  
31-40 years 119 (56.1%) 108 (47.8%) 227 (51.8%)  
≥ 41 years 7 (3.3%) 13 (5.8%) 20 (4.6%)  
     
Ethnicity                 (n=212)                    (n=226)  0.025  
All Whites  7 (3.3%) 22 (9.7%) 29 (6.6%)  
Afro-Caribbean  54 (25.5%) 51 (22.6%) 105 (24.0%)  
Asians  151 (71.2%) 153 (67.7%) 304 (69.4%)  
     
Booking BMI  (n=208) (n=220)                 0.494  
Underweight (<18.5) 3 (1.4%) 1 (0.5%) 4 (0.9)  
Normal weight (18.5-24.9) 41 (19.7%) 53 (24.1%) 94 (22.0%)  
Overweight (25.0-29.9) 77 (37.0%) 74 (33.6%) 151 (35.3%)  
Obese (≥30) 87 (41.8%) 92 (41.8%) 179 (41.8%)  
     
Chronic medical 
conditions  
(n=193) (n=220)  0.740  
Yes 39 (20.2%) 30 (13.6%)  69 (16.7%)  
No 154 (79.8%) 190 (86.4%) 344 (83.3%)  
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Table 5.2 shows the interrelationship between age, BMI, ethnicity and chronic medical 
conditions. Of those between ages 21-30 and 31-40, 77% and 63%, respectively, were 
Asians and 18% and 29% (respectively) Afro-Caribbeans and the remaining 5% and 8% 
(respectively), were Caucasians (p < 0.053). Within those age groups, 42% and 49% 
respectively were overweight and 33% and 61% (respectively) were obese (p < 
0.000). In the overweight category, 3% were Caucasians, 20% Afro-Caribbeans and 77% 
were Asians, while 11%, 37% and 52% respectively were obese (p < 0.000). Of the 72 
women who presented with chronic medical conditions, 93% were between ages 21-40 (p 
< 0.604); 35% were of Afro-Caribbean and 60% of Asian descent (p < 0.059), and they 































Table 5.2: Interrelationship between age, BMI, ethnicity and chronic medical 
conditions   






≥ 41 years 
 
P value 
Age distribution of 
ethnic groups 
  (n=7; 1.5%) (n=195; 42.6%) (n=234;51.1%) (n=22; 4.8) 0.053 
All White 0 (0.0%) 10 (5.1%) 19 (8.1%) 2 (9.1%)  
Afro-Caribbean 3 (42.9%) 35(17.9%) 67 (28.6%) 3 (13.6%)  
Asians 4 (57.1%) 150 (76.9%) 148 (63.2%) 17 (77.3%)  
      
Age distribution and 
BMI  





Underweight (<18.5) 0 (0.0%) 4 (66.7%) 1 (16.7%) 1 (16.7%)  
Normal weight 
(18.5-24.9) 
0 (0.0%) 58 (59.2%) 38 (38.8%) 2 (2.0%)  
Overweight (25.0-
29.9) 
6 (3.8%) 66 (41.8%) 78 (49.4%) 8 (5.1%)  
Obese (≥30) 1 (0.5%) 62 (33.3%) 114 (61.3%) 9 (4.8%)  
  
















All White 0 (0.0%) 4 (4.1%) 4 (2.5%) 21 (11.3%)  
Afro-Caribbean 0 (0.0%) 6 (6.1%) 32 (20.3%) 68 (36.6%)  
Asians 6 (100.0%) 88 (89.8%) 122 (77.2%) 97 (52.2%)  
  
 Chronic medical conditions  
 (n=72) (n=360)  0.604 
Age  Yes  No  
≤ 20 years 1 (1.4%) 5 (1.4%)  
21-30 years 25 (34.7%) 156 (43.3%)  
31-40 years 42 (58.3) 181 (50.3%)  
≥ 41 years 4 (5.6%) 18 (5.0%)  
    
Ethnicity   (n=72) (n=360) 0.059 
All White 4 (5.6%) 22 (6.1%)  
Afro-Caribbean 25 (34.7%) 78 (21.7%)  
Asians 43 (59.7%) 260 (72.2%)  
    
BMI  n=71 n=358 0.909 
Underweight (<18.5) 1 (1.4%) 5 (1.4%)  
Normal weight (18.5-24.9) 17 (23.9%) 78 (21.8%)  
Overweight (25.0-29.9) 22 (31%) 127 (35.5%)  
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5.8.2 Risk factors   
   
5.8.2.1 Risk factors of GDM and gestational ages at diagnosis 
Of those women who consented to take part in the study, 203 {38 (18.7%) previous GDM 
vs. 165 other risk factors} and 218 {27 (12.4%) previous GDM vs. 191 other risk factors} 
were GDM positive at <24 and ≥24weeks respectively (p <0.291) (Table 5.3).  
 
   Table 5.3: Risk factors of GDM at different gestational weeks  
 Family 
History 
BMI ≥30 Previous GDM Other Groups* P value 
Gestational 
weeks 
n=229 n=88 n=65 n=39 0.291 
<24 (n=203) 108 (43.2%) 41 (20.2%) 38 (18.7%) 16 (7.9%)  
≥24 (n=218)  121 (55.5%) 47 (21.6%) 27 (12.4%) 12 (10.6%)  
   *Other groups comprise of previous macrosomia, ages 40+, previous poor obstetric outcome (SB & ND), raised random blood     
      glucose (≥7.0 & ≤11.1mmol/l) and glucosuria  
   
 
The interrelationship between the risk factors and age, ethnicity and BMI are outlined 
below in Table 5.4. Age 21-30 was 67%, 16% and 9% respectively and 31-40 were 45%, 
24% and 21% respectively (p <0.001); ethnicity was all White 21%, 55% and 17% 
respectively, Afro-Caribbean 36%, 32% and 20% respectively and Asians 65%, 13% and 
13% respectively (p <0.000). For BMI, the values were 76%, 6%, and 10% respectively; 










Table 5.4: Risk factors and maternal age, ethnicity and BMI  
 Family 
History 
BMI ≥30 Previous GDM Other Groups* P value 
Age  n=237 n=89 n=65 n=41 0.001 
≤ 20 years 6 (85.7%) 1 (14.3%) 0 (0.0%) 0 (0.0%)  
21-30 years 121 (66.5%) 29 (15.9%) 16 (8.8%) 16 (8.8%)  
31-40 years 101 (45.3%) 54 (24.2%) 47 (21.1%) 21 (9.4%)  
≥ 41 years 9 (45.0%) 5 (25.0%) 2 (10.0%) 4 (20.0%)  
      
Ethnic groups     0.000 
All White 6 (20.7%) 16 (55.2%) 5 (17.2%) 2 (6.9%)  
Afro-Caribbean 37(35.6%) 33 (31.7%) 21(20.2%) 13 (12.5%)  
Asians 194 (64.9%) 40 (13.4%) 39 (13.0%) 26 (8.7%)  
      
BMI      0.000 
Underweight 
(<18.5) 
5 (100.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)  
Normal weight 
(18.5-24.9) 
68 (75.6%) 0 (0.0%) 9 (10.0%) 13 (14.4%)  
Overweight 
(25.0-29.9) 
96 (64.4%) 4 (2.7%) 25 (16.8%) 24 (16.1%)  





5.8.3 Pregnancy outcomes 
  
5.8.3.1 Pregnancy outcomes and gestational ages at diagnosis of GDM 
 
In Table 5.5 women who were diagnosed <24 weeks gestation, premature birth was 13% 
(26), other groups 3.6% (7) {stillbirth 1% (2), neonatal death 0.5% (1), miscarriages 2% 
(4)} and the remaining 83% (163) delivered at full term. For those who delivered after 24 
weeks, 84% (182) delivered at full term with 17% (36) delivered prematurely (p <0.014). 
Of those diagnosed before and after 24 weeks gestation, 1% / 2% had macrosomia, 12% / 
8% low birth weight and the remainder were normal 88% / 90%, respectively (p <0.380). 
Eighty-three per cent (83.3%) of babies with macrosomia were born to mothers who were 
obese and (16.7%) overweight. Mode of delivery of those diagnosed <24 weeks was 41.5% 
172 
 
vaginal, 7.7% instrumental and 50.8% caesarean section and 45.2%, 7.8% and 47.0%, 
respectively ≥24 weeks of gestation (p <0.735).  
 
 Table 5.5: Pregnancy outcomes and gestational ages at diagnosis of GDM  
 Gestational ages at diagnosis of 
GDM 
                    P value 
Pregnancy outcomes <24 weeks of 
gestation 
≥24 weeks of 
gestation 
 
Gestational ages at birth (n=196) (n=218) 0.014 
Full term birth 163 (83.2%) 182 (83.5%)  
Preterm birth 26 (13.3%) 36 (16.5%)  
*Other outcomes 7 (3.6%) 0 (0.0%)  
Birth Weight  ¤(n=193) (n=218) 0.380 
Low birth weight (≤2499grams) 22 (11.4%) 17 (7.8%)  
Normal birth weight (2500 - 4449grams) 169 (87.6%) 197 (90.4%)  
Macrosomia (≥4500grams) 2 (1.0%) 4 (1.8%)  
Mode of delivery n=195 n=219 0.735 
Vaginal 81 (41.5%) 99 (45.2%)  
Instrumental 15 (7.7%) 17 (7.8%)  
Caesarean 99 (50.8%) 103 (47.0%)  






5.8.3.2 Obstetric complications and gestational ages at diagnosis of GDM 
 
Within the index pregnancy, 21% and 31% developed maternal and foetal/neonatal 
complications <24 weeks gestation, respectively, and19% and 32% (respectively) ≥24 






Table 5.6: Obstetric complications and gestational weeks at diagnosis of GDM  
 Gestational ages at diagnosis of GDM P value 
 <24 weeks of gestation  ≥24 weeks of gestation   
Obstetric complications (n = 155) (n = 190) 0.925 
No complications 75 (48.4%) 94 (49.5%)  
Maternal complications 32 (20.6%) 36 (18.9%)  
Foetal / neonatal 
complications 
48 (31.0%) 60 (31.6%)  
   
 
   
  
Gestational ages at birth for those with maternal and foetal/neonatal complications were 
17.7% / 26.3% full term live and 28.1% / 54.4% preterm, respectively (p <0.000). Birth 
weight for maternal and foetal/neonatal complications were 27.3% / 46% low birth weight, 
18.4% / 29.4% normal weight and 18.4% / 29.4% macrosomia, respectively (p <0.046). 
Deliveries vaginally 15.8% / 32.1%, instrumentally 22.2% / 48.1% and by caesarean 
section 22.0% / 28.0% were of women with maternal and foetal/neonatal complications, 














Table 5.7: Obstetric complications and pregnancy outcomes  
 Obstetric complications 
 
P value 
Pregnancy outcomes No complications Maternal 
complications 
Foetal / neonatal 
complications 
 
Gestational ages at 
birth  
(n=178)  (n=69)  (n=113)  0.000 
Full term birth 168 (56.0%) 53 (17.7%) 79 (26.3%)  
Preterm birth 10 (17.5%) 16 (28.1%) 31 (54.4%)  
*Other outcomes 0 (0.0%) 0 (0.0%) 3 (100.0%)  
Birth Weight  (n=177) (n=69)  (n=112)  0.046 
Low birth weight 
(≤2499grams) 
9 (27.3%) 9 (27.3%) 15 (45.5%)  
Normal birth weight 
(2500 - 4449grams) 
167 (52.2%) 59 (18.4%) 94 (29.4%)  
Macrosomia 
(≥4500grams) 
1 (20.0%) 1 (20.0%)  3 (60.0%)  
Mode of delivery  (n=178)  (n=69)  (n=113)  0.120 
Vaginal 86 (52.1%) 26 (15.8%) 53 (32.1%)  
Instrumental 8 (29.6%) 6 (22.2%) 13 (48.1%)  
Caesarean 84 (50.0%) 37 (22.0%) 47 (28.0%)  




5.8.4 Ethnic categories and consanguinity 
  
Consanguinity was found only among the Asians (6.8%) (p <0.001) accounting for 
approximately 10% of all Asians screened (Table 5.8).  
 
  
  Table 5.8: Ethnic categories and consanguinity  
 
  
   
 Consanguinity P value 
 Yes No  
Ethnic categories  (n=31)  (n=424)   0.001 
All Whites 0 (0.0%) 31 (100.0%)  
Afro-Caribbean 0 (0.0%) 108 (100.0%)  





5.8.5 Diabetes management and gestational ages at diagnosis  
 
Diabetes management in <24 weeks gestation was diet only 42.5%, 62.1% diet and oral 
medication and 53.4% diet and insulin or combination therapy, compared to 57.5%, 37.9% 
and 46.6% respectively in ≥24 weeks (p <0.034) (Table 5.9). 
 
   Table 5.9: Gestational ages at diagnosis and diabetes management 
 
 Gestational ages at diagnosis                P value 
 <24 weeks of gestation ≥24 weeks of gestation  
Diabetes management n = 193 n = 214 0.034 
Diet only 105 (42.5%)  142 (57.5%)  
Diet and Oral medication 18 (62.1%) 11 (37.9%)  
Diet and Insulin and 
Combination therapy 
70 (53.4%) 61 (46.6%)  
 
   
 
5.8.6 Diabetes management and pregnancy outcomes 
Pharmacological therapy of diet only, diet and oral therapy and diet and insulin / 
combination therapy were 61.2%, 7.5% and 31.3%, respectively for full term births and 
51.6%, 4.8% and 43.5%, respectively for preterm birth (p < 0.0269); 63.2%, 10.5% and 
26.3% respectively, low birth weight, 59.7%, 6.5% and 33.8% respectively for normal 
birth weight. Macrosomia was 83.3% diet only and 16.7% diet, insulin and combination 
therapy (p < 0.589).  Deliveries vaginally 70.2% / 7.2% / 22.7%, instrumentally 48.4% / 
12.9% / 38.7% and by caesarean section 53.2% / 5.9% / 41.0% were managed with diet 
only, diet and oral therapy and diet, insulin or combination therapy, respectively (p < 






 Table 5.10: Diabetes management and pregnancy outcomes 
 Diabetes management 
 
           P value 
Pregnancy outcomes Diet 
only 
Diet and Oral 
Medication 
Diet and Insulin and 
Combination therapy  
 
Gestational ages at 
birth  
(n=250)  (n=29)  (n=137)  0.0269 
Full term birth 213 
(61.2%) 
26 (7.5%) 109 (31.3%)  
Preterm birth 32 
(51.6%) 
3 (4.8%) 27 (43.5%)  
*Other outcomes 5 
(83.3%) 
0 (0.0%) 1 (16.7%)  
Birth Weight     0.589 




4 (10.5%) 10 (26.3%)  
Normal birth weight 
(2500 - 4449grams) 
220 
(59.7%) 





0 (0.0%)  1 (16.7%)  
Mode of delivery     0.002 
Vaginal 127 
(70.2%) 
13 (7.2%) 41 (22.7%)  
Instrumental 15 
(48.4%) 
4 (12.9%) 12(38.7%)  
Caesarean 109 
(53.2%) 




   
  
5.8.7 Post-delivery outcomes and gestational ages at diagnosis 
Post-delivery, of those with GDM diagnosed <24 weeks, 25% had abnormal OGTT of 
which 12 % had T2 DM. In the ≥24 weeks group, 4% had T2 DM and 9% had either 
impaired glucose tolerance (IGT) (blood glucose between 7.8 & 11.1mmol/l after 2 hours 
glucose load) or impaired fasting glucose (IFG) (fasting glucose >6.1mmol/l). Overall, 
twenty-five (16 %) were diagnosed with T2 DM and 23% had either IGT or IFG on 
postnatal OGTT (p <0.010) (Table 5.11). Post-partum blood glucose status for Afro-
Caribbeans and Asians were 87.8% / 78.0% normal, 6.8% / 12.6% IGT/IFG and 5.4% / 
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9.3% Type 2 DM, respectively. Whites were 83.3% normal and 16.7% Type 2 DM (p 
<0.144) (Table 5.12). 
 
 
 Table 5.11: Postpartum glycaemic status and gestational ages at diagnosis    
 Normal           Impaired Glucose 
Tolerance (IGT) / Impaired 






ages on GDM 
diagnosis 
(weeks) 
(n=262) (n=36) (n=25) 0.010 
< 24/40 112 (74.7%) 20 (13.3%) 18 (12.0%)  
≥ 24  150 (86.7%) 16 (9.2%) 7(4.0%)  
 Normal = <6.1mmol/l on fasting and <11.1mmol/l two hours after glucose load; Impaired Glucose Tolerance (IGT) = normal fasting           
plasma glucose with 2-hour value ≥7.8mmol/l and ≤11.1mmol/l and Impaired Fasting Glucose (IFG) = fasting glucose ≥ 6.1mmol/l but 





Table 5.12: Postpartum glycaemic status and ethnic groups 
 Normal           Impaired Glucose 
Tolerance (IGT) / 





Ethnic groups (n=272) (n=36) (n=30) 0.144 
All Whites 15 (83.3%) 0 (0.0%) 3 (16.7%)  
Afro-Caribbeans  65 (87.8%) 5 (6.8%) 4 (5.4%)  












5.9.1 Prevalence of GDM 
In this study, GDM was more common among the Asians, followed by the Afro-
Caribbeans with the indigenous group less likely to have the condition and this was highly 
significant. Although the Asians were the more dominant group detected with GDM, there 
were a similar number of women detected early and late gestation, likewise for the Afro-
Caribbeans. Compared to the Whites, Afro-Caribbean were 4 times and Asians 10 times 
more likely to develop GDM. This prevalence exceeds national figures (NICE, 2015) but is 
reflective of the ethnic distribution of the local population. In support of the findings of this 
study, GDM was found to be more prevalent among Asians than Whites (Ferrara, 2007; 
Yang et al, 2002 & Dornhurst et al, 1992).  
 
Obesity, sedentary lifestyle and changes in dietary habits ‘superimposed on 
genetic/epigenetic’ predispositions are believed to contribute to the high prevalence of 
diabetes in general among Asians (Hu, 2011). Also, the incidence and prevalence can be 
rapidly increased when further complicated with consanguineous marriages. Consanguinity 
is more common among Asians and this was reflected in this study which showed no 
incidence in the other ethnic groups. Therefore, a significant number of local women were 
presenting in pregnancy with other confounding factors, which at booking, make their 
pregnancy ‘High Risk’, even without the complications of diabetes.  
 
In 2012, a West Indian study conducted to assess the effects of family history of diabetes 
and consanguinity on the siblings of T2 diabetics found a positive correlation between 
these factors and metabolic disturbance within this group (Shahid et al, 2012). This study 
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was conducted on a non-diabetic population and should GDM have been present in the 
study group, one can conclude that there could have been a stronger correlation, and this 
coupled with the aetiology of the condition, could be partly responsible for the cyclical 
effect of diabetes among and within this group. 
 
5.9.2 Family history and BMI 
In this study, family history and BMI ≥30 were strong indicators of developing GDM early 
in pregnancy with the latter being as strong as those having had a previous history of GDM 
and the former being over twice the strength. Over one-third of the women screened were 
either overweight or obese and they were mainly Asians followed by Afro-Caribbeans. 
These findings suggest a link between familial factors and increasing BMI and GDM 
within the local population.  
Our findings are substantiated in a systematic review with meta-analysis on pre-pregnancy 
BMI and the risk of GDM, which found that compared to women of normal weight, 
women who were overweight and moderately/severely obese were at higher risk of 
developing GDM and that risk increased for every 1kg/m increase in BMI (Torloni et al, 
2009).  
 
Recently, a study had revealed that the incidence of GDM increased, the higher the pre-
pregnancy BMI (Abu-Heija et al, 2017). A systematic review which examined maternal 
anthropometrics on pregnancy outcomes of South Asians found that pre/early pregnancy 
weight and body fat were associated with anthropometric changes, mode of delivery, birth 
weight and GDM, suggesting an increased risk of adverse pregnancy outcome among this 
ethnic group (Slack et al, 2018). Additionally, in a large-scale population-based study, a 
strong correlation was established between a woman’s birth weight and her subsequent risk 
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of developing GDM suggesting that early life factors contributed to the aetiology of the 
condition (Innes et al, 2002).  
 
Also, when BMI ≥25.0 kg/m2 was used as a screening tool for the detection of GDM, the 
incidence was highest among African Americans (76%), followed by Latinas (58%), 
Caucasians (46%) with Asians (25%) least at risk (Shah et al, 2011). In a large London-
based study, BMI was found to be associated with diabetes in pregnancy, regardless of 
ethnicity. However, the application of BMI cut-off of 30.0 kg/m2 is believed to fail 
detection of East and South Asian women who have shown to be at higher risk of diabetes 
at a lower BMI threshold as low as 21 kg/mg2. It is therefore suggested that universal 
screening for all Asians might be the way forward (Nishikawa et al, 2017).   
 
An Australian study that compared ethnicity with GDM diagnosis have demonstrated 
similar low BMI thresholds in South East Asians in the diagnosis of GDM based on 
elevated 2-hr values compared to Anglo-American and women from the Pacific who had 
higher BMIs and GDM diagnosis on elevated fasting values (Wong, 2012). Other studies 
have shown similar association between low BMI and the detection of diabetes among 
Asians (Ma & Chan, 2013 & Nyamdori et al, 2010). Having used BMI ≥30.0 kg/m2 as a 
cut-off for this study may prove to be of a disservice to Asians in particular. Hence, ethnic 
specific BMI thresholds for the diagnosis of GDM may be necessary for more accurate risk 
identification with a more targeted approach for intensive care including during the 
postnatal period (Mukerji et al, 2012). Nevertheless, obesity prevention among all ethnic 





Like BMI, advancing maternal age is also a risk factor in the detection of GDM and this is 
more of a concern among South Asians and Black Africans (Makgoba et al, 2011). 
Makgoba et al (2011) also found that the interaction of age and BMI with racial groups can 
determine the prevalence of GDM. Also, Black Caribbeans were less likely to develop 
GDM compared to Black Africans, suggesting inaccuracies of reporting epidemiological 
findings among and within these groups. Despite these findings, having a shift in 
separating these groups may be avoided to provide larger sample sizes for strong statistical 
analyses for the understanding of the aetiology of diseases like GDM/diabetes. 
Nevertheless, as Afro-Carribeans were the second largest group in this study, consideration 
must be given to separate the Black Caribbeans from the Black Africans for future work. 
 
A recent study which looked at the prevalence of GDM and associated risk factors among 
Chinese women found that there was a high prevalence of GDM within this group with key 
risk factors being advanced maternal age, pre-pregnancy BMI and a history of first degree 
relative with diabetes (Wu et al, 2018). Likewise, there was a direct link between 
increasing maternal age and developing GDM with a family history of diabetes and 
previous history of GDM being the main predictors of the condition. There was also a 
strong correlation between increasing maternal age and having a positive oral glucose 
challenge test (OGCT) when screened between 24-28 weeks (Abu-Heija et al, 2017). In the 
Northern California Kaiser Permanente study, the prevalence of GDM increased in all age 
groups with the highest increase among the youngest group (Ferrara et al, 2004). The 





In a Saudia Arabian study, multiparous women were approximately 8 times more likely 
than nulliparous women to develop GDM and the latter group had an increased risk of 2-
21% when age was increased from 20 to 40 years (Al Rowaily MA & Abolfotouh MA, 
2010). In this study, age was not a determinant factor with regards to early or late diagnosis 
of GDM. However, as Al Rowaily & Abolfotouh (2010) and Abu-Heija et al (2017)’s 
studies only evaluated the late-onset GDM, it is difficult to make wholesome comparisons. 
Nevertheless, it would have been useful to explore parity in relation to the time of 
diagnosis as this factor seems to have some correlation to GDM diagnosis. Likewise, with 
our local population being predominantly young, this information would have been 
invaluable for future care planning. 
  
5.9.3 Early and late diagnosis of GDM 
NICE (2015) recommends that early screening should be offered only to those with a 
previous history of GDM. However, this study has demonstrated that almost 50% of the 
women developed GDM before week 24 and a considerable number of these high-risk 
pregnant women, nearing 80% had no previous history of gestational diabetes.  
 
These findings concur with previous studies which concluded that selective screening may 
fail to detect about one-third of women with GDM (Benhalima et al, 2015) whereas 
universal screening has a higher detection rate (Tieu et al, 2017; Benhalima et al, 2015). 
This is despite a Cochrane review demonstrating insufficient evidence to conclude a 
positive impact on maternal and foetal health (Tieu et al, 2017).  
 
NICE’s (2015) current guidelines may have its foundations from similar origins. However, 
based on the evidence of this study whereby a considerable number of high-risk pregnant 
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women without previous histories of gestational diabetes developed GDM before week 24, 
a strict adherence to the NICE guidelines may be inappropriate if the target population is 
genetically predisposed to metabolic abnormalities.  
 
Therefore, in regions of the UK, such as the London Borough of Newham which have a 
significant number of residents of Asian origin, pregnant women with a family history of 
diabetes and raised BMI should be screened for gestational diabetes as early as possible. 
Furthermore, universal screening in an area like this which is highly multi-cultural may 
have a high detection rate and further research may be needed to explore this area. 
Additionally, the fasting value on OGTT (≥6.1mmol/l) used for the diagnosis of GDM for 
this study were based on NICE’s (2008) guidelines. This value is significantly higher than 
current recommendations of ≥5.6mmol/l and should the latter have been used, there would 
have been an increased detection rate, with these tighter guidelines. 
 
This is of concern because poorly controlled gestational diabetes is associated with adverse 
maternal and foetal outcomes (Billionnet et al, 2017). Moreover, there is evidence that 
women with a history of gestational diabetes have a high risk of developing type 2 diabetes 
(Kwak et al, 2013) and their children type 2 diabetes in later life (Garcia-Vargus et al, 
2012) and autism (Xiang et al, 2015).  
 
5.9.4 Diabetes management 
In this study, approximately 61 percent of all women were managed on diet only and this 
form of management was more common among those diagnosed ≤24 weeks gestation. Of 
those who received pharmacotherapy, the main form of treatment was diet and insulin 
therapy, and the incidence was similar in both early and late diagnosed GDM groups. 
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Although the number of women on combination therapy was small the incidence was three 
times greater in those diagnosed <24 weeks gestation compared to those diagnosed later. 
However, for statistical analysis, this group was combined with those receiving the next 
intensive form of treatment - insulin. Overall, those diagnosed early needed more intensive 
pharmacotherapy, possibly impacting on nearing half the number of preterm births and 
instrumental and caesarean section deliveries.  
A recent study which evaluated pregnancy outcome in early and late-onset GDM with risk 
factors of BMI and family history of diabetes has shown that the insulin requirement was 
85 percent and 55 percent in early and late-onset GDM, respectively (Easmin et al, 2015).   
It is difficult to postulate whether the limitation of using only two risk factors and insulin 
as the only form of pharmacological therapy, coupled with the clinician’s preference in 
treatment modalities and the environment in which treatment was administered, could have 
impacted on the pharmacotherapy regimen and the subsequent impact on pregnancy 
outcomes. Additionally, as the subjects studied were of Bangladeshi origin living in their 
native country, genetic predisposition may have been a factor necessitating intensive 
therapy resulting in higher use of insulin therapy compared to this study which studied a 
wider cross-section of ethnic groups living in the UK with four treatment options.  
 
Nevertheless, most recently, a systematic review on the effects of treatment on pregnancy 
outcomes of women diagnosed with GDM has shown no significant difference except for a 
reduction in shoulder dystocia in intensive versus less intensive treatment in the former 






5.9.5 Pregnancy outcomes (maternal and foetal)  
In this study, although nearing half of the women presented having had previous obstetric 
problems (adjusting for the primagravidas) and almost half had no clinical problems within 
the existing pregnancy. One can argue that early intervention may have contributed to that 
positive outcome, having had extensive screening before 24 weeks of pregnancy to include 
women with risk factors other than a previous history of GDM. Obstetric complications 
which were mainly associated with the foetus/neonate developed at any stage of pregnancy 
regardless of gestational age when GDM was diagnosed. A significant number of these 
women with complications delivered prematurely compared to healthy women. 
 
Macrosomia was more common among women diagnosed ≥24 weeks and whose babies 
had ante- and intrapartum complications but with no statistical significance. Low birth 
weight was higher in diagnosed GDMs <24 weeks gestation. Fifty percent of those who 
developed complications were delivered by caesarean section while approximately one-
third of those who had an instrumental delivery also had complications.  
 
A possible explanation for the higher incidence of macrosomia in ≥24 weeks gestation 
could be due to the very nature of the late diagnosis and possible late specialist 
intervention. It is well documented in previous evidence the benefits of early intervention 
to promote optimal well being for mother and baby (Görig et al, 2015). Conversely, IUGR 
in those diagnosed <24 weeks could be as a result of intensive treatment requirements due 





In a prospective Austrian study which examined clinical and pathophysiological 
characteristics of women with early and late diagnosis of GDM (using the IADPSG 
criteria), a higher degree of insulin resistance in the early onset group was found 
implicating that pre-existing insulin resistance and beta cell dysfunction during pregnancy 
may determine early onset of GDM diagnosis. Conversely, a manifestation of beta-cell 
dysfunction was found in early pregnancy of women diagnosed with GDM later in 
pregnancy, suggesting possible compensatory mechanisms during later pregnancy 
(Bozhurt et al, 2015). 
 
Compared to Caucasians, Asians and South Asians have increased insulin resistance in late 
pregnancy. Also, pre-pregnancy BMI has greater insulin resistance in pregnancies in 
Asians compared to Caucasians and this may have resulted in the great disparity between 
the former and latter ethnic groups in this study. When these factors are combined, 
ethnicity may determine the effect of obesity on insulin resistance in pregnancy 
(Retnakaran et al, 2006). 
  
There were a similar number of full-term births within the two groups (83% vs 84%). 
However, the number of stillbirths, neonatal death and miscarriages although small was 
found only amongst those diagnosed <24 weeks gestation. This reinforces the notion that 
the earlier the diagnosis of GDM, the more detrimental the likely impact on both mothers 
and their babies’ health, and the need for early screening and specialist support and 





Although stillbirth rates among GDMs have decreased due to screening, treatment and 
antenatal surveillance of these mothers, about 4% of all stillbirths remain attributable to 
diabetes, and diabetic pregnancies continue to be at risk of prenatal mortality (Weissgerber 
& Mudd, 2015). Ben Slama et al (1997) estimated that the risk of stillbirth is increased 
after thirty-five (35) years even after the exclusion of conditions like hypertension and 
diabetes. In our study, age was not a contributory factor, and the adverse pregnancy 
outcome may have been associated with early onset of GDM or the likelihood of 
undiagnosed Type 2 DM pre-pregnancy, and morbidity associated with those conditions. 
Findings from Hosseini et al’s (2018)’s study confirm that pregnancy outcomes are poorer 
in early-onset GDMs compared to the late-onset group.  
 
A retrospective study has demonstrated that pre-pregnancy overweight and obesity are 
linked to large for gestational age infants, even without a diagnosis of GDM (Black et al, 
2013). Almost ninety percent of the babies had normal birth weight in this study. Of those 
diagnosed with macrosomia, their mothers were either obese or overweight. One can 
postulate that local guidance on extensive screening of those other than with a previous 
history of GDM has not only been effective in detecting high-risk women early, but with 
early intervention, the incidence of macrosomia and related co-morbidities may have been 
prevented or reduced. However, despite pre-pregnancy overweight and obesity being 
linked to GDM and poor pregnancy outcomes (Catalano et al, 2012; Perez-Ferre et al, 
2012), even without a diagnosis of GDM (Black et al, 2013), it can be argued that excess 
weight and GDM share similar physiopathological characteristics of insulin resistance and 
therefore it is difficult to isolate the effects of each on maternal and neonatal outcomes 




High first-trimester fasting glucose levels, even when below the values of diagnostic 
diabetes, increase the risk of macrosomia, LGA birth weight and caesarean (Riskin-
Mashiah et al 2009). When combined these factors may suggest that women who present 
before 24 weeks gestation may have had advanced pathophysiology and this may have 
resulted in poorer maternal and neonatal outcomes (Feghal et al, 2018).  
 
High rates of adverse pregnancy outcomes were detected in women diagnosed with GDM 
before 24 weeks with the highest risk in those diagnosed less than 12 weeks but after 
accounting for maternal characteristics like obesity and timing of diagnosis, there was no 
longer associated with macrosomia and LGA birth weight (Sweeting et al 2016).  
 
A recent study which looked at the timing of diagnosis of GDM and pregnancy outcome 
confirmed that those with a history of previous GDM were more likely to have an early 
diagnosis before 24 weeks gestation. They were also more likely to be older, less likely to 
have a college education and be nulliparous. They were also more likely to be obese but 
had a reduced chance of having excess gestational weight gain (Feghal et al, 2018).  
 
Women diagnosed before 24 weeks gestation were more at risk of adverse outcomes 
compared to those after 24 weeks. Macrosomia was more common in the earlier diagnosed 
group, but only a slight difference was reported in gestational age at delivery. In terms of 
diabetes management, women diagnosed before 24 weeks were more likely to be treated 
with oral therapy or insulin. This group of women diagnosed before 24 weeks is believed 
to have unique features and therefore a targeted approach to therapy is recommended 




Preterm birth was higher in women diagnosed ≥before 24 weeks gestation with no 
statistical significance. This is unlike the finding of a most recent retrospective study which 
showed a high incidence of preterm birth in those diagnosed early. This study evaluated 
the pregnancy outcomes of women with early (< 24 weeks) and late (≥24 weeks) diagnosis 
of GDM using the WHO 2013 screening criteria (75g OGTT) and found a higher incidence 
of preterm birth and caesarean section rate in the former group compared latter, supporting 
the notion of early screening and diagnosis of high-risk women. Also, there was an 
association between gestational age at GDM diagnosis and macrosomia and neonatal 
hypoglycaemia (Bashir et al, 2019). Conversely, no significant difference was found in 
neonatal outcomes, in another retrospective study which used both the WHO 2013 
screening criteria (75g OGTT) versus fasting plasma glucose ≥92mg/dl and HBA1c ≥5.7% 
at ≤24 weeks gestation. However, women diagnosed early had a greater need for 
pharmacotherapy and BMI was highly significant in the prediction of this need (Alunni et 
al, 2015). 
 
Nevertheless, it is argued that despite early detection of GDM (<12 weeks gestation) and 
best treatment, the pregnancy outcome of these women remains poor and is comparable to 
women with type 2 diabetes. Therefore, it is suggested that alternative approaches to 
management are necessary to improve the pregnancy outcomes in these high-risk 
pregnancies (Sweeting et al, 2016). It is postulated that this could be due to the early 
establishment of foetal hyperinsulinaemia thus supporting the need for pre-pregnancy 
planning and early establishment of maternal glycaemic control (Desoye & Nolan, 2016). 
These researchers have described this phenomenon as ‘fetal glucose steal’ which is also 
responsible for some foetuses having the characteristics of diabetic fetopathy despite their 




In a large retrospective Australian pregnancy study, it was found that compared to 
Caucasians, Chinese women had a higher risk of developing GDM but with fewer risk 
factors which included lower BMI. Caucasians had poorer pregnancy outcomes while there 
was no difference in outcome in those diagnosed with GDM and those without the 
condition. Consequently, ethnicity needs to be considered when screening for GDM and 
managing the potential risks associated with the condition. Hence, the ‘precision medicine 
risk prediction approach’ has been suggested (Wan et al, 2019).  
  
5.9.6 Postnatal Outcomes 
In this study, there was a significant increase in those diagnosed with T2 DM <24 weeks 
compared to those diagnosed after 24 weeks. As there was an additional 115 who were not 
screened because they forfeited their appointments for postnatal testing, one can conclude 
that an additional 12% could have had T2 DM, if the same percentage is applied. Of those 
diagnosed with overt diabetes, 77% were Asians, although not statistically significant. 
Thirteen percent (13%) were Afro-Caribbeans and the remaining 10% were Whites.  
 
A previous study which evaluated the impact of GDM on postpartum diabetes has shown 
that 6.5% were of South Asians origin and a third developed diabetes within 8 years, 
although they and women of Chinese origin were at decreased risk of postpartum diabetes 
(9-10 -fold) compared to Whites in whom the risk was 13-fold (Mukerji et al, 2012).  
 
Post-GDM, women are at risk of developing T2DM within 5-10years and their children, 
the condition in their early years because they have a higher risk of being obese (Metzger 
et al, 2002). Obesity is a known contributory factor to GDM but root causes relate to 
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socioeconomic factors (Chu et al, 2007). In a cross-sectional USA study, central obesity 
was common among Asians and the prevalence increased over time and was associated 
with increased risk of T2 DM (Liu et al, 2017). It is postulated that this obesity epidemic is 
fuelled by increased calorific intake and decreased physical activity (Assaf-Balut et al, 
2016; Hunt & Schuller, 2007) and has now become a public health issue.  
 
Follow-up of this lost group is critical if future morbidities associated with GDM in 
subsequent pregnancies and T2 DM are to be reduced or even prevented; as women 
diagnosed with GDM have a 70% risk of developing GDM in subsequent pregnancies and 
T2 DM within 10 years post-delivery (Schwartz et al, 2015). 15-50% of women diagnosed 
with GDM develop T2 DM post-delivery (Wu et al, 2016). Having a postnatal OGTT and 
consultation are critical to the follow-up program (Beischer et al 1997; McClean et al, 
2010) which needs to be unambiguous (McClean et al, 2010) and could be best organised 
by team administrators than clinicians (Beischer et al, 1997).  
 
In a descriptive qualitative US study, women described being motivated to manage their 
GDM condition for their babies and not for themselves. Most believed that their future 
health would not be affected, and they were unaware of their risk of early-onset T2 DM 
(Bernstein et al 2016) – a condition that could be prevented with reduced portion sizes and 
increased activity (Hunt & Schuller, 2007).  
 
To reduce the morbidity associated with the long-term effects of GDM, having a health 
education model can be useful to improve knowledge, and related beliefs and practices for 
prevention and early detection of T2 DM (Tawfik, 2017). Community engagement 
programmes offering increased activity are also necessary for all ethnic groups but 
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particularly Asians, as most women diagnosed were within this group. However, care must 
be taken when conducting any health research because Asians are a heterogeneous group 
and should be studied and evaluated within sub-groups (Chu et al, 2009). In an Australian 
randomised controlled trial of a postnatal diabetes prevention program, it was concluded 
that as little as1kg weight loss has the potential to be significant in the reduction of 
diabetes risk (O’Reilly et al, 2016).  
A study conducted to evaluate the effectiveness of the prevention of Type 2 diabetes 
presented by a commercial weight management provider using a primary pathway has 
achieved a significant reduction in weight loss and subsequent diabetes risk (Piper et al, 
2017 b). However, one may argue that one needs to cautious because commercial interest 
can be seen as a bias and may influence the findings. Nevertheless, due to the economic 
constraints that the NHS is under, this could be a viable option to curb the obesity crisis 
















Our findings demonstrated that in communities like Newham which are genetically 
susceptible to T2 DM, early screening should be offered to pregnant women with BMI ≥30 
and with a family history of diabetes as these risk factors are strong predictors for early 
detection of GDM. Early detection of GDM within these groups will facilitate the 
reduction of adverse birth outcomes and postnatal risks.  
GDM remains a challenge for clinicians. Screening for the condition remains ambiguous 
and debatable. Current NICE guidelines appear to be limited in its offer for early screening 
to only those with a history of previous GDM. Adherence to these guidelines would be 
inappropriate in highly diverse populations with a family history of diabetes and BMI ≥30. 
Therefore, current NICE guidance on screening for GDM may need to be re-evaluated to 
assess its efficacy of use and application in areas with a high prevalence of diabetes. 
Further research is needed in this area. 
 
Oral supplementation with omega-3 fatty acids in pregnant women is believed to one way 
of improving the health and well-being of mothers and their offspring. This will be 














Chapter 6:  
 
The beneficial effects of omega 3 fatty 
acids on maternal and foetal health and 
birth outcomes of women diagnosed 










6.1 Chapter overview   
5 In this chapter, I have explored the beneficial effects of omega-3 fatty acids on 
maternal and foetal health and birth outcomes of women diagnosed with GDM.  To do this, 
women with GDM were approached by random selection and offered the opportunity to 
take part in the nutritional study. For women who consented to be part of the nutritional 
study, they were randomised into two groups and given DHA or high oleic acid sunflower 
seed oil placebo capsules from recruitment until delivery.  
 
 
6.2 Introduction  
Maternal nutrition at the time of conception and throughout pregnancy is critical to a 
woman’s health during pregnancy and pregnancy outcomes for her and her baby (Myatt & 
Powell, 2010). Included in the recommendation for a balance and health diet, are essential 
fatty acids (EFAs) {(arachidonic acids (AA) and docosahexaenoic acids (DHA)}. EFAs 
have been shown to be essential components in the foetal placental unit (Crawford et al, 
1989) with implantation, vascular growth and organogenesis (Demetris et al, 2005), and 
subsequent embryonic morphology (Hammiche et al, 2011). Both mother and baby benefit 
from enhanced levels of omega 3 fatty acids supplementation (Dunstan et al, 2004).  
For the foetus, newborn and infant, EFAs, particularly AA are necessary for foetal growth 
and development (Innis, 2007; Crawford, 2004). DHA is an important component of the 
developing central nervous system and is vital for cognitive and visual development 
(Connor et al, 1992, Crawford et al, 1976). DHA accumulates rapidly in the brain and 
retina during the 2
nd
 (Martinez, 1992; Min & Crawford, 2004) and 3
rd
 trimester and soon 
after delivery (Jensen, 2006). A child’s behaviour, level of concentration and learning 
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improve with supplementation with EFAs (Perera et al, 2012; Yui et al, 2012 & Gustafsson 
et al, 2010). Increased birth weight and reduction in preterm births (Onwude et al, 1994 & 
Olsen et al, 1986), low levels of hyperbilirubinemia and hospitalisation are other potential 
benefits.  
For the mother, likely benefits include prolonged gestational age (Olsen et al, 1991), 
reduction of preeclampsia (Dyerberg & Bang, 1985 & Romeo et al, 1988) and anti-
hypertensive properties (Miller et al, 2014 & Hartweg et al, 2007) and lowering effects of 
cardiovascular disease (Chowdhury et al, 2014 & Von Schacky & Haris, 2004). 
 
During pregnancy, the foetus demands its requirement of AA & DHA from the mother 
(Clandinin et al, 1980; Martinez 1992) sometimes leaving the mother with depleted stores, 
particularly at the end of pregnancy (Ghebremeskel et al, 2000 & Otto et al, 1995). AA & 
DHA cannot be synthesized by the body (Otto et al, 1999). Therefore, adequate maternal 
stores of these EFAs through ingestion of foods or supplements are necessary for their 
selective and efficient placental transfer to meet the demands of the foetus during the pre- 
and post-natal periods (Dutta-Roy, 2000 & Haggarty et al, 1997).  
However, experimental (human & animal) studies into diabetes have shown impairment in 
the delta-5 and delta-6 desaturases which are responsible for the synthesis of LCPUFAs (El 
Boustani et al, 1989). Additionally, since GDM is characterised by possibly short-term 
insulin resistance, which has an adverse effect on LCPUFAs (Min et al, 2006), and not 
adequately compensated by insulin hyper-stimulation due to defective beta cells function 
(Davis, 1990), added supplementation may be required to improve insulin sensitivity and 





The aims are to investigate the: 
a) Effects of maternal supplementation with arachidonic and docosahexaenoic 
acids on maternal and foetal wellbeing during pregnancy and on pregnancy 
outcomes of women diagnosed with GDM. 
b) Effects of supplementation with arachidonic and docosahexaenoic acids on 
maternal postpartum glycaemic status. 
6.4 Subjects and methods 
This was a placebo-controlled, randomised nutritional trial conducted at Newham 
University Hospital. Women ages 17 to 45 were recruited from the hospital’s SADC and 
GDESs (previously discussed). Eligible pregnant women diagnosed with GDM were 
recruited up to 32 weeks gestation and randomly allocated either omega-3 fatty acids or 
placebo, taken from the time of recruitment up until delivery.   
A questionnaire (appendix 3.7) was used to collect data on pregnancy complications (eg. 
hypertensive disorders and pregnancy loss), diabetes management and maternal and foetal 
outcomes (eg. prematurity, post-maturity, macrosomia and low birth weight, neonatal 
admission to special care baby unit). Women were also asked about their and their babies 
health and wellbeing, supplement use which included how, when, quantity taken, side 
effects, storage of supplements and women’s decision on whether or not they wanted to 





6.5 Statistical analysis 
Data on age, parity and BMI are presented as mean ± standard deviation (df), median 
(range) and n (%) as number of occurrences with percentages, where appropriate. 
Pearson’s Chi square test was used to test demographical and clinical characteristics with 
the study groups which received placebo or active (fish oils) supplements. The Chi square 
test was also used to evaluate the similarities and differences in maternal and foetal 
outcomes of women supplemented with AA and DHA and those without. Independent t-
test was used to compare the effects of differences in age, parity and BMI between the 
groups. Statistical significance equated to p < 0.05. The IBM SPSS Statistics version 25 
was used to conduct all analyses.  
 
6.6 Results 
6.6.1 Subjects recruited 
Maternal demographic and clinical characteristics of subjects are provided in Table 6.1 and 
Figure 6.1. Of the women diagnosed with GDM and randomised (n = 149), supplemented 
with fish oils were (n = 75) and placebo (n = 74). In the placebo group, withdrawn were (n 
= 7), moved out of the area (n = 4), miscarried (n=1), stillbirth (n = 1), neonatal death (n = 
1) resulting in full term live births (n = 53) and preterm births (n = 6) completing the study 
and 1 lost to follow up.  Full term and preterm live births in the active group were 49 and 
15, respectively after accounting for withdrawals (n = 7) and women who moved out of 





Figure 6.1: Flow chart of recruits 
 
Subjects in the active and placebo groups had similar characteristics. Overall, the women 
studied were between ages 21 – 40 (n = 141; 95%) (Mean age 31.23; range 19-44 years) (p 
< .277). The majority were of Asian descent (n = 98; 66%) followed by Afro-Caribbeans 




) and an average of 
2 (mean, 1.4; range 0-6) children. Most women (n = 104; 70%) were English speaking. 
Subjects starting the study with chronic medical problems were 16 (23%) and 9 (13%) in 
the active and placebo groups (p < .132), respectively; while others developed maternal (n 
200 
 
= 9, 17% / n = 6, 10%) and foetal (n = 29, 54% / n = 37, 62%) complications in the active 
and placebo groups (p < .525), respectively. Pregnancy complications developed in the 
index pregnancy were intrauterine growth retardation (IUGR) on ultrasound scan (USS) 4 
(6.3%) / 2 (3.2%), big baby on USS 6 (9.4%) / 6 (9.7%) hypertensive disorders 7 (10.9%) / 
4 (6.5%) presumed foetal compromise 4 (6.3%) / 4 (6.5%) in the fish oils and placebo 
groups, respectively. Other complications also developed in the active (n = 15, 23%) and 
the placebo group (n = 13, 21%) with 1 incident of malpresentation in the latter group (p < 
.826) (Table 6.1).  
 
6.6.2 Diabetes management and control at recruitment and pre-delivery   
Diabetes management among women in the active and placebo groups was diet only (n = 
35, (57.4%) / n = 37 (61.7%), diet and oral medication (n = 6, (9.8%) / n =4, 6.7%), diet 
and insulin (n =18, (29.5%) / n = 14, (23.3%), and combination therapy (n= 2, (3.3%) / n = 
5, 8.3%) (p < .525), respectively (Table 6.2). In the active and placebo groups, average 
HBA1c on recruitment and pre-delivery was 6.0% (42 mmol/l) / 6.1% (43 mmol/l) and 
5.9% (41 mmol/l) / 5.8% (40mmol/l), respectively. Average gestational age on recruitment 
was 23 weeks in both groups and pre-delivery was 33 weeks / 32 weeks in the fish oils and 







Table 6.1: Demographic and clinical characteristics of subjects     
 Study groups Gestational diabetics 
 Intervention Active Placebo 
P value {Standard 
deviation (df)}    
No. of Subjects (n)  75 74   
Age, (years) n (%) 
mean 30.73; minimum 20 - 
maximum 44  
mean 31.74; minimum 19 - maximum 
43  .277 (3) 
 ≤ 21 1 (1.3)  1 (1.4)   
 21 - 30 41 (54.7) 29 (39.2)   
31 - 40 31 (41.3) 40 (54.1)   
≥ 40 2 (2.7) 4(5.4)   
Ethnicity, n (%)     .990 (2) 
All Whites 
 
                   7 (9.3) 
 










49 (66.2)   










21 (28.4)   
Parity, n (%) 
mean 1.27,  
minimum 0 - maximum 6 mean 1.53, minimum 0 - maximum 6 .263 (3) 














32 (43.2)   




4 (5.4)   
Body mass index (BMI) (kg/m2), n (%) 
mean 28.77; minimum 16 - 
maximum 48 
mean 29.21; minimum 19 - maximum 





0 (0.0)   




17 (23.0)   









31 (41.9)   










60 (87.0)   















37 (61.7)   
Pregnancy complications, n (%) 64 62 
.826 (6) 
None                               28 (43.8) 32 (51.6) 
 
IUGR by scan 4 (6.3) 2 (3.2) 
 
Big baby by scan 6 (9.4) 6 (9.7) 
 
Congenital abnormality 0 (0.0) 0 (0.0) 
 
Malpresentation 0 (0.0) 1 (1.6) 
 
PIH, Pre-eclampsia or Eclampsia  (10.9) ----4 (6.5) 
 
¤ Presumed foetal compromise 4 (6.3) 4 (6.5) 
 
✤Other pregnancy complications 15 (23.4) 13 (21.0) 
 
¤ Presumed foetal compromise: suspicious cardiotocograph, spontaneous rupture of membranes, premature rupture of membranes, 
prolonged premature rupture of membranes, meconium-stained liquor and reduced amniotic fluid index. ✤Other pregnancy 
complications: cholestasis, anaemia, ante-partum haemorrhage, postpartum haemorrhage, thrombocytopenia, non-alcoholic fatty liver & 




Table 6.2: Diabetes management and HBA1c values    
 GDMs P value (df) 
Clinical management  Active   Placebo   
Diabetes management (at 
recruitment), n (%) 
121 61 (50.4) 60 (49.6) .525 (3) 
Diet only 72  35 (57.4) 37 (61.7%)  
Diet & Oral medication 10 6 (9.8%) 4 (6.7%)  
Diet & Insulin  32 18 (29.5%) 14 (23.3%)  
Combination therapy 7 2 (3.3%) 5 (8.3%)  
Diabetes management (during 
pregnancy), n (%) 
121 61 (50.4) 60 (49.6) .525 (3) 
Diet only 72  35 (57.4) 37 (61.7%)  
Diet & Oral medication 10 6 (9.8%) 4 (6.7%)  
Diet & Insulin  32 18 (29.5%) 14 (23.3%)  
Combination therapy 7 2 (3.3%) 5 (8.3%)  
 
Active 
 DCCT (%) (df) (minimum / 
maximum)  
IFCC (mmol/l) (df) (minimum / 
maximum)  
 
HBA1c (at recruitment) (mmol/l) 
mean (df)  
61 6.0, df .91  
(4.4 – 9.8) 
 42.05, df 9.94  
(25 - 84)  
 
HBA1c (at recruitment) (mmol/l) 
mean, df (gestational weeks - range)  
 23, df 5.9 (10 – 32)  
HBA1c (pre-delivery) (mmol/l) 44 5.9, df .95  
(4.3 – 10.1) 
41.0, df 10.54  
(23.0 – 88.0) 
 
HBA1c (pre-delivery) (mmol/l) mean, 
df – (gestational weeks, range) 
 33, df 3.4 (21 – 37)  
Placebo  DCCT (%) (df) (minimum / 
maximum) 
IFCC (mmol/l) (df) (minimum / 
maximum) 
 
HBA1c (at recruitment) (mmol/l) 
mean (df)  
61 6.1, df 1.14  
(4.6 – 11.0) 
 43.2, df 12.5  
(27 - 97)  
 
HBA1c (at recruitment) (mmol/l) 
mean, df (gestational weeks - range)  
 23, df 6.5 (7 – 32)  
HBA1c (pre-delivery) (mmol/l) mean, 
(df) 
43 5.8, df .57  
(4.6 – 7.2) 
 40.4, df 6.21  
(27 - 55)  
 
HBA1c (pre-delivery) (mmol/l) mean, 
df – (gestational weeks, range) 
 32, df 4.7 (21 – 40)  
HBA1C – glycated haemoglobin (A1c)     DCCT – Diabetes Control and Complications trial – units measured in (%) 








6.6.3 Pregnancy outcomes – maternal and foetal / neonatal 
6.6.3.1 Maternal outcomes 
Pregnancy outcome data is provided in table 6.3. In the active and placebo groups, 64 
(100%) / 62 (98%) respectively, completed the study, with 1 stillbirth and 1 neonatal death 
in the latter group.  
Modes of delivery were vaginal 25 (39%) / 28 (44%), assisted 8 (13%) / 3 (5%) and 
caesarean section 31 (48%) / 32 (51%) in the active and placebo groups (p < .294), 
respectively. Compared to women who received omega 3 & 6 supplements and those who 
received placebo, spontaneous onset of labour was 25 (39%) / 17 (27%), caesarean section 
before the onset of labour was 8 (13%) / 11 (18%), and induction of labour (IOL) 31 (48%) 
/ 35 (57%) (p < .328), respectively. The reasons given for IOL were varied as outlined in 
table 5.2.  Diabetes related complications (n = 12 (39%) / n = 19 (54%) and hypertensive 
disorders (n = 9 (29%) / n = 10 (29%) were the main reasons for IOL in the fish oils and 
placebo groups (p < .616), respectively.  
 
6.6.3.2 Foetuses / Neonates Outcomes 
The clinical outcome data of the foetuses and neonates are outlined in table 6.4. Of the live 
births, the incidence of prematurity was 6 (10%) among those who were in the placebo 
group compared to those who received fish oils (n = 15; 23.4%) (p < 0.96). Of the babies 
born prematurely in the active group, the distribution was 1 (1.6%) extremely premature, 1 
(1.6%) very premature and the remaining 20% moderately premature compared to 1(1.6%) 




No macrosomia was noted in either of the groups but low birth weight (n =11; 17%) was 
twice more common among the active group than women in the placebo group (p < 0.124) 
(table 6.4), although not significant.   
 When birth weight was examined using the Levene’s test of variance, mean = 2971 grams 
(df = 648.53) for women who received fish oils and 3046 grams (df = 546.48); t (137) =     
-0.74 for women in the placebo group, respectively (p < 0.15).  Apgar at 1-, 5- and 10-
minutes mean were = 8.2 (df = 1.77) / 9.46 (df = 1.33) / 9.27 (df = 2.16) for women who 
received fish oils and 9.14 (df = 1.53) / 8.29 (df = 2.16) / 9.49 (df = 2.05); t (138) = -0.26 / 
0.45 / 0.54 for women in the placebo group, (p < 0.66 / 0.31 / 0.54), respectively. 
Of the babies born to mothers who had fish oils, 8 (13%) were admitted to special care unit 
compared to 2 (3.3%) of babies born to mothers in the placebo group (p < 0.057) and the 
reasons given were varied with hypoglycaemia and respiratory distress recorded as the 
main reasons (p < 0.586) and significant.  
 
6.6.4 Diabetes management and pregnancy outcome  
Of 71 women who were on ‘diet only’ management for their GDM condition, birth 
outcome was prematurity 10, stillbirths 1, miscarriage 1 and low-birth weight 8. Mode of 
delivery was vaginal 37, instrumental 6 and caesarean section 28. For those on medication, 
the birth outcomes and modes of delivery for women on oral medication, insulin and 
combination therapy were pre-term birth 2, 5 & 2 respectively; low-birth weight 2, 4 and 1 
respectively; vaginal 4, 9 & 1 respectively; instrumental delivery 2, 2 & 0, respectively and 




6.6.5 Postnatal glycaemic status 
Postnatally, 4 (8%) were diagnosed with Type 2 diabetes with 3 (5.9%) having either 
IGT/IFG among those who received fish oils compared to 6 (13%) and 1 (2.2%), 


















Table 6.3: Pregnancy outcomes - maternal  
 Study groups  GDM  
Pregnancy outcome 
measures (Maternal) Active Placebo 
P value {Standard 
deviation (df)}  
No. of Subjects (n)  64 63  
Pregnancy complications, n (%)   
.826 (6) 
None 28 (43.8) 32 (51.6) 
 
IUGR by scan 4 (6.3) 2 (3.2) 
 
Big baby by scan 6 (9.4) 6 (9.7) 
 
Congenital abnormality 0 (0.0) 0 (0.0) 
 
Malpresentation 0 (0.0) 1 (1.6) 
 
PIH, Pre-eclampsia or Eclampsia 7 (10.9) 4 (6.5) 
 
¤ Presumed foetal compromise 4 (6.3) 4 (6.5) 
 
✤Other pregnancy complications 15 (23.4) 13 (21.0) 
 
Onset of labour, n (%)   .328 (2) 
Spontaneous 25 (39.1) 17 (27.0)   
Induced 31 (48.4) 35 (55.6)   
Elective Caesarean 8 (12.5) 11 (17.5)   
Induction of labour (IOL), n (%)   .368 (1) 
 Yes 31 (50.0)  36 (58.1)   
 No 31 (50.0) 26 (41.9)   
Indications for IOL, n (%) 31 35  .616 (5) 
Postdates 1 (3.2) 0 (0.0)   
Premature / 
Prolonged Rupture of 
membranes 2 (6.5) 2 (5.7)   
Diabetes related 12 (38.7) 19 (54.3)   
Hypertension, PIH, Pre-eclampsia 
or Eclampsia  9 (29.0) 10 (28.6)  
Foetal Reasons 4 (12.9) 3 (8.6)  
Other Reasons 3 (9.7) 1 (2.9)  
Mode of delivery, n (%) 64 63 .294 (2) 
Spontaneous Vaginal (normal) 25 (39.1) 28 (44.4)   
Assisted (ventouse / forceps)  8 (12.5) 3 (4.8)   
Caesarean section (CS) 31 (48.4) 32 (50.8)  
 ¤ Presumed foetal compromise: suspicious cardiotocograph, spontaneous rupture of membranes, premature rupture of membranes, 
prolonged premature rupture of membranes, meconium-stained liquor and reduced amniotic fluid index. ✤Other pregnancy 
complications: cholestasis, anaemia, ante-partum haemorrhage, postpartum haemorrhage, thrombocytopenia, non-alcoholic fatty liver & 







Table 6.4: Pregnancy outcomes - foetal/neonatal 
 Study groups GDM  
Pregnancy outcome measures 
(foetal/neonatal)  Active Placebo 
P value {Standard 
deviation (df)}  
No. of Subjects (n) (%) 64 63   
Birth Outcome (n) (%)     .096 (4) 
Full Term live 48 (75.0) 54 (85.7)  
Preterm live 16 (25.0) 6 (9.5)  
Stillbirth/IUD 0 (0.0) 1 (1.6)  
Neonatal Death 0 (0.0) 1 (1.6)  
Miscarried 0 (0.0) 1 (1.6)   
    
Birth maturity (b) (weeks) (n) (%)   64 62 .285 (4) 
Extremely Preterm (<28) 1 (1.6) 1 (1.6)   
Very Preterm (28-31) 1 (1.6)  0 (0.0)   
Moderate Preterm (32-36) 13 (20.3) 6 (9.7)  
Term (37-40) 48 (75.0) 55 (88.7)   
Post-maturity (≥41) 1 (1.6) 0 (0.0)   
Birth Weight, n (%) 64 62 .124 (1) 
Low birth weight (≤2499grams) 11 (17.2) 5 (8.1)  
Normal birth weight (2500 -4449grams) 53 (82.8) 57 (91.9)  
Macrosomia (≥4500grams) 0 (0.0) 0 (0.0)  
Admission to Special Care Baby Unit 
(SCBU) (n) (%)  64 61  .057 (1) 
Yes 8 (12.5) 2 (3.3)  
No 56 (87.5) 59 (96.7)  
Reasons for admission to SCBU (n) (%)  8 2  .586 (5) 
Hypoglycaemia 2 (25.0) 2 (100.0)  
Respiratory Distress Syndrome 2(25.0) 0 (0.0)  
Prematurity  1 (12.5) 0 (0.0)   
Poor feeding/ 
Jaundice 1 (12.5) 0 (0.0)  
Suspected Infection 1 (12.5) 0 (0.0)   










Table 6.5: Diabetes management and pregnancy outcomes  
 Diabetes management 
Pregnancy outcomes Diet only Diet and Oral 
Medication 






Birth outcome n (%)  71 10  32 7 .951 (12) 
Full term birth 59 (83.1) 8 (80.0) 26 (81.3) 5 (71.4)  
Preterm birth 10 (14.1) 2 (20.0) 5 (15.6) 2 (28.6)  
Stillbirth 1 (1.4) 0 (0.0) 0 (0.0) 0 (0.0)  
Neonatal death 0 (0.0) 0 (0.0) 1 (3.1) 0 (0.0)  
Miscarriage 1 (1.4) 0 (0.0) 0 (0.0) 0 (0.0)  
Birth Weight  70 10 32 7 .896 (3) 
Low birth weight 
(≤2499grams) 
8 (11.4) 2 (20.0) 4 (12.5) 1 (14.3)  
Normal birth weight (2500 
- 4449grams) 
62 (88.6) 8 (80.0) 28 (87.5) 6 (85.7)  
Macrosomia 
(≥4500grams) 
0 (0.0) 0 (0.0)  0 (0.0) 0 (0.0)  
Mode of delivery  71 10  32 7 .062 (6) 
Vaginal 37 (52.1) 4 (40.0) 9 (28.1) 1 (14.3)  
Instrumental 6 (8.5) 2 (20.0) 2 (6.3) 0 (0.0)  
Caesarean 28 (39.4) 4 (40.0) 21 (65.6) 6 (85.7)  
 
 
Table 6.6: Postnatal diabetes status: GDMs (fish oils supplemented) 
 No. of Subjects (n) (%)  
 
Glycaemic status (n) (%) GDM (Omega 3 & 6) GDM (Placebo) 
P value {Standard 
deviation (df)} 
 51 46                                                                                                               
                                      
.485 (2) 
Normal 
44 (86.3) 39 (85.8)   
IGT & IFG 
3 (5.9) 1 (2.2)  
T2 DM 
4 (7.8) 6 (13.0)   






6.7.1 Demographic and clinical characteristics of subjects  
In this study, the average gestational age at recruitment was 23 weeks which was nearing 
the gestational age of 24 weeks when true gestational diabetes can begin to develop. Of the 
women diagnosed with GDM, Asians were the predominant ethnic group, followed by 
Afro-Caribbeans then Whites and there was an equal distribution of women of those ethnic 
groups who engaged with the study in the active and placebo groups. Asians were 3 times 
and 7 times more likely than the Afro-Caribbeans and Whites, respectively, to develop 
GDM. The incidence and distribution of GDM was similar to that detected in previous 
studies where GDM was more common among Asians and Afro-Caribbeans compared to 
Whites (Diabetes UK, 2016 & 2018). Most women who were between ages 21 – 40 spoke 
English. However, age, ethnicity and language had no impact on whether or not women 
chose to engage with the study. Also, the majority of women were either over-weight or 
obese and had an average of 2-4 children, but these factors had no influence on women’s 
decision on whether or not to participate in the study and this was regardless of their 
general health and well-being, as previously demonstrated in Chapter 4.  
 
6.7.2 Maternal Outcomes 
6.7.2.1 Onset of labour and mode of delivery 
Spontaneous onset of labour was higher among women in the active group, but the number 
of women induced in the placebo and fish oils groups was similar. Diabetes related issues 
were the main reasons for women being induced and this is common practice when caring 
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for pregnant women with this condition to promote optimal maternal and foetal pregnancy 
outcomes (Gorig et al, 2015 & National Institute for Clinical Excellence, 2015). This may 
be suggestive that regardless of whether or not women received fish oils, the decision for 
induction was made purely for clinical reasons and taking fish oils was not an influential 
factor in the decision making.  From the women induced, the majority failed to deliver 
vaginally, resulting in a high caesarean section rate and in some cases the need for 
instrumental delivery. Again, these modes of delivery are not uncommon within this group 
(Bernstein et al, 2016 & Billionnett et al, 2012).  Similar number of women had a vaginal 
delivery in both groups, and this accounted for only a third of the deliveries overall and 
supports this evidence.   
Approximately half the women in both groups had an emergency caesarean section and a 
similar distribution of elective caesarean section. A higher number of women started their 
pregnancy with chronic problems and many developed complications during the index 
pregnancy. Combined those factors would have impacted on the high caesarean section 
rate. A high incidence of caesarean section deliveries is common among diabetic 
pregnancies which are considered ‘high risk’ and this would have also been another factor.    
Most study subjects were either overweight or obese.  Lifestyle interventions are usually 
recommended when managing GDM, but previous studies have demonstrated the lack of 
effectiveness of this strategy. Omega-3 PUFAs have been shown to have beneficial effects 
on glucose metabolism, lipid fractions, and inflammatory factors in women with GDM 
(Garmendia et al, 2018). However, a systematic review and meta-analyses by (Brown et al, 
2019) has found no effect of increasing Omega-3 & -6 and total PUFAs on glucose 
metabolism. A RCT which examined the effectiveness of home-based dietary counselling 
with and without various strengths of DHA on pregnant mothers and their off-spring’s 
metabolic control has shown that effect (Garmendia et al, 2018). But, perceived benefits of 
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the fish oils may not have been achieved because women with diabetes and are overweight 
or obese have a greater incapacity of synthesizing DHA.  Obesity can adversely affect the 
red blood cell membranes AA & DHA levels of GDMs (Min et al, 2004) and the effects of 
pre-gestational BMI insulin insensitivity is well documented (Catalano et al, 2012, & 1999 
& 1998). Subsequently, these factors combined may have exacerbated the problem. They 
may have impacted on pregnancy outcome measures including the postnatal glycaemic 
status, where there was no difference in women who received omega 3 & 6 compared to 
those who received placebo. Obesity is also associated with spontaneous abortion 
(Conway, 2011; Lashen et al, 2004) and could have contributed to the incidence of 
miscarriage (n=88.2%) – overweight & obese) and preterm birth (n=81.1% - overweight & 
obese) (p < 0.026) within the study group, with the result been significant. A meta-analysis 
of 16 studies on obese women has reported an overall OR of 1.67 for miscarriages and can 
justify this result (Metwally et al, 2008).  
 
Also, singleton pregnant local women had an average of 2-4 children and usually in quick 
succession. This is a trend which is common among Asians, which represented the 
predominant ethnic group in the study. Previous evidence has shown that women with 
short durations between pregnancies may be starting with depleted stores of fatty acids, 
particularly as quick successions of pregnancies can contribute to low birth weight and 
preterm births (Rawlings et al, 1995). Combined, these factors may have affected the 
placental supply of fatty acids available for transportation to the foetus impacting adversely 
on the maternal and foetal outcomes, although not proven. This may suggest that 
depending on ethnicity and duration between pregnancies, supplementation of essential 
fatty acids during pregnancy may be necessary to meet the ongoing demand from the 
foetus and primarily the shortfall as some women would have started pregnancy with 
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depleted stores. Nevertheless, long chain polyunsaturated fatty acid concentrates are higher 
after a singleton pregnancy than multiple pregnancies (Ziejdner et al, 1997) and could have 
been beneficial.   
6.7.2.2 Prolonged pregnancy 
In this study, fish oils had no impact on prolonging the pregnancies of women with GDM. 
When compared to women who received fish oils, approximately 14% more women in the 
placebo group delivered at term, but the result was not significant. Also, only one woman 
supplemented with fish oils delivered beyond 41 weeks and twice the number of women 
who received fish oils had pre-term delivery. These findings were  contrary to that of a 
multicentre RCT pregnancy study which found prolonged pregnancy in fish consumers 
(low - middle) after fish oils supplementation and dietary fish consumption in women with 
previous pregnancy complication (Olsen et al, 2007). A recent review by Middleton et al 
(2018) which demonstrated that supplementation with fish oils may reduce the incidence 
of premature births and may prolong pregnancy. Our local population with a high 
morbidity rate and being predominantly from the lower social class may not have been 
able to afford a daily balanced diet and that may have contributed to the disparity in 
findings, which could have adversely impacted on the pregnancy outcomes. Conversely, 
one may argue that the incidence of pre-maturity may have been reduced based on the 
finding of Olsen et al’s study. 
 
Also, a similar number of women in each group was induced and had a spontaneous 
delivery, suggesting that fish oils supplementation was not influential in any way in those 
two areas of care. Additionally, another RCT conducted on primagravidas who were 
supplemented in early pregnancy (17-19 weeks) until post delivery (3 months) showed a 
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likely correlation between DHA concentration and gestational length, but this was found 
from supplementation with cod liver and corn oils (Helland et al, 2001), which were 
different from the supplements used in our study.  
 
6.7.2.3 Hypertensive disorders 
In this study, there was no association between PIH, pre-eclampsia and eclampsia and fish 
oils supplementation. These findings were similar to findings from a meta-analysis 
conducted by Chen et al (2015) and a European multi-centre study by Olsen et al (2000) 
which evaluated the effects of fish oils supplementation during pregnancy and found no 
association with supplementation and the risk reduction of PIH. One could argue that 
should early supplementation be introduced immediately after conception or early in the 
first trimester, the results could have been different. GDM (Ben Slama, 1997) and 
hypertensive (Zhou et al, 2014) disorders share the same metabolic pathways which are 
characterised by insulin resistance and they often coexist. Insulin resistance can be 
corrected with insulin therapy (Shin et al, 1995). Therefore, early supplementation may 
have improved the effects of hypertensive disorders, particularly in women treated with 
insulin therapy.     
 
6.7.3 Foetal and Neonatal Outcomes 
6.7.3.1 Foetal and neonatal loss 
Although not significant, there was slightly worsening birth outcome in the GDM placebo 
compared to the fish oils group in term of miscarriage (n=1), stillbirth (n=1) and neonatal 
death (n=1). Based on these findings, one may argue that supplementation with AA & 
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DHA may have made slightly positive contributions to the wellbeing of infants of mothers 
who received fish oils. Similar results have been found in previous systematic review 
conducted by Saccone et al (2015) which demonstrated no reduction in perinatal death.  A 
larger sample size would have given a better overview of whether supplementation could 
reduce the incidence of miscarriages, stillbirths and neonatal deaths.  
 
6.7.3.2 Low birth weight  
There was no macrosomia in any of the groups, but low birth weight infants were higher 
(two-fold) among GDM women who received fish oils compared to women in the placebo 
group, although the result was not significant. Previous reported evidence supported the 
view that the use of fish oils has no positive impact on reduction of low birth weight 
(Onuwude et al, 1995).  But, could the lack of benefits be associated to the low dose 
strength of supplements (1.62g of eicosapentaenoic acid (AA) and 1.8g of DHA) used? 
However, since that study was a double-blind placebo controlled randomised trial of fish 
oils in pregnancies complicated with intrauterine growth retardation and pregnancy 
induced hypertension, those factors may have impacted on the lack of benefits. GDM is a 
metabolic syndrome and when complicated by characterised hypertension the degree of 
insulin resistance could have worsened, adversely impacting on fish oils absorption. But, 
considering that half of the women recruited into this study started with medical and/or 
obstetric complications, those findings may be considered applicable for this group of 
women, but still need to be explored. Nevertheless, as a higher strength supplement was 
used for this study, the morbidity of the local population comes into question as presumed 
benefits may have been noted. Low levels of AA & DHA were shown to be associated 




The prematurity rate, although high, was sporadic in both groups; those who received fish 
oils and placebo. These findings are dissimilar from an RCT conducted on high-risk 
pregnancies which showed supplementation reduced the recurrence risk of preterm birth, 
although not IUGR, preterm delivery and PIH (Olsen et al, 2000). Preterm babies are 
believed to have little fat stores and are more susceptible to reduction in AA and DHA 
(Min & Crawford 2004).   
 
6.7.3.4 SCBU admission 
Although most babies were born in good condition, four-fold those in the active group 
needed admission to special care baby unit compared to those in the placebo group. 
Therefore, supplementation of fish oils had no effect on the reduction of babies being 
admitted to SCBU. It was difficult to correlate taking of fish oils with the wellbeing of 
those infants, particularly as the incidence of admission appeared to match the norm of 
babies born to diabetic mothers are more likely to be admitted to SCBU for reason such as 
hypoglycaemia, respiratory distress syndrome and hyperbilirubinemia. Regardless, a RCT 
conducted by Jamilian et al, (2015) has shown a reduction in hospitalisation and 
hyperbilirubinemia. 
 
6.7.4 Diabetes management 
Management of diabetes for GDMs was mainly diet only and this was similar for those 
who received fish oils supplements and placebo. However, when treatment was introduced, 
it appeared to be aggressively managed with mainly insulin therapy, in both groups with a 
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slight increase in number among those in the active group, although that increase was not 
significant. Oral medication (metformin) was the next drug of choice and its use was more 
common among the active group compared to those in the placebo group which had above 
twice the incident of usage of combination therapy compared to those in the active group.  
As GDM is diagnosed during pregnancy, there is a short period of time for the condition to 
be controlled and therefore having good diabetes control may require aggressive treatment 
and can justify the decision for intensive treatment with insulin therapy to reduce the 
morbidity associated with the condition (Gorig et al, 2018 & Billionnett et al, 2012). Also, 
some women may have been among the millions of undiagnosed type 2 diabetics (Diabetes 
UK, 2018 & 2014) and presented early in pregnancy with characteristics / symptoms like 
women with T2 DM which included high levels of blood sugars. It is well documented that 
the pregnancy outcomes of women with T2 DM are poorer than women without the 
condition and, as the pregnancy outcomes of women diagnosed with GDM can be similar 
to those with overt diabetes, intensive treatment would have been necessary to reduce the 
potential morbidity and mortality associated with the condition.   
 
6.7.5 Diabetes management and pregnancy outcomes  
Intensive treatment coupled with lifestyle factors of healthy eating and exercise can help to 
normalise HBA1c values and optimise maternal and foetal well-being. HBA1c values 
should be below 48 mmol/l (6.5%) to reduce the risk of miscarriages, birth defects, 
stillbirths and neonatal deaths (NICE, 2015). Local diabetic women were extremely high 
risk because of their complex health needs and therefore, according to local policy, the aim 
was to get HBA1c < 41 mmol/l (5.9%) by 16 weeks of pregnancy because it is difficult to 
interpret that test result after that gestation. Regardless, the average HBA1c at booking was 
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42 mmol/l (6.0%), reducing slightly pre-delivery to where it should have been at 16 weeks 
(41 mmol/l / 5.9%).  One miscarriage and one stillbirth were in the placebo group and 
these women were managed on diet only. This raises the question whether intensive 
diabetes treatment could have prevented these adverse outcomes. It was difficult to make 
such a conclusion, since the only case of neonatal death, which was also in the placebo 
group, was insulin treated. However, since these three adverse cases were among women 
in the placebo group, one may argue that fish oils may have helped to optimise the 
pregnancy outcome, despite the result not being significant.  
Of the 15 women who had a low-birth-weight infant, approximately half were treated with 
diet only with the remaining combined total treated with medication (Table 6.5). When 
reference is made to Table 6.4 (foetal / neonatal outcomes), 15 women who had fish oils 
had a pre-term birth with 13 moderately pre-mature.  That result would indicate that fish 
oils had no positive effect on prolonging the pregnancy and reducing the risk of premature 
delivery.  
Also, although not significant, there was a higher incidence of preterm births among 
women who were managed on ‘diet only’ compared to those who received 
pharmacotherapy. A higher number of women treated with insulin therapy and on diet only 
had a caesarean section delivery, but this was not significant. Therefore, the decision for 
delivery by caesarean section, likewise an instrumental delivery, was not determined by 
whether or not medication was used for the antenatal management of women’s diabetes. 
This would suggest that individualised plans of care were developed, and the mode of 
delivery was a derivative of those plans except in cases where there were failed vaginal 
deliveries and inductions leading to either an instrumental or caesarean section delivery. 
Likewise, as similar number of subjects in the active and placebo groups had normal, 
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instrumental and caesarean section deliveries, individualised plans of care appeared to be 
























6.8 Conclusion  
Empirical data has shown enhanced maternal DHA status after fish oil supplementation in 
women with GDM and some benefits of maternal nutrition with omega-3 fatty acid on 
foetal growth and development and maternal health.   
The results from this study have indicated that gestational supplementation with fish oils in 
women with GDM is not associated with improved maternal and foetal health and 
outcomes. Supplementation with fish oils had no impact on induction and caesarean 
section rates, reasons for induction, prolonging pregnancy and reduction in pre-term birth, 
macrosomia, IUGR, hypertensive disorders of pregnancy (pre-eclapmsia and eclampsia) 
and postpartum glycaemic control. Further studies are needed to explore other possible 
benefits of gestational supplementation with fish oils in this high risk group and/or whether 
a higher dose regimen would be beneficial. 
 
Although oral supplementation with omega-3 fatty acid had no impact on the pregnancy 
outcomes of women with GDM, it would be useful to explore whether fish oil 
supplementation had any impact on the pregnancy health and outcomes of non-diabetic 
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7.1 Chapter overview    
In this chapter, I have explored the beneficial effects of omega-3 fatty acids on maternal 
and foetal health and birth outcomes of women diagnosed with and without T2 DM.   
Empirical data has shown that pregnancy outcomes of women with T2 DM are worse 
compared to non-diabetic women. Maternal nutrition high with fish oils is believed to 
promote better pregnancy health and outcomes in mothers and their babies. Foetal demand 
for AA and DHA in pregnancy is high. Previous evidence suggest that T2 DM affect the 
function of delta-5 and delta-6 which are enzymes necessary for the synthesis of AA and 
DHA but this can be corrected by insulin therapy. Recent sub-study data has shown that 
DHA rectified the impairment of red cell membrane lipids in pregnant T2 diabetic women 
and their neonates. It was worth exploring whether that improved DHA status had any 




Diabetes is one of the most common medical disorders in pregnancy of which T2 DM is 
the second most common type after gestational diabetes mellitus (GDM) (WHO, 2018). 
Newham had a population of nearing 340,000 (NCCG, 2017a) of which 8.5% has diabetes 
which is higher than the London average (6.51%) and the UK national average (6.8%) 
(Diabetes UK, 2019). This prevalence impacts on the number of women who present in 
pregnancy with the condition within the borough.  
A pregnancy when complicated with T2 DM is considered ‘high risk’ and caring for these 
women pose huge challenges for clinicians. Consequently, NICE (2015) has recommended 
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a multidisciplinary approach when caring for this group of women from antenatal and 
throughout to the postnatal period, to reduce the morbidity and mortality associated with 
pregnancy and diabetes. 
As explained in the preceding chapter, diabetes whatever the type involves some degree of 
insulin resistance. When type 2 diabetes is present, the degree of insulin resistance 
increases considerably. Insulin resistance can be modulated by DHA (Shin et al, 1995) 
which is usually challenged in pregnancy, in particular women with DM. Like T1 DM, T2 
DM impairs the activity and delta-5 and detal-6; enzymes responsible for the synthesis of 
AA and DHA (El Boustani et al, 1989 & Brenner, 2000). Also, to promote optimal 
pregnancy outcomes for women with overt diabetes and their babies good metabolic 
control prior to and throughout pregnancy is critical. Lifestyle factors of exercise and 
healthy eating can achieve good diabetes control and when these factors fail to achieve 
good control, an adjunctive therapy with medication would be the next option. New 
management strategies are continually being explored to optimise the pregnancy outcomes 
of women with T2 DM through continuous glucose monitoring to achieve euglycaemia 
(Buhary et al, 2016) and supplementation with EFAs to normalise lipids levels (Montori, et 
al 2000). A recent sub-study has shown that supplementation with DHA is beneficial in 
rectifying maternal and foetal cell membranes DHA anomaly in women with Type 2 
diabetes and may subsequently have a positive impact on pregnancy outcomes (Min et al, 
2016) and offers hope that that modification may have an impact on the pregnancy 







The aims are to investigate the: 
Effects of maternal supplementation with arachidonic and docosahexaenoic acids on 
maternal health and foetal wellbeing during pregnancy and on pregnancy (maternal and 
foetal) outcomes of women diagnosed with Type 2 diabetes mellitus (T2 DM) and without 
diabetes. 
 
7.4 Subjects and Methods 
This was a placebo-controlled, randomised nutritional trial conducted at Newham 
University Hospital. Eligible pregnant women diagnosed with T2 DM and ages 17 to 45 
were recruited from the hospital’s SADC (previously discussed) up to 17 weeks gestation 
and randomly allocated either omega-3 fatty acids or placebo, taken from the time of 
recruitment up until delivery.  Allocation of omega-3 fatty acids or placebo was of the 
same duration for their matching comparisons who were healthy controls (women without 
diabetes) and within the same age groups. Women without diabetes were recruited from 
the hospital’s maternity booking centre where women first presented for history taking 
when pregnancy was confirmed and routine antenatal clinics.  
Demographic, socio-cultural, economic and clinical data were collected using a 
questionnaire (appendix 3.7). Data was collected on pregnancy complications (eg. 
hypertensive disorders and pregnancy loss), diabetes management and maternal and foetal 
outcomes (eg. prematurity, post-maturity, macrosomia and low birth weight, neonatal 
admission to special care baby unit). Women were also asked about their and their babies 
health and wellbeing, supplement use which included how, when, quantity taken, side 
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effects, storage of supplements and women’s decision on whether or not they wanted to 
continue on the study. Please refer to chapter 3 for further information. 
 
7.5 Statistical analysis 
Data on age, parity and BMI are presented as mean ± standard deviation (df), median 
(range) and n (%) as number of occurrences with percentages, where appropriate. 
Pearson’s Crosstabulation Chi square test was used to test demographical and clinical 
characteristics with the study groups which received placebo or active (fish oils) 
supplements. The Chi square test was also used to evaluate the similarities and differences 
in maternal and foetal outcomes. The One-way ANOVA test was used to test the equality 
of variance between birth weight and Apgar scores at 1, 5 and 10 minutes among women 
with and without T2 DM and supplemented with or without fish oils. Statistical 
significance equated to p < 0.05. The IBM SPSS Statistics version 25 was used to conduct 













7.6.1 Baseline demographic and clinical characteristics  
7.6.1.1 Subjects recruited 
Maternal characteristics of subjects are provided in Tables 7.1 & 7.2 and Figure 7.1. The 
women studied (T2 diabetics and non-diabetics) had similar ethnic profile. Subjects were 
predominantly between ages 21– 40 (n = 162; 88.1%) with a mean age of 31 (33.30 / 34.92 
and 28.33 / 29.25) for women with T2 DM and healthy controls), respectively (p < .000). 
The majority were of Asian descent (90; 49.2%) followed by Afro-Caribbeans (61; 33.3%) 
then Whites (32; 17.5%) (p < .066), with an average BMI of 28.56 kg/m
2





and a distribution of 36.6% (65) and 37.1% (37) being either 
overweight and obese respectively and the remaining 23.6% (42) of normal weight (p < 
.002). Most women (145; 78.8%) were English speaking (p < .012) and had an average of 
1 - 2 children (121; 76.2%) with over a quarter (54; 29.6%) having had no previous child 
(p < .006) (Tables 7.1 & 7.2).  
Of the subjects recruited (n = 184), randomised were women diagnosed with Type 2 
diabetes mellitus (T2 DM) (n = 96) and non-diabetics (n = 88) who were supplemented 
with either fish oils (n = 47 / n = 40) or placebo (n = 49 / n = 48), respectively. Three 
women who developed GDM (from the control group) continued on the study. Thirty-nine 
women were withdrawn from the study, 8 moved out of the area while 1 was lost to 
follow-up; 1 had a medical termination of pregnancy (MTOP) and 21 miscarried 
accounting for 30 (active) / 34 (placebo) T2 DMs and 24 (active) / 31 (placebo) completing 
the study. Two babies were stillborn from women who had T2 DM and in the placebo 








7.6.1.2 Chronic medical and pregnancy complications 
Nearing forty percent (38.6%) of subjects started the study with a history of chronic 
medical complications with the majority being women with T2 DM as demonstrated in 
Table 7.1. Chronic medical problems noted in the active and placebo groups in women 
with T2 DM and healthy controls were 27 (69.2%) / 7 (25%) and 32 (76.2%) / 5 (12.8) (p 
< .000), respectively. Pregnancy complications (maternal and foetal/neonatal) also 
developed during the index pregnancy in active and placebo groups with a higher 
incidence among T2 DMs compared to healthy controls (p < .029). Pregnancy 
complications were intrauterine growth retardation (IUGR) on ultrasound scan (USS) 1 
(3.1%) / 3 (8.8%), big baby on USS 2 (6.3%) / 3 (8.8%), hypertensive disorders 5 (15.6%) 
/ 7 (20.6%) and presumed foetal compromise 3 (9.4%) / 1 (2.9%) in the fish oils and 
placebo groups among T2 DMs, respectively. Among healthy controls in the placebo group 
were IUGR on USS 2 (6.5%), mal-presentation 1 (3.2%) and presumed foetal compromise 
1 (3.2%) while the latter was 1 (4.2%) and hypertensive disorders 1 (4.2%) in the healthy 
active group. Other pregnancy complications which included cholestasis, anaemia, 
antepartum haemorrhage etc (see footnote on Table 7.1) also developed among active T2 
DMs and controls (n = 10, 31.3%) / 5 (20.8%) and the placebo groups 12 (35.3%) / 11 








Table 7.1: Demographic and clinical characteristics of subjects  
Study groups Type 2 DM Non-diabetics (Healthy Controls) 
 





No. of Subjects (n)  47 49 40 48   
Age, (years) n (%) 
Overall: Mean 31.59 
 
mean 33.30; minimum 
20 - maximum 44 
mean 34.92; minimum 
25 - maximum 45 
mean 28.33; minimum 
17 - maximum 42 
mean 29.25; 
minimum 17 - 
maximum 43  .000 (9) 
 ≤ 21 1 (2.1)  0 (0.0) 5 (12.5) 3 (6.3)   
 21 - 30 11 (23.4) 12 (24.5) 20.(50.0) 27 (56.3)   
31 - 40 33 (70.2) 29 (59.2) 14 (35.0) 16 (33.3)   
≥ 40 2 (4.3) 8 (16.3) 1 (2.5) 2 (4.2)   
Ethnicity, n (%)         .066 (6) 
All Whites 6 (12.8) 7 (14.3) 11 (28.2) 8 (16.7)   
Afro-Caribbeans 17 (36.2) 10 (20.4) 15 (38.5) 19 (39.6)   
Asians 24 (51.1) 32 (65.3) 13 (33.3) 21 (43.8)   
Language, n (%)         .012 (3) 
English 38 (80.9) 31 (63.3) 33 (82.5) 43 (89.6)   
Non-English 9 (19.1) 18 (36.7) 7 (17.5) 5 (10.4)   
Parity, n (%) 
Overall: Mean 1.45 
 
mean 1.67,  
minimum 0 - 
maximum 6 
mean 1.68, minimum 
0 - maximum 7 
mean .98; minimum 0 
- maximum 8 
mean 1.02; 
minimum 0 - 
maximum 5 .006 (9) 
No previous child 11 (23.9) 8 (16.3) 16 (40.0) 19 (39.6)   
1 child 11 (23.9) 12 (24.5) 17 (42.5) 15 (31.3)   
2-4 children 22 (47.8) 25 (51.0) 6 (15.0) 13 (27.1)   
≥ 5 children 2 (4.3) 4 (8.2) 1 (2.5) 1 (2.1)   
Body mass index (BMI) 
(kg/m2), n (%) 
Overall: Mean 28.56 
mean 30.80; minimum 
20 - maximum 44 
mean 29.92; minimum 
15 - maximum 43 
mean 26.53; minimum 
18 - maximum 46 
mean 26.73; 
minimum 18 - 
maximum 37 .002 (9) 
Underweight (<18.5) 0 (0.0) 1 (2.1) 2 (5.1) 2 (4.3)   
Normal weight (18.5-24.9) 7 (15.9) 6 (12.5) 17 (43.6) 12 (25.5)   
Over weight (25.0-29.9) 13 (29.5) 19 (39.6) 10 (25.6) 23 (48.9)   
Obese (≥30) 24 (54.5) 22 (45.8) 10 (25.6) 10 (21.3)   
Chronic medical problems, n 
(%)   39 42  30 39 .000 (3) 
Yes 27 (69.2) 32 (76.2) 7 (25.0) 5 (12.8)   
No 12 (30.8) 10 (23.8) 21 (75.0) 34 (87.2)   





                            34 
                     24 31 .826 (6) 
None 10 (31.3) 8(23.5) 17 (70.8) 16 (51.6) 
 IUGR by scan 1 (3.1) 3 (8.8) 0 (0.0) 2 (6.5) 
 Big baby by scan 2 (6.3) 3 (8.8) 0 (0.0) 0 (0.0) 
 Malpresentation 0 (0.0) 0 (0.0) 0 (0.0) 1 (3.2) 
 Stillbirth 1 (3.1) 0 (0.0) 0 (0.0) 0 (0.0) 
 PIH, Pre-eclampsia or 
Eclampsia 
5 (15.6) 7 (20.6) 1 (4.2) 0 (0.0) 
 ¤ Presumed foetal 
compromise 
3 (9.4) 1 (2.9) 1 (4.2) 1 (3.2) 
 ✤Other pregnancy 
complications 
10 (31.3) 12 (35.3) 5 (20.8) 11 (35.5) 
 ¤ Presumed foetal compromise: suspicious cardiotocograph, spontaneous rupture of membranes, premature rupture of membranes, 
prolonged premature rupture of membranes, meconium-stained liquor and reduced amniotic fluid index. ✤Other pregnancy 




7.6.1.3 Diabetes management and control at recruitment and pre-delivery   
Of the women who had T2 DM and supplemented with fish oils and placebo, diabetes 
management at recruitment was 5 (14.3%) / 3 (7.7%) diet only, 17 (48.6%) / 16 (41.0%) 
oral medication, 1 (2.9%) / 3 (7.7%) insulin treated while 12 (34.3%) / 17 (43.6%) had 
combination therapy (oral medication and insulin) respectively (p < .535). The 
management regimen pre-delivery was oral 3 (8.3%) / 1 (2.6%) diet only, 14 (38.9%) / 9 
(23.1%) oral medication, 7 (19.4%) / 11 (28.2%) insulin treated while 12 (33.3%) / 18 
(46.2%) had combination therapy (oral medication and insulin) respectively 36.6% / 
23.9%, 19.5% / 26.1% insulin and 34.1% / 47.8% combination therapy, in the active and 
placebo groups, respectively (p < .255) (Table 7.3).  
Among the active group at recruitment, mean HBA1c performed at approximately 9 weeks 
was 7.3% Diabetes Control and Complications Trial (DCCT) / 56.86 mmol/l International 
Federation of Clinical Chemistry (IFCC) compared to 6.1% (DCCT) / 44.0 mmol/l (IFCC) 
at a mean gestational age of 30 weeks prior to delivery. For those who received placebo, 
mean gestational age at recruitment was 10 weeks and 33 weeks at delivery with HBA1c 
of 7.4% (DCCT) / 58.5 mmol/l (IFCC) and 6.5% (DCCT) / 47.4 mmol/l (IFCC, 











Table 7.2: Diabetes management and glycaemic control of women with T2 DM  
 T2 DM 
 
P value (df) 
Diabetes management   Fish oils Placebo   
At recruitment, n (%) 74 35 (47.3) 39 (52.7) .535 (3) 
Diet only 8 5 (14.3) 3 (7.7%)  
Diet & Oral medication 33 17 (48.6%) 16 (41.0%)  
Diet & Insulin  4 1 (2.9%) 3 (7.7%)  
Combination therapy 29 12 (34.3%) 17 (43.6%)  
Pre-delivery, n (%) 75 36 (48%) 39 (52%) .255 (3) 
Diet only 4 3 (8.3) 1 (2.6%)  
Diet & Oral medication 23  14 (38.9%) 9 (23.1%)  
Diet & Insulin  18 7 (19.4%) 11 (28.2%)  
Combination therapy 30 12 (33.3%) 18 (46.2%)  
 
Active 
 DCCT (%) (df) (minimum 
/ maximum)  
IFCC (mmol/l) (df) 
(minimum / maximum)  
 
HBA1c (at recruitment), n, 
(mmol/l) mean (df)  
29 7.3, df .1.4  
(5.3-10.9) 
 56.86, df 15.8  
(34-96)  
 
HBA1c (at recruitment) 
(mmol/l) mean, df (gestational 
weeks - range)  
 9, df 2.6 (5-15)  
HBA1c (pre-delivery) n, 
(mmol/l) 
19 6.1, df 1.1 
(4.9 – 10.1) 
44.0, df 11.8  
(30.0 – 87.0) 
 
HBA1c (pre-delivery) (mmol/l) 
mean, df – (gestational weeks, 
range) 
 30, df 5.2 (20 – 38)  
Placebo  DCCT (%) (df) (minimum 
/ maximum) 
IFCC (mmol/l) (df) 
(minimum / maximum) 
 
HBA1c (at recruitment) n, 
(mmol/l) mean (df)  
33 7.4, df 1.59  
(5.5 – 11.0) 
 58.5, df 17.6  
(37 - 97)  
 
HBA1c (at recruitment) 
(mmol/l) mean, df (gestational 
weeks - range)  
 9.7, df 3.4 (4-16)  
HBA1c (pre-delivery) n, 
(mmol/l), mean, (df) 
25 6.5, df .81  
(5.2 - 8.6) 
 47.4, df 9.03  
(33 - 72)  
 
HBA1c (pre-delivery) (mmol/l) 
mean, df – (gestational weeks, 
range) 
 33, df 3.06 (28 - 37)  
HBA1C – glycated haemoglobin (A1c)     DCCT – Diabetes Control and Complications trial – units measured in (%) 




7.6.2 Pregnancy outcomes 
7.6.2.1 Maternal outcomes 
Pregnancy outcome data is provided in table 7.3. Compared to women with T2 DM and 
non-diabetics who were supplemented with fish oils and those who received placebo, 
spontaneous onset of labour was 13 (41.9%) vs 20  (83.3%) and 15 (42.9%) vs 23 (74.2%), 
rate of induction 10 (32.3%) vs 2 (8.3%) and 8 (22.9%) vs 4 (12.9%) and caesarean section 
before the onset of labour 8 (25.8%) vs 2 (8.3%) and 12 (34.3%) vs 4 (12.9%), respectively 
(p < .007).  
Sixty-four women (52.9%) had a vaginal delivery, 4 (3.3%) were assisted deliveries and an 
overall caesarean section rate of 53 (43.8%) of which 37 (69.8%) had T2 DM (n = 16, 
43.2% active / n = 21, 56.8% placebo) and 16 (30.2%) were healthy controls (n = 6, 37.5% 
active / n = 10, 62.5% placebo) (p < .060). Approximately 50% caesarean section was 
classified as emergencies. Of all women induced, 36% had an emergency caesarean section 
while the remaining 64% had a vaginal delivery. Diabetes was the main reason for 











Table 7.3: Pregnancy outcomes - maternal 
 Study groups  Type 2 diabetes Non-diabetics (Healthy controls)  





No. of Subjects (n)  36 42 29 41   
Onset of labour, n 
(%) 31 35 24 31 .007 (6) 
Spontaneous 13 (41.9) 15 (42.9) 20 (83.3) 23 (74.2)   
Induced 10 (32.3) 8 (22.9) 2 (8.3) 4 (12.9)   
Elective Caesarean 8 (25.8) 12(34.3) 2 (8.3) 4 (12.9)   
Induction of labour 
(IOL), n (%) 32 34 24 30 .129 (3) 
 Yes 10 (31.3)  8 (23.5) 2(8.3) 4 (13.3)   
 No 22 (68.7) 26 (76.5) 22.(91.7) 26 (86.7)   
Indications for IOL, 
n (%) 10  8  2 4 .095 (12) 
Postdates 0 (0.0) 0 (0.0 1 (50.0) 1 (25.0)   
Premature / 
Prolonged Rupture 
of membranes 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)   
Diabetes related 5 (50.0) 4 (50.0) 0 (0.0) 0 (0.0)   
Hypertension, PIH, 
Pre-eclampsia or 
Eclampsia  2 (20.0) 1 (12.5) 1 (50.0) 0 (0.0) 
 Foetal Reasons 1 (20.0) 2 (25.0) 0 (0.0) 3 (75.0) 
 ✤Other Reasons 2 (20.0) 1 (12.5) 0 (0.0) 0 (0.0) 
 Mode of delivery, n 
(%) 31 35 24  31  .060 (6) 
Vaginal (normal) 14 (45.2) 13 (37.1) 17 (70.8) 20 (64.5)   
Assisted (ventouse / 
forceps)  1 (13.2) 1 (2.9) 1 (4.2) 1 (3.2)   
Caesarean section 
(CS) 16 (60.0) 21 (61.9) 6 (25.0) 10 (32.3) 
 ✤Other pregnancy complications: cholestasis, anaemia, ante-partum haemorrhage, postpartum haemorrhage, thrombocytopenia, non-










7.6.2.2 Foetuses / Neonates outcomes 
The clinical outcome data of the babies are outlined in table 7.4. Among fish oils and 
placebo supplemented T2 diabetics and non-diabetics, preterm birth was 4 & 13 and 1 & 4, 
respectively. Miscarriages were 8 and 6 in the active and placebo groups among T2 DMs 
and 3 in each of the supplemented non-diabetics. Stillborn (n = 2) was among subjects with 
T2 DM and received fish oils (p < .011). Two (2) babies were very preterm and 2 were 
moderately preterm in the active T2 DM group compared to 1 very preterm and 12 
moderately preterm who received placebo within that same group. In the control group, 1 
baby vs 3 babies were moderately preterm in the active and placebo groups, respectively (p 
< .005).  
Compared to women with T2 DM and healthy controls who were supplemented with fish 
oils and those who received placebo, low birth weight was 5 vs 3 and 5 vs 6, respectively 
(p < .932) and admission to special care baby unit 4 vs 0 and 8 vs 1, respectively (p < 
.017). The reasons for admission to SCBU were varied and can be seen in table 6.4 (p < 
.678).  
7.6.2.2.1 Birth weight & Apgar scores  
An analysis of variance has shown that the effect of fish oils on birth weight was not 
significant, F (3, 143) = 1.16, p < 0.258. Apgar scores at 1 minute, 5 minutes and 10 
minutes, the effect of fish oils were F (3, 143) = 0.37 p < .262, F (3, 69.4) = 0.538, p < 





Table 7.4: Pregnancy outcomes - foetal/neonatal 
 Study groups Type 2 diabetes 
Non-diabetics (Healthy 
controls)  
 Foetal / Neonatal 





No. of Subjects (n) (%) 
    
  
1a. Birth maturity 
(weeks) (n) 40 41 28 33 .012 (6) 
Full term (≥37) 26 (65.0) 22 (53.7) 23 (82.1) 26 (78.8)   
 Preterm (<37) 4(10.0) 13 (31.7) 1 (3.6) 4 (12.1)   
*Other  10 (25.0) 6 (14.6) 4 (14.3) 3 (9.1)   
1b. Birth maturity 
(weeks) (n) (%)   31 35 24 31 .005 (9) 
Extremely Preterm (<28) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)   
Very Preterm (28-31) 2 (6.5)  1 (2.9) 0 (0.0) 0 (0.0)   
Moderate Preterm (32-
36) 2(6.5) 12(34.3) 1 (4.2) 3 (9.7) 
 Term (37-40) 27 (87.1) 22 (62.9) 21 (87.5) 25 (80.6)   
Post-maturity (≥41) 0 (0.0) 0 (0.0) 2 (8.3) 3 (9.7)   
2. Birth Outcome (n) 
(%)  40 41 28 34  .011 (12) 
Full Term live 26 (65.0) 22 (53.7) 23 (82.1) 28 (82.4) 
 Preterm live 4 (10.0) 13 (31.7) 1 (3.6) 3 (8.8) 
 Stillbirth/IUD 2 (5.0) 0 (0.0) 0 (0.0) 0 (0.0) 
 Neonatal Death 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
 Miscarried 8 (20.0) 6 (14.6) 3 (10.7) 3 (8.8)   
Medical termination of 
pregnancy (MTOP) 0 (0.0) 0 (0.0) 1 (3.6) 0 (0.0) 
 Birth Weight, n (%) 31 34 24 
32 
                  
.932 (3) 
Low birth weight 
(≤2499grams) 
5 (16.1) 5 (14.7) 3 (12.5) 6 (18.8) 
 Normal birth weight 
(2500 -4449grams) 
26 (83.9) 25 (85.3) 21 (87.5) 26 (81.3) 
 3. Admission to Special 
Care Baby Unit (SCBU) 
(n) (%)  31 35 23 32  .017 (3) 
Yes 4 (12.9) 8 (22.9) 0 (3.6) 1 (3.1) 
 No 27 (87.1) 27 (77.1) 23 (100.0) 31 (96.9) 
 4. Reasons for 
admission to SCBU (n) 
(%)  4 8 1 13  .678 (8) 
Hypoglycaemia 1 (25.0) 1 (12.5) 0 (0.0) 1 (100.0) 
 Respiratory Distress 
Syndrome 0 (0.0) 1 (12.5) 0 (0.0) 0 (0.0) 
 Prematurity  3 (75.0) 4 (50.0) 1(100.0) 0 (0.0)   
Poor feeding/ 
Jaundice 0 (0.0) 1 (12.5) 0 (0.0) 0 (0.0) 
 Suspected Infection 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)   
Abnormality 0 (0.0) 1(12.5) 0 (0.0) 0 (0.0) 
 * Other = stillbirths, miscarriages, termination of pregnancies and neonatal deaths 
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7.6.3 Glycaemic control and pregnancy outcomes 
Pregnancy outcome for women based on diabetes management are presented in Table 7.5. 
Among women who delivered preterm, treatment was 3 oral medication, 5 insulin and 9 
combination therapy; stillbirths 2 & neonatal deaths 2 insulin therapy; miscarriages 1, 4 & 
6 diet only, oral medication and combination therapy, respectively (p < .274); low birth 
weight 2, 3 & 5 oral medication, insulin and combination therapy, respectively (p < .645). 
Caesarean section deliveries were 1, 8, 11 & 15 oral medication, insulin & combination 
therapy, respectively. Assisted deliveries 1 oral medication and 1 combination therapy (p = 
.546). 
Table 7.5 Diabetes management and pregnancy outcomes  
 Diabetes Management 
 
Pregnancy outcomes Diet only Diet and Oral 
Medication 






Gestational ages at birth, n 
(%)  
4 23 18 30 .274 (9) 
Full term birth 3 (75.0) 16 (69.6) 9 (50.0) 15 (50.0)  
Preterm birth 0 (0.0) 3 (13.0) 5 (27.8) 9 (30.0)  
Stillbirth 0 (0.0) 0 (0.0) 2 (11.1) 0 (0.0)  
Neonatal death 0 (0.0) 0 (0.0) 2 (11.1) 0 (0.0)  
Miscarriage 1 (25.0) 4 (17.4) 0 (0.0) 6 (20.0)  
Birth Weight  3 19 15 23 .645 (3) 
Low birth weight 
(≤2499grams) 
0 (0.0) 2 (10.5) 3 (20.0) 5 (21.7)  
Normal birth weight (2500 - 
4449grams) 
3 (100.0) 17 (89.5) 12 (80.0) 18 (78.3)  
Macrosomia (≥4500grams) 0 (0.0) 0 (0.0)  0 (0.0) 0 (0.0)  
Mode of delivery  3 19  15 24 .546 (6) 
Vaginal 2 (66.7) 10 (52.6) 4 (26.7) 8 (33.3)  
Instrumental 0 (0.0) 1(5.3) 0 (0.0) 1 (4.2)  





7.7.1 Demographic and clinical characteristics of subjects  
Approximately 70% non-diabetic first time mothers versus 40% of T2 diabetics 
participated in this phase of the study. The excitement and enthusiasm which comes with 
being pregnant for the first time, and the need to do what was best for baby, may have 
accounted for that difference in the level of engagement between the two groups. There 
was an increasing trend among women with T2 DM, whereby, levels of engagement 
increased with increased parity. Assuming that some, if not all of those women had 
previously endured the experience of being pregnant with diabetes, there was possibly a 
need to reduce likely complications associated with a diabetic pregnancy. The knowledge 
gained from that experience and/or previous possible bad experiences and/or adverse 
outcomes related to diabetes in pregnancy may have influenced those women’s decision to 
participate in the study, leading to the increasing levels of engagement with parity among 
that group.  
Also, women were predominantly of Asian descent, followed by Afro-Caribbeans then 
Whites with the majority being able to speak English across the groups. Non-English 
speakers were mainly Asians. The diversity noted within this study was reflective of the 
borough of Newham which has a high prevalence of T2 DM. The DECODA study has 
shown that the prevalence of diabetes is highest among Asians, intermediate in Japanese 
and Chinese and lower in Europeans (Nyamdorj et al, 2010).  
For over two decades, it was reported that Asians develop DM with lower BMI (Yoon, et 
al, 2006) at approximately 23 kg/m
2
 (Ko et al, 1998). Since then, this was confirmed in a 
meta-analysis conducted by (Deurenberg et al, 1998) and in a RCT by He et al (2001) and 
adiposity was a huge factor. This observation has led to the International Association for 
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the Study of Obesity (IASO) and the International Obesity task force (IOTF) to redefine 
overweight and obesity as BMI ≥23 kg/m
2
 and ≥25 kg/m
2
, respectively in Asians 
(WHO/IASO/IOTF, 2002). In this study which was predominantly of Asians, the mean 
BMI was 29 kg/m
2
. This raises huge questions about the health of the pregnant population 
within Newham and sets a potential mammoth but vital task for stakeholders, particularly 
as the majority of women were either obese or overweight and this was significant.  
Being obese or overweight has a socio-economic link and is a determinant of health and 
well being (Psaltopoulou et al, 2017). They are also associated with hyperlipidaemia 
(Broom, 2006) and many adverse conditions like hypertension (Greenstein & Wood, 
2011). Therefore, it was not surprising that compared to non-diabetics, approximately five-
fold women with T2 DM started their pregnancy with chronic medical problems and this 
was highly significant. Previous studies have shown the correlation between T2 DM and 
chronic medical complications. The longer the duration of living with the T2 DM, the 
higher the likelihood of developing micro- and macro-vascular complications (Meeking, 
2011). Therefore, the duration of disease could have contributed to some women with T2 
DM having started their pregnancy with several co-morbidities and this impacted on the 
high incidence of deliveries by planned caesarean section among women with T2 DM 
(77%). 
The epidemiological trend of Asians being the more dominant ethnic group with overt 
diabetes is well documented. Contributory factors are urbanisation and socio-economic 
growth (Ramachadran et al, 2012), the tendency of Asians to be more averse to exercise 
and living a more sedentary lifestyle (Nayamdorj et al, 2010). Also, compared to other 
ethnic groups, it is postulated that Asians have a strong genetic predisposition for diabetes 
with lower threshold for environmental risk factors resulting in them developing the 
condition at a younger age with lower thresholds (Ramachadran et al, 2012). The impact of 
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physical inactivity and fatty foods intake can lead to obesity which is a precursor for 
development of T2 DM (Boffetta et al, 2011) and its high prevalence among Asians. 
Subsequently, the incidence of the disease state among Asians and its impact on pregnancy 
and maternal and foetal outcomes can be profound. Also, some Asians associate ‘eating in 
pregnancy’ with providing the mother and baby with the strength they need to thrive well 
and ‘exercise in pregnancy’ as damaging for the mother and baby (Greenhalgh et al, 2015). 
These cultural notions go against the lifestyle advice given to pregnant women with 
diabetes on healthy eating and exercise to achieve euglycemia and reduce the potential 
risks associated with the condition on maternal and foetal outcomes (NICE, 2015).  
 
7.7.2 Pregnancy outcomes 
7.7.2.1 Maternal outcomes 
7.7.2.1.1 Onset of labour  
Compared to women with T2 DM, most non-diabetic women went into spontaneous 
labour. This was significant. A higher percentage of those women had fish oils compared 
to those who received placebo whereas the distribution was similar in both groups for 
women with T2 DM. In non-diabetic women, a 2-fold increased number of women 
spontaneously went into labour compared to women with T2 DM who also received fish 
oils. Local and national (NICE, 2015) guidelines on the management of women with T2 
DM would have warranted that women were delivered at approximately 38 weeks 
gestation to promote a positive outcome for mother and baby. This would have reduced the 
number of women within this group going into spontaneous labour. Conversely, as the 
non-diabetics were in better health, having started their pregnancies with less chronic 
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medical conditions than women with T2 DM and this was significant, there was a higher 
likelihood of non-diabetics being ‘left’ to spontaneously go into labour.  
The adverse outcomes associated with T2 DM have driven clinicians to employ various 
clinical management strategies to optimise the wellbeing of mother and baby. Measures 
taken include increased foetal surveillance and induction of labour at various gestational 
ages (Berger & Melamed, 2014). In the UK, the rate of IOL varies between maternity units 
(NMPA Project Team, 2018) but approximately one-third of all pregnancies were induced 
in 2018 (NHS Digital, 2018) for medical reasons, post-maturity, pregnancy pathologies 
and multiple pregnancies (Royal College of Midwives, 2019). In this study, the overall 
induction rate was one-fifth (20%) with thrice the number of women with T2 DM being 
induced compared to non-diabetics. The majority of T2 diabetics induced had fish oils and 
was above 2-fold higher than in the placebo group; but this was not significant. Again, that 
disparity would have been policy and health related as described earlier on the potential 
reasons for increased spontaneous onset of labour among the non-diabetic group. 
Although not significant, diabetes related issues were the main reasons for women being 
induced. To promote optimal maternal and foetal outcomes, women with T2 DM were 
induced and delivered between 37-38 weeks in keeping with local and national guidelines 
(NICE, 2008 & 2015). This is suggestive that regardless of whether or not women with T2 
DM were supplemented with omega 3 & omega 6, the decision for induction was made 
purely for clinical reasons. As no woman within this group (T2 diabetics) delivered beyond 
40 gestational weeks, it is difficult to conclude whether omega 3 & omega 6 had any effect 
on prolonged gestational age, particularly as diabetes management in the active and 
placebo groups was insignificant at recruitment and pre-delivery. This was substantiated by 
the fact that diabetes related issues were the main reason given for women with T2 DM 
being induced, whether or not they received supplementation with omega 3 & omega 6. 
240 
 
Foetal reason was the next highest indicator for IOL and was more common among both 
placebo groups. This suggested that foetal wellbeing as opposed to diabetic or non-diabetic 
status appeared to be the key decision making indicator.  
Despite the pregnancies of women with T2 DM being considered ‘high risk’, women 
whose pregnancies were uneventful and diet-controlled, were at the lower end of the 
spectrum of the ‘high risk’ trajectory and were sometimes given the opportunity to go into 
labour naturally before planning for IOL after 38 weeks gestation. Any delay could have 
contributed to the overall total number of women having delivered at term within this 
group. The increased risk of stillbirths (Weissgerber & Mudd, 2015), macrosomia (Jardim 
et al, 1997Visser & de Valk, 2015), IUGR (Sibai et al, 2005) are among some of the 
morbidities and mortality associated with pregnancies complicated with diabetic 
pregnancies. The clinicians’ desire to prevent these complications from occurring could 
have constituted to those foetal reasons; all of which were evaluated within this study.    
Among non-diabetics, five (2 fish oils & 3 placebo) women delivered beyond 40 weeks 
gestation. This is reflective of normal practice where women with low-risk pregnancies are 
usually given every opportunity to go into labour naturally and where this did not occur, 
IOL was offered for post-maturity. Yet, the optimal timing of offering IOL in this group 
remains unclear and this is compounded by the findings of a Cochrane database of 
systematic review which demonstrated that there was no clear difference in neonatal 
outcomes of women induced prior to and after 41 weeks gestation (Middleton et al, 2018). 
This evidence can set precedence for future care planning for women with uneventlful 
pregnancies. 
Among non-diabetics, there was a slightly increased number of women who delivered 
beyond 40 weeks gestation in the placebo group than in the fish oil group. Consequently, it 
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may be concluded that fish oils had no effect on prolonging the pregnancy, but this needs 
further investigation as the sample size was small. Compared to non-diabetics, women with 
T2 diabetes received more intensive management, including pharmacotherapy, and 
subsequently, were more than three times more likely to be induced; although not 
significant. The higher rate of IOL among women with T2 DM, the higher the likelihood 
of an emergency C/S due to failed IOL.  
7.7.2.1.2 Mode of delivery 
Mode of delivery distribution was vaginal deliveries (53%), caesarean section (44%) and 
assisted delivery (3%). The incidence of normal vaginal delivery among women who were 
non-diabetics and had uneventful pregnancies were 58% compared to 42% among the T2 
diabetics, and this was nearing significance. Among T2 diabetics, the distribution was 
similar in active & placebo groups, and therefore led to the conclusion that spontaneous 
vaginal delivery occurred regardless of women’s diabetic status and whether or not they 
received active supplements.  
Forty-four per cent (44%) of women were delivered by CS with seventy per cent (70%) 
having had T2 DM. Within that group and non-diabetics, the rate of caesarean section was 
lower among women who received fish oils and this was nearing significance. This would 
suggest that fish oil supplementation may have had a positive impact on maternal and 
foetal health and may have contributed to reducing of the caesarean section rate within 
these groups but further research is needed in this area.  
Elective C/S deliveries were also reduced among women who received fish oils in both 
groups, indicating some beneficial effect, and this was significant. The difference was 2-
fold among non-diabetics and 1.5-fold among T2 diabetics. Elective C/S was 
approximately 3 times more common among women with pre-existing T2 DM compared 
242 
 
to women without diabetes. The aetiology of the disease coupled with local and national 
guidance on the management of T2 DM in pregnancy, could be possible reasons for this 
difference.    
The complications of a diabetic pregnancy are multi-factorial impacting on a higher rate of 
caesarean section deliveries among women with T2 DM compared to non-diabetic women. 
That rate could be further compounded with co-morbidities associated with pre-existing 
diabetes was the case in this study, particularly as a significantly high number of women 
with T2 DM presented at booking with chronic medical problems and this was highly 
significant. Some women also developed pregnancy complications with a higher incidence 
among the placebo groups, but mainly among Type 2’s, although not significant. In view 
of this, one may conclude that most complications prior to and developed within pregnancy 
were associated with the aetiology of the disease (T2 DM) and could have impacted on the 
high CS rate among women with T2 DM.  
Also, increased maternal age has elevated risks for pregnancy complications and adverse 
maternal outcomes (Luke & Brown, 2007), and could have also been a contributory factor 
as most women with T2 DM (75%) were aged 31 and above. Women without diabetes 
were mainly below this age group (63%), and significantly, were approximately 5 times 
less likely to present at booking with chronic medical problems and 1.5 times less likely to 
develop maternal and foetal complications, although not significant. As most women 
without diabetes had a normal delivery and were in the placebo group, active 
supplementation had no effect on mode of delivery within this group. Conversely, an 
increased number of women with T2 DM and in the placebo group had a CS delivery and 
although the level was nearing significance, it is difficult to say whether or not EFAs had 




7.7.2.1.3 Prolonged pregnancy 
Previous evidence has revealed that compared to women with T2 diabetes who received 
placebo, women with that disease state who received fish oils delivered at a later 
gestational age. Within both study groups (non-diabetic and pre-gestational diabetic), 3-
fold and 6-fold less women who received active supplements delivered at moderately pre-
mature, respectively. That result would suggest possible benefit of fish oils in reducing 
preterm delivery, particularly as the rate was significant.  
Overall, more women who received the active supplements delivered at term, indicating 
that fish oils were beneficial in prolonging the pregnancy in both groups. A RCT 
conducted on primagravidas who were supplemented in early pregnancy (17-19 weeks) 
until post delivery (3 months) showed a likely correlation between DHA concentration and 
gestational length from supplementation with cod liver and corn oils, without any proven 
benefits or harm (Helland et al, 2001). Findings from a multicentre RCT pregnancy study 
were similar. Prolonged pregnancy in fish consumers (low - middle) after fish oils 
supplementation and dietary fish consumption was found (Olsen et al, 2007). The profile 
of those subjects bears similar resemblance to Newham’s population which is 
predominantly from the lower social class and may not afford a daily balanced diet. 
Women of Bangladeshi origin tend to consume more fish than other ethnic groups and 
could have started pregnancy with higher levels of membranes fatty acids composition 
which could have impacted on maternal and foetal outcomes. But, baseline data taken by 
Min et al, (2006) did not see any difference in fatty acids level between Caucasians & 
other ethnic groups. This could be because they eat fish which are less oily and low in fatty 




 generation are highly likely to be born 
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in the UK and may have modified their diet to the Western diet and do not consume a diet 
rich in fish as their 1
st
 generation parents.  
 
7.7.2.1.4 Demographic and clinical characteristics  
Most recruits (79%) were either overweight (37%) or obese (42%) and this was highly 
significant. Forty-four per cent had pre-existing diabetes with 41% and 59% being 
overweight and obese, respectfully. Similar trends were noted in published data from 
Public Health England (2014) which has shown that 90% of individuals with T2 DM were 
either overweight or obese. Also, 40% were from the most deprived areas (like Newham) 
where people from the ethnic minority groups live and tend to develop DM with lower 
BMIs compared to White Europeans. Comparatively, there was the same distribution 
among the non-diabetic women except for an increased number of women who received 
placebo and were overweight, and that increase was above two-fold.   
As most study subjects were either overweight or obese and have T2 DM, perceived 
benefits of active supplements may not have been achieved because women with diabetes 
have a greater incapacity of synthesizing DHA (Ghebremeskel et al, 1998 & 2004). A 
previous study by Min et al (2004) has shown that obesity may adversely affect the red 
blood cell membranes AA & DHA levels of GDMs (with similar characteristics like T2 
diabetics) and the effects of pre-gestational BMI insulin insensitivity is well documented.  
Subsequently, these factors combined may have adversely impacted on maternal outcomes 
where there was no difference in onset of labour, rate of induction and mode of delivery 
between women who received fish oils compared to those who received placebo and 
within those groups. Also, except for preterm birth, no significant foetal/neonatal 
difference was found between women who received fish oils and those who did not, and 
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the effects of pre-gestational BMI insensitivity may have been an influential factor. But, 
more recent related data has shown that a daily dose of 600mgs DHA rectifies the 
impairment of red cell membranes in women with T2 DM and their offspring and alters 
foetal body composition (Min et al, 2016). This begs the question whether a higher dose of 
active supplement was needed to have a positive impact on pregnancy outcomes?  
Obesity (Gutaj et al, 2013; Conway, 2011; Lashen et al, 2004) and T2 DM (de Valk, et al, 
2006) are associated with an increased risk of spontaneous abortion, and combined, those 
risk factors could have contributed to the incidence of miscarriage (n=20; 14%). Most 
miscarriages occur in the first trimester, as was the case in this study, with a significantly 
higher incidence among T2 diabetics compared to healthy controls. As there was an equal 
distribution of miscarriages in the active and placebo groups among healthy women and 
more common among women with T2 DM who received active supplements, fish oils had 
no effect on whether or not women miscarried. 
Of all preterm births (n=21, 15%), above eighty percent had T2 DM. This was highly 
significant. There was a six-fold increase of babies that were moderately preterm. Also, 
there was a marked difference between the active and the placebo groups. When compared 
to women with and without T2 DM, there was a 3-fold increase of prematurity in the 
placebo groups. This significant increased would indicate that fish oils were beneficial in 
reducing pre-term deliveries, and possibly prolonging pregnancy, particularly among T2 
diabetics where the majority delivered at term. Conversely, a RCT conducted on high-risk 
pregnancies showed that supplementation reduced the recurrence risk of preterm birth, 
although not preterm delivery (Olsen et al, 2000). Preterm babies are believed to have little 




Pregnant local women had an average of 2-4 children and usually in quick succession. 
Previous evidence has shown that women with short durations between pregnancies may 
also be starting with depleted stores of fatty acids. Likewise, quick successions of 
pregnancies can contribute to low birth weight and preterm births (Rawlings et al, 1995). 
Consequently, the placental supply of fatty acids available for transportation to the foetus 
could have been affected, impacting adversely on the maternal and foetal outcomes, 
despite the higher concentrate of LCPUFAs in a singleton pregnancy compared to multiple 
pregnancies (Ziejdner et al, 1997). As all recruits had singleton pregnancies, they all 
should have had an adequate supply of LCPUFAs which would have been boosted in those 
who had taken additional oral active supplements. But, with the population profile being 
overweight/obesity; some of which had pre-existing DM, most women would have started 
pregnancy with depleted stores of essential fatty acids and added supplementation may 
have contributed to rectifying the depleted stores of LCPUFAs and meeting the ongoing 
demand for the foetus, but to what extent?   
 
7.7.2.2 Foetal and Neonatal Outcomes 
7.7.2.2.1 Birth weight & Apgar scores  
An analysis of variance has shown that the effect of fish oils on birth weight and Apgar 
scores at 1 minute was not significant, unlike Apgar scores at 5 and 10 minutes, where the 
effect of fish oils was significant. However, as most Apgar scores at 5 and 10 minutes 






7.7.2.2.2 Low birth weight  
The incidence of low-birth-weight infants was similar among T2 diabetic women who 
received fish oils and placebo. A Cochrane Database of Systematic Reviews has shown 
that control of blood sugar levels in people with T2 DM was not affected by fish oils 
supplementation (Hartweg et al, 2009) and could be the possible explanation for this 
similarity. Additionally, a systematic review which examined the effects of fish oil 
supplementation in women with GDM has shown no beneficial effects in the prevention or 
treatment of diabetes (Ostadrahimi et al, 2016).   
Non-diabetic women who received placebo were twice more likely to have a low-birth-
weight infant, but this was not significant. Overall, there was no significant difference 
between & within the active and placebo groups, which indicated that fish oils 
supplementation in pregnancy was not associated with the prevention of low birth weight 
infants. Similar findings were found in a systematic review conducted by Saconne et al 
(2016) unlike a similar and more recent review conducted Middleton et al (2018) which 
showed that fewer babies are likely to have low birth weight among women who received 
fish oils.   
Previous reported evidence supports the view that fish oils supplementation with 1.62g of 
eicosapentaenoic acid (AA) and 1.8g of DHA had no positive impact on pregnancy 
outcome (Onuwude et al, 1995).  But, could the lack of benefits be associated with the 
dose strength of supplements used? Onuwude et al’s study was a double-blind placebo 
controlled randomised trial of fish oils in pregnancies complicated with intrauterine growth 
retardation and pregnancy induced hypertension which makes comparisons difficult. 
Considering that half of the women recruited into this study started with medical and/or 
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obstetric complications, findings from that study may be considered inapplicable. 
Nevertheless, as a higher strength supplement was used for that study, the morbidity of the 
Newham population comes into question as presumed benefits may have been obliterated. 
Various doses and types of fish oils have been used in pregnancy outcome studies. This 
lack of uniformity makes it difficult to assess the efficacy of fish oils use on maternal and 
foetal health. A review has shown that uncertainty still exists on the correct dose of omega-
3 and omega-6 fatty acids required for use in pregnancy and the correct ratio of omega-3 to 
omega-6 and possible contraindications when used in combination with other drugs, foods 
and other supplements (Gogus & Smith, 2010). Complications developed in the index 
pregnancy and the medical and previous obstetric history with which women present can 
also affect an accurate assessment on pregnancy health and outcomes. Low levels of AA & 
DHA were shown to be associated with low birth weight and gestational age (Leaf et al, 
1992). To reduce the morbidity; a higher dose of omega-3 fatty acid supplement may need 
to be considered.  
 
7.7.2.2.3 Admission to SCBU 
Most babies were born in good condition, regardless of the health status and whether or not 
women were supplemented with fish oils. However, compared to women without diabetes, 
babies born to women with pre-existing diabetes (T2 DM) were 12 times more likely to be 
admitted to SCBU with the incidence twice increased among those who received placebo. 
These findings were not significant but were similar to the norm whereby the admission 
rate of babies born to diabetic mothers is higher than that of mothers whose pregnancies 
are uncomplicated with diabetes. The main reasons for admission were prematurity 
followed by hypoglycaemia, and this is commonplace. Consequently, it is difficult to 
249 
 
correlate taking of fish oils with improved wellbeing of those infants and reduced 
likelihood of admission to SCBU.  
 
7.7.3 Diabetes management and pregnancy outcomes 
Management of diabetes in women with T2 DM who received fish oils was mainly oral 
medication and combination therapy compared to more intensive treatment of insulin and 
combination therapy in those who received placebo. To obtain optimum diabetes control, 
aggressive treatment is required to reduce the morbidity and mortality associated with 
diabetes in pregnancy (Gorig et al, 2018 & Billionnett et al, 2012). Pregnancy is for a 
shortened period in which good control is critical to optimise the wellbeing maternal and 
foetal. This would explain why treatment intensified during pregnancy compared to when 
women were in their early stages of pregnancy.  
The average HBA1c results at recruitment and pre-delivery among women who received 
fish oils were slightly better than for women who received placebo. A possible explanation 
could be that oral intake of fish oils may have had some impact on glycaemic control, even 
if it was not to a significant level. But, one needs to be cautious as overall, there was a 
higher use of combination therapy for diabetes management among women who received 
placebo compared to women who received fish oils. These results have demonstrated that 
women in the active group had better glycaemic control which may have been associated 
with their intake of omega-3 and omega-6 fatty acids, although that difference was not 
significant. Additionally, since there is a level of inaccuracy in HBA1c results in 
pregnancy (Little & Rohlfing, 2013); it is difficult to establish any correlation. 
The average gestational age at recruitment among women who received fish oils and the 
placebo group was 9 weeks and 10 weeks, respectively. This raises the question, whether 
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that week difference in recruitment (although small), resulted in earlier specialist 
involvement and diabetes management which contributed to better diabetes control and 
possibly the need for less intensive therapy.  
 
Women who received pharmacotherapy for diabetes control had poorer outcomes 
compared to those who did not. For example, compared to women on ‘diet only’, 
miscarriages were 4-fold and 6-fold more likely in women who received oral medication 
and combination therapy, respectively. Women managed on ‘diet only’ were few. One 
could conclude that those women were possibly newly diagnosed with borderline diabetes 
and therefore had good control or that they were strongly motivated to manage their 
condition. Conversely, the use of pharmacotherapy may be indicative of the aetiology of 
the disease, years of diagnosis and change in regimen.  
The incidence of miscarriage was higher among women who received combination therapy 
than the other treatment groups, combined. That result contravenes the evidence which 
recommends intensive treatment to achieve optimal glycaemic control and reduce the 
incidence of miscarriages (CEMACH, 2007). But, since one in five pregnancies in the UK 
end in a miscarriage (Miscarriage Association UK, 2021) and the incidence is higher 
among women with T2 DM (CEMACH, 2007), having a definitive conclusion on the 
causal effect of miscarriages is difficult.  
The impact of the disease (T2 DM) on individuals and individuals’ response to intensive 
treatment may have varied, despite their ethnic grouping. Previous studies have shown that 
Asians have a lower threshold of developing diabetes (Nyamdorj et al, 2010). Similarly, 
their response to medication may also vary and combined, these factors could have 
contributed to the increased incidence of miscarriages among women who received 
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combination therapy, particularly as most subjects recruited were Asians. The effects of 
being overweight and obese on the prevention of optimal insulin absorption (Hassam & 
James, 2005) could have been another factor. Also, as individuals with T2 DM and GDM 
share similar metabolic pathways (Ben Slama, 1997) and obesity was found to have 
adverse effects on red cell membrane AA and DHA in GDMs, this could be another 
possible explanation.  
Preterm births and low birth weight (≤2499 grams) were more likely, the more intensive 
the treatment regimen. One can assume that the more complicated or high risk the 
pregnancy, the more intensive the treatment regimen and therefore the more likely risk of 
preterm delivery and low-birth weight infant. Stillbirths and neonatal deaths were only 
common among those who received insulin therapy. This raises the question whether those 
poor outcomes would have occurred if women received the highest form of treatment 
(combination therapy)?  
Most women had operative deliveries which increased the more intense the treatment 
regimen; but this was not significant. Vaginal deliveries were more common among those 
who were on oral medication. Oral medication use is generally the second line of treatment 
regime after management on ‘diet only’. Having not required insulin treatment or 
combination therapy would suggest that those women had adequate glycaemic control on 
tablets which meant that many could have gone into spontaneous labour and had vaginal 
deliveries having had a plan for delivery at a later stage compared to women on more 






7.8 Conclusion  
The findings of this phase indicated that fish oils supplementation reduced the number of 
babies born preterm, neonates admitted to SCBU and caesarean section deliveries but had 
no impact on the reduction of stillbirths, neonatal deaths, miscarriages, hypertensive 
disorder in pregnancy, and glycaemic control. Uncertainty still remains on the effect of fish 
oils on prolonging gestational age and reducing the IOL rate. Further research is needed to 
explore any additional benefits on pre-existing diabetes including whether supplements 
should be consumed from the pre-conceptual period and throughout pregnancy to have 
increased benefits.  
 
The final chapter (8) follows. It has summarised the main findings of this thesis and the 
unique contribution this thesis has made. The strengths and limitations of each phase of the 















  Chapter 8:  
 
Overview, summary, future 













In this concluding chapter, I will provide an overview of the general thesis. I will reflect on 
my experience of conducting the study and having completed the study, I will revisit the 
study aims, objectives and hypotheses to establish whether or not they were achieved. A 
summary of the findings of each chapter will also be provided with explanation on new 
knowledge derived from the study. Strengths and limitations will be discussed and areas 
for future investigation will be highlighted. 
 
8.2 Reflection 
It was very cathartic, having reflected on my journey from the start and throughout to the 
completion of this thesis. Reflection on my experience was two-fold. It was one of self-
reflection and more importantly, it was one of critical evaluation of whether or not my 
initial aims, objectives and hypotheses were supported or annulled with the data presented 
in each phase of this study.  
With English as my first language and having studied at Masters Level, I believed that I 
had a satisfactory level of academic persuasion to pursue this doctorate. Yet, with limited 
research experience, I was at times conflicted, but the support and guidance of my 
supervisors were invaluable.  
Having reflected on the actual study, I am amazed at my overall achievements. But, when I 
examined each phase of the study more closely, and the data presented, it is noticeable that 
although some things were done well, there were some limitations which may have 
impacted of the findings and these need to be considered when interpreting the results. 
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Given the time, money and opportunity again to undertake this project, there were some 
things that could have been approached and done differently. Likewise, there were other 
areas which could have been further explored, and combined, these are described below 
after providing a brief overview of the study to add context to the issues raised.  
 
8.3 Study overview 
Pregnancy is usually a time of happiness, but it is fraught with many challenges which if 
addressed appropriately and effectively, can optimise the well-being of mother and baby, 
their pregnancy outcomes, as well as the long-term health of mothers and their offspring. 
Diabetes, which is a metabolic disorder, present significant complex challenges to care 
providers. However, previous studies have shown that despite the likely morbidity and 
mortality associated with the condition, pregnancy experience and outcomes can be 
positive for both mother and baby, should an individualised and multidisciplinary approach 
to care, be adopted.   
Nutrition plays a critical role in the effective management of diabetes care. All pregnant 
women are advised to have a balanced diet which includes foods high in omega 3 fatty 
acids [arachodonic acids (AA) and docosahexaeonic acids (DHA)] which are needed for 
incorporation into the lipids of proliferating membranes from conception and throughout 
pregnancy. Hence, the recommendation by the Food Standards Agency for pregnant 
women to have two portions of oily fish weekly. Oily fishes are high in DHA which is 
essential for baby’s brain and visual development. Foods rich in AA are necessary for 
baby’s growth and development.  
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In women whose pregnancies are complicated with type 2 or gestational diabetes mellitus, 
insulin resistance of varying degrees is present. Experimental studies have shown that 
diabetes impairs the activity of delta-6 and delta-5 which are enzymes necessary for the 
synthesis of AA & DHA. Placental transfer of DHA from mother to foetus becomes 
affected and AA and DHA are significantly reduced in the red blood cells of women with 
GDM and T2 DM, and in the plasma and red blood cells of their children, which when 
combined may impact on pregnancies and pregnancy outcomes.  
The UK is becoming increasingly more diverse. Each ethnic group brings its own 
peculiarities and service providers need to acknowledge, respect and embrace this notion, 
when caring for all pregnant women in their care, because this in turn can foster positive 
levels of engagement with HCPs and subsequently reduce morbidities associated with 
diabetes in pregnancy and lack of engagement. Ethnic minorities from deprived areas like 
Newham can present with complex health issues in pregnancy which can provide 
substantially rich empirical data for the provision of quality evidence-based care. 
Previous chapters of this thesis have highlighted the impact on maternal and foetal 
outcomes of women with GDM and T2 DM due to lack of engagement with HCPs, 
inadequate maternal nutrition lacking in AA and DHA and inadequate screening of 
pregnant women at risk of GDM. The main findings within this thesis and the implications 
of these findings are reported below. The strengths, limitations and areas for future 










8.4.1 Phase 1(chapter 4): Client engagement with HCPs and its impact on pregnancy 
outcomes 
This phase evaluated the main factors which facilitated or hindered women’s engagement 
with HCPs. Demographic and socio-economic factors play a key part in the decision-
making process, which varied among and between ethnic groups, religion and one’s ability 
to speak English. Regardless, the overarching reason given for positive engagement with 
HCPs was the likely benefits to the baby while having no research interest was the main 
reason for lack of engagement. 
Inclusion of Non-English-speaking women provided a true representation of the local 
population which is highly diverse. The provision of the PIS in the 5 most dominant (non-
English) locally spoken languages may have engendered recruitment of a larger cohort but 
this needs further investigation. Regardless, English speaking women who were Asian 
Muslims and given adequate time to make a decision with the help of their social network 
(husbands and/or family members) had positive levels of engagement. Home and/or 
hospital appointments provided women with choice and the opportunity for family 
engagement and may have helped with positive engagement but needs to be explored 
further. Also, singleton non-Asian Christians were more likely to engage but their decision 
on whether or not to engage was made more promptly.  
Women with a positive level of engagement <24 weeks gestation developed less pregnancy 
complications but a slightly higher number of women within this group had hypertensive 
disorders (PIH, pre-eclampsia or eclampsia) and had poorer birth outcomes, in that, they 
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suffered more pregnancy loss (stillbirth, miscarry or neonatal death) compared to non-
engaged women. Babies of women who engaged early with HCPs were twice less likely to 
develop macrosomia but more likely to be born pre-maturely and of low birth weight. 
From this data, one can conclude that further work is needed to ascertain whether these 
disparities in outcomes were associated with positive engagement with HCPs or lack of it, 
or due to socio-economic and environmental factors. Overall, data on client engagement 
with HCPs is limited, particularly in the UK, and there is a need for more robust data to be 
better able to establish the factors which impede or enhance client engagement and its 
impact on maternal and foetal outcomes.   
Also, some women who engaged were pre-existing diabetics (T2 DM) and previous GDMs 
who were perhaps knowledgeable on diabetes and its potential risks in pregnancy and may 
have felt motivated to engage to reduce the morbidity/mortality associated with the 
condition. Subsequently, the engagement process may have become self-selective and 
those who needed to engage were those who were less likely to do so, and this could have 
impacted of the findings. 
 
8.4.2 Phase 2 (chapter 5): Culture-specific screening guidelines for women at risk of 
GDM 
Current guidance from NICE is that women with a history of GDM must be tested as early 
as possible and, if the result is negative, re-tested along with women with other risk factors 
between 24-28 weeks of gestation. This recommendation was evaluated within this phase 
to establish the appropriateness of NICE guidance when caring for women with other risk 
factors which included family history of diabetes, body mass index (BMI) ≥30 kg/m
2
, 
history of previous GDM and macrosomic babies (birth weight ≥4kg). Having a family 
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history of diabetes and a body mass index (BMI) ≥30 kg/m
2
, were strong indicators for 
early detection of GDM and were more common as risk factors for screening than women 
having had previous GDM. These finding would suggest that in communities like Newham 
which are genetically susceptible to T2 DM, early screening should be offered to pregnant 
women with a family history of diabetes and those with BMI ≥30. Therefore, NICE 
guidance would be inappropriate when caring for women with similar disposition. Lack of 
universal agreement on who and when to screen continue to pose a huge challenge but the 
strength of these findings should not be ignored, particularly as diagnosis of GDM was 
made following the use of WHO criteria of 75mgs of glucose load which allows for 
comparisons with similar studies.  
This chapter also discussed whether there was any difference in pregnancy outcome in 
women who were diagnosed with GDM before 24 weeks of pregnancy. Findings within 
this phase were similar to adequate available data on previous studies which have shown 
that the maternal and foetal outcomes are poorer the later the diagnosis of GDM. 
Therefore, early screening and detection of GDM is critical to reduce the morbidity 
associated with the condition. 
 
8.4.3 Phase 3 (chapter 6): Impact of fish oil in pregnant women with GDM 
Maternal nutrition contributes significantly to maternal and foetal wellbeing during 
pregnancy and beyond. Nutrition therapy is also an integral strategy in the prevention and 
treatment of GDM. Pregnant women with GDM are believed to have reduced levels of 
plasma fatty acid composition resulting in depleted levels for her and her baby’s health 
needs. This phase examined whether supplementation with EFAs (omega 3 & omega 6) 
had any beneficial effects on maternal and foetal health and pregnancy outcomes of 
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women diagnosed with GDM. Maternal and foetal health and outcomes were similar in 
those who received active supplements and placebo. Supplementation with fish oils had no 
impact on induction and caesarean section rates, prolonging pregnancy and the reduction 
of pre-term birth, macrosomia, IUGR, hypertensive disorders of pregnancy and postpartum 
glycaemic control. There was a possible reduction in the incidence of stillbirths, 
miscarriages and neonatal deaths, but further research is needed to provide empirical 
evidence in these areas.  
From these findings, a daily dose of supplementation with two capsules containing 600mg 
DHA and 200mg AA showed no marked effect on maternal and neonatal outcomes despite 
previous sub-set data having shown that in women whose pregnancies were complicated 
with GDM, daily dose of DHA 600mgs enhanced maternal DHA status but not that of their 
offspring. Also, previous studies suggest that the transfer of DHA from mother to foetus 
may be impaired in women with GDM and that DHA modulates insulin resistance which is 
a characteristic of GDM. Regardless, having an increased daily dose of AA & DHA to 
rectify fatty acid status in infants of mothers with GDM should be considered to enhance 
the immediate and long-term potential benefits of these fatty acids in vascular and 
neurological development and function of the offspring, as shown in previous studies.  
Also, overwhelmingly, the evidence has shown that the pregnancy outcomes of women 
with GDM are poorer than those without diabetes and optimising blood glucose levels can 
be highly beneficial. It would therefore be invaluable to further explore whether an 
increased dose of AA & DHA would be imperative to improve insulin sensitivity, and 
subsequently promote euglycaemia leading to better pregnancy outcomes. 
Many large-scale studies were used to support this phase but one of the main limitations 
was that the pregnancies of women studied were predominantly not complicated with 
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diabetes. Furthermore, there were marked differences in the socio-economic and 
demographic profile of subjects studied and therefore the comparisons of the findings were 
restrictive. Homogeneous comparisons were also inhibited because previous studies used 
lower and varying doses of DHA. Also, the sample size within this phase was relatively 
small, but data generated would have provided stronger effects of the intervention if that 
data was compared with healthy controls, that is, women without GDM. Data derived from 
this group was excluded from the analysis to enhance the integrity of the findings, due to 
the low response rate.  
Compliance was sometimes difficult to monitor. Medication bottles were not always 
returned on follow-up visits for counting; making it difficult to have a comprehensive log 
of the number of supplements taken and this aspect needs to be considered when 
interpreting the results. Also, dietary logs (food diaries) were excluded from the analysis 
due to low return rates and of those returned, most were incomplete, and the quality of the 
data was sub-standard. Data obtained from the food diaries would have provided a 
comprehensive record of individualised baseline EFAs (omega-3 & omega-6) status and 
established the difference in EFAs intake from dietary foods and supplementation and that 
data considered when analysing the outcome data.   
 
8.4.4 Phase 4: Impact of fish oil in pregnant women with T2 DM 
Previous studies have reported altered membrane fatty acid composition being a feature of 
T2 DM and red cell membrane phospholipids anomaly in women with T2 DM and their 
neonates, characterised by a significant reduction in DHA levels. However, previous sub-
set data has shown that a daily dose of DHA 600mgs enhanced maternal and foetal DHA 
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status in women whose pregnancies were complicated with T2 DM, indicating a possible 
improvement in maternal and foetal outcomes.  
This phase examined whether supplementation with fish oils improved the maternal and 
foetal health and pregnancy outcomes of women with T2 DM. The findings have revealed 
that fish oil supplementation had a positive impact on birth maturity and reduced pre-term 
births. Fewer neonates were admitted to SCBU among women with T2 DM, and had 
elective caesarean sections. The overall caesarean section rate was also reduced. Fish oils 
supplementation had no impact on reducing the rate of induction and birth weight. 
Glycaemic control was also not impacted by fish oils supplementation.  
Based on these findings, fish oils consumption should be encouraged to reduce the 
incidence of preterm birth, neonates’ admission to SCBU and caesarean section deliveries. 
Omega-3 fatty acids are inexpensive and are available on the high streets. All high-risk 
women, particularly those with pre-existing diabetes may benefit from fish oils 
consumption as part of their pre-conceptual care but more empirical studies conducted in 
this area. Also, further studies are required to evaluate the impact of fish oils 










8.5 Future investigations      
When I first started this project, I knew what the scope of my thesis was but the more that I 
explored the evidence, the more aware I became that there were wider issues that needed to 
be explored. As a practicing midwife, my duty of care is to mothers and their babies and 
my scope includes caring for them up to 28 days post-delivery. But, since I work in an area 
(Newham) which has a predominantly young population, it is commonplace to see women 
returning, usually within a short duration, with future pregnancies.  
It is well documented that women with T2 DM and GDM have poorer pregnancy outcomes 
compared to non-diabetic women. Therefore, it is critical to ensure that women adequately 
engage with HCPs prior to and early when pregnancy is confirmed, respectively, for them 
to get optimal care which will positively impact on their pregnancy health and outcomes, 
and the future health of them and their babies. Additionally, having had GDM women are 
at risk of developing the condition in subsequent pregnancies and this justifies the need for 
early contact with HCPS for adequate and timely screening and management of those with 
a positive diagnosis. As demonstrated within this study, having a raised BMI ≥30 kg/m
2
 
and family history of DM are strong indicators of developing GDM in future pregnancies 
and these factors should be considered when screening at-risk women in areas with a 
similar demographic profile like Newham, which is highly diverse and deprived. Areas of 
interest which need future exploration to enhance the phases of this study are highlighted 
hereunder.   
 
The long-term effects of diabetes are well documented and various theories exist on foetal 
programming and the disease risks of babies in their adult life. Therefore, it would be 
useful to gather data not only during pregnancy and the immediate post-delivery period but 
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beyond. Further epidemiological studies would be beneficial to follow up the children of 
women with GDM and T2 DM after supplementation with AA & DHA. Previous 
longitudinal studies have demonstrated that LCPUFAs insufficiency is linked to 
impairment in infants’ growth and development, vision and neurological development. 
Other studies have reported that the offspring of diabetic mothers have cognitive 
impairment, are obese and develop T2 DM. These findings could establish whether early 
years’ intervention in children’s neurological development would be necessary to reduce 
learning difficulties and/or prevent long term morbidity. 
 
Women with GDM and T2 DM are characterised by some form of insulin resistance which 
impair their ability to adequately meet their foetal demands for AA & DHA which are 
necessary for foetal growth and development including their neurological and visual 
wellbeing. Oral supplementation of these fatty acids (AA & DHA) is believed to rectify 
these depleted levels. In this study, a daily dose of 600mg DHA and 200mg AA 
supplementation from as early as the first trimester until delivery, had some positive impact 
on the pregnancy outcomes (reduction of premature births and prolonging pregnancies) of 
women with T2 DM but not women with a diagnosis of GDM. It would therefore be 
invaluable to further explore whether insulin resistance and red cell membrane 
phospholipids can be rectified and/or enhanced by an increased dose of EFAs (AA & 
DHA) and subsequently promote euglycaemia leading to better pregnancy outcomes.  
 
I believe that the number of women diagnosed with GDM within Newham could be higher 
than in some areas. At present only women who are high risk of developing GDM are 
screened but there may be women who develop GDM who are not high risk. Over the 
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years, I have come across women who had no notable risk factors but developed the 
condition, but they were only screened for GDM when they became unwell, usually during 
the 3
rd
 trimester. Data from screening women who are not at high risk of developing GDM 
for the condition, over a period of a year will provide a more comprehensive overview of 
women who are at risk of developing GDM, locally, nationally and possibly worldwide 
and set precedence for further studies.   
Also, it would be useful to establish the percentage of women who had GDM and 
subsequently developed T2 DM within a five-year period because previous studies have 
shown that within 5-10 years and in some cases even earlier, some women developed T2 
DM. This information would be critical for future preventative work, care planning and 
allocation of resources. Huge cost savings could be made considering the high likelihood 
of T2 DM in later life after GDM diagnosis and since diabetes costs the NHS millions on a 
daily basis. 
It will be useful to evaluate women’s knowledge of GDM before and after attending the 
education session to establish whether or not their knowledge improved and how that may 
have impacted on diabetes control and pregnancy outcome, while paying particular 
attention to the English- and non-English speaking women. This data would establish 
whether the sessions are ‘fit for purpose’ and provided equity across ethnic groups. Also, it 
would have been useful to assess any new learning and whether that new knowledge 
empowered women to adopt lifestyle changes to optimise their glycaemic control and have 
influenced their decision on whether or not to engage with the services available to them. 
Comparing the pregnancy outcomes of previously and newly diagnosed GDMs to establish 
whether the former with their previous knowledge felt more motivated to engage and 
whether that had any impact on pregnancy health and outcomes, is another area for study 
which will provide substantial data on whether or not teaching should be streamlined 
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differently or not, when the diagnosis of GDM is confirmed. It will also establish the level 
of input that is required from HCPs.  Also, some women may have been ‘functional 
illiterates’ who were unable to adequately process the information provided in the 
education session and subsequently unable to engage effectively and responsibly. 
Evaluating this in the context of blood glucose control and pregnancy outcomes would 
provide invaluable information on the structure of the education session in the future.   
Having a record of the type and frequency of exercise in which women engaged, the 
number of dietetic encounters and support they received from the antenatal period and 
throughout to delivery and evaluating whether those lifestyle factors contributed to 
women’s knowledge and understanding about diabetes, influenced their levels of 
engagement with HCPs and positively impacted on glycaemic control, maternal and foetal 
wellbeing and pregnancy outcomes are areas for future study.  Healthy eating and exercise 
are the cornerstone for optimum diabetes control and management, and acquisition of that 
data would help with the provision of more targeted individualised care to a multi-ethnic 
clientele; some of which are usually not amenable to making lifestyle changes due to 
cultural and socio-economic reasons. 
Although some factors have been identified for lack of engagement among local women, 
data on women’s level of education, experience of domestic violence, role as carers and 
occupancy rates per number of rooms in their housing accommodation would have been 
useful to assess those social factors on engagement, through further work. Also, it would 
have been useful to evaluate the number of encounters that were made with subjects before 
they engaged with HCPs to help with budgeting and when conducting research within this 
population profile.  
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Data collection on women’s previous experiences on service access and availability from 
their birth countries would be useful to establish whether there was any correlation with 
those factors and engagement in this country. This information could be matched with 
women’s previous experiences using the health service, concerns and expectations to help 
in supporting women to access available services and make choices that were amenable to 
them. Previous negative experiences of health care and services of one’s country of origin 
can dictate how one engages with new services and service providers. Also, women’s 
experiences of all services, including health, since arriving in the UK may have contributed 
to their willingness to engage or not and future study in this area would be critical for 
future promotional work on client engagement.  
 Since completion of this study, emerging new evidence was found in an observational 
study conducted by Murphy (2020). The management of pregnancy diabetes before, during 
and after COVID-19 was explored. Conclusions from that study were that as HCPs we 
need to find new ways of supporting pregnancy women in managing their diabetes. 
Positive feedback was received on video consultation and patients’ experiences of 
requiring face to face visits were improved.  
The results of this study are most fitting for Phase 1 of this study which explored the 
factors which influenced positive client engagement with HCPs. Women need flexibility in 
the choices made available to them to do what is right for their babies. One thing that I 
would have done differently was the offer of video consultation, in addition to the choice 
of home visit and hospital consultation. This additional choice may facilitate increased 
levels of engagement which would have had a more positive impact on client the RCTs in 





The programme of research in this study would make a unique contribution to bridging the 
gap in existing knowledge. There are no well designed pregnancy outcome studies on fatty 
acids supplementation in pregnancies complicated with type 2 and gestational diabetes 
mellitus. This study would help in filling that gap. 
The findings of this study have demonstrated that NICE current guidelines on screening for the 
early detection of GDM are inappropriate for use in communities like Newham with a high 
disposition of DM. Family history of diabetes and BMI ≥30kg/m
2
 are strong indicators for early 
detection of GDM.  In communities like Newham which are genetically susceptible to T2 DM, 
women with these risk factors, as well as a previous history of GDM, should be screened early. 
Further explored were the impact of supplementation with AA & DHA in women with 
GDM and T2 DM on pregnancy outcomes and factors which influence engagement with 
HCPs among these high-risk groups and the subsequent impact of their decision on 
maternal and foetal outcomes. Social, cultural and religious factors are critical to decision 
making. Women need time, flexibility in care delivery and appropriate and adequate 
information in language they understand to engage effectively. Stakeholders would be 
better able to prioritise services for early management interventions to reduce any 
associated risks to mother and baby.  
Also, this study has demonstrated that supplementation with fish oils in T2 diabetics 
improved maternal and foetal outcomes in prolonging pregnancies, reducing preterm 
births, caesarean section deliveries and admission to SCBU. Having clarity in these area 
can foster changes in the local maternity diabetes services and help HCPs to improve the 
nutritional advice provided to pregnant women to rectify maternal and foetal fatty acids 
status, in particular women with pre-existing diabetes and possibly those with GDM.  
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For reasons of accountability, HCPs need to take a broad culturally sensitive view when 
dealing with all pregnant women but particularly, non-Whites, who for the greater part are 
socio-economically deprived, marginalised, and more susceptible to developing T2 DM 
and GDM and have poorer pregnancy outcomes. Each ethnic group has its own nuances 
and stakeholders and service providers need to acknowledge, respect and positively 
embrace this notion. A start would be to refrain from grouping all non-Whites under the 
umbrella of ‘BAME’, to achieve truly individualised woman-centred care and reduce 
inequalities in health which is not a historic problem.  
Finally, the findings of this study should be interpreted as the first step towards future 
research on maternal and foetal outcomes of the local pregnancy diabetes service. 
Parameter used within this study can be used for future work on GDM screening, 
promotion of positive client engagement and enhancement of nutritional status and 
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